<SEC-DOCUMENT>0001683168-23-005524.txt : 20230810
<SEC-HEADER>0001683168-23-005524.hdr.sgml : 20230810
<ACCEPTANCE-DATETIME>20230810171530
ACCESSION NUMBER:		0001683168-23-005524
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		54
CONFORMED PERIOD OF REPORT:	20230630
FILED AS OF DATE:		20230810
DATE AS OF CHANGE:		20230810

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AETHLON MEDICAL INC
		CENTRAL INDEX KEY:			0000882291
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				133632859
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37487
		FILM NUMBER:		231160667

	BUSINESS ADDRESS:	
		STREET 1:		11555 SORRENTO VALLEY ROAD, SUITE 203
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-459-7800

	MAIL ADDRESS:	
		STREET 1:		11555 SORRENTO VALLEY ROAD, SUITE 203
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BISHOP EQUITIES INC
		DATE OF NAME CHANGE:	19930602
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>aethlon_i10q-063023.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:aemd="http://aethlonmedical.com/20230630">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_03D_aemd_aethlonmedical.com_20230630 -->
<!-- Field: Set; Name: xdx; ID: xdx_04F_20230401_20230630 -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DEntityCentralIndexKey_0000882291 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_057_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0wMy0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_053_edei%2D%2DDocumentFiscalYearFocus_2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DDocumentFiscalPeriodFocus_Q1 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-04-01to2023-06-30" name="dei:EntityCentralIndexKey">0000882291</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-04-01to2023-06-30" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-04-01to2023-06-30" name="dei:CurrentFiscalYearEndDate">--03-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-04-01to2023-06-30" name="dei:DocumentFiscalYearFocus">2023</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-04-01to2023-06-30" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0199" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0206" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0207" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-04-012023-06-30_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0208" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="aemd:IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExercise" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0215" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="aemd:IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExercise" contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0216" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="aemd:IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExercise" contextRef="From2023-04-012023-06-30_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0217" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0222" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0224" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0225" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-04-012023-06-30_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0226" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0229" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0230" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0232" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-04-012023-06-30_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0233" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0236" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0237" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0238" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2023-04-012023-06-30_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0240" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0247" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0255" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0263" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-04-012022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0264" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-04-012022-06-30_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0265" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0270" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0272" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-04-012022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0273" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-04-012022-06-30_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0274" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0277" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0278" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-04-012022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0280" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0287" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="From2023-04-012023-06-30_us-gaap_OptionMember" id="xdx2ixbrl0538" name="aemd:RangeOfExercisePricesOptionGranted" xs:nil="true"></ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-04-012023-06-30_us-gaap_WarrantMember" id="xdx2ixbrl0582" name="aemd:RangeOfExercisePriceCancelledExpired" xs:nil="true"></ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="aemd-20230630.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-04-01to2023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-09">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_RestrictedCashMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">aemd:RestrictedCashMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_custom_OfferingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">aemd:OfferingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_custom_HcWainwrightMember_custom_OfferingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">aemd:HcWainwrightMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">aemd:OfferingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_custom_OfferingAgreementMember_custom_OtherOfferingExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">aemd:OfferingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">aemd:OtherOfferingExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_custom_EligibleDirectorsEachMember_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">aemd:EligibleDirectorsEachMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_AccruedBoardFeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aemd:AccruedBoardFeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_AccruedBoardFeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aemd:AccruedBoardFeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_AccruedVacationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aemd:AccruedVacationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_AccruedVacationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aemd:AccruedVacationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_custom_StockBasedCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">aemd:StockBasedCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_custom_StockBasedCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">aemd:StockBasedCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_OptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:OptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_OptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:OptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_OptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:OptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_custom_OfficeAndLaboratoryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">aemd:OfficeAndLaboratoryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_custom_ManufacturingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">aemd:ManufacturingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_OfficeLabAndManufacturingLeasesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">aemd:OfficeLabAndManufacturingLeasesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_NewOfficeAndLabSpaceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">aemd:NewOfficeAndLabSpaceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt"><a href="#q1_002">Table of Contents</a></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM <span id="xdx_900_edei--DocumentType_c20230401__20230630_z7BBQqNdstG2"><ix:nonNumeric contextRef="From2023-04-01to2023-06-30" name="dei:DocumentType">10-Q</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Mark One)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_905_edei--DocumentQuarterlyReport_c20230401__20230630_zUw1SDr5spr6"><ix:nonNumeric contextRef="From2023-04-01to2023-06-30" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span>&#160;&#160;&#160;&#160;&#160;QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the quarterly period ended <span id="xdx_90B_edei--DocumentPeriodEndDate_c20230401__20230630_zreEqNVDWJu8"><ix:nonNumeric contextRef="From2023-04-01to2023-06-30" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">June 30, 2023</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">OR</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_900_edei--DocumentTransitionReport_c20230401__20230630_zKAhuq2kSIr"><ix:nonNumeric contextRef="From2023-04-01to2023-06-30" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>&#160;&#160;&#160;&#160;&#160;TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the transition period from _____to_____</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">COMMISSION FILE NUMBER <span id="xdx_903_edei--EntityFileNumber_c20230401__20230630_zDojU7EAPka2"><ix:nonNumeric contextRef="From2023-04-01to2023-06-30" name="dei:EntityFileNumber">001-37487</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 14pt"><b><span id="xdx_90A_edei--EntityRegistrantName_c20230401__20230630_ze0oGWlycXp9"><ix:nonNumeric contextRef="From2023-04-01to2023-06-30" name="dei:EntityRegistrantName">Aethlon Medical, Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 50%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><span id="xdx_909_edei--EntityIncorporationStateCountryCode_c20230401__20230630_z29eXhl1ENz9"><ix:nonNumeric contextRef="From2023-04-01to2023-06-30" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">nevada</ix:nonNumeric></span></span></td>
    <td style="width: 50%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--EntityTaxIdentificationNumber_c20230401__20230630_z5kxY5QGo0i9"><ix:nonNumeric contextRef="From2023-04-01to2023-06-30" name="dei:EntityTaxIdentificationNumber">13-3632859</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction of incorporation or organization)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer Identification No.)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--EntityAddressAddressLine1_c20230401__20230630_zZMrrjefokc4"><ix:nonNumeric contextRef="From2023-04-01to2023-06-30" name="dei:EntityAddressAddressLine1">11555 SORRENTO VALLEY ROAD</ix:nonNumeric></span>, <span id="xdx_90B_edei--EntityAddressAddressLine2_c20230401__20230630_zYsIZRwaAGoa"><ix:nonNumeric contextRef="From2023-04-01to2023-06-30" name="dei:EntityAddressAddressLine2">SUITE 203</ix:nonNumeric></span>, <span id="xdx_90B_edei--EntityAddressCityOrTown_c20230401__20230630_zPZQh3JCSGOl"><ix:nonNumeric contextRef="From2023-04-01to2023-06-30" name="dei:EntityAddressCityOrTown">SAN DIEGO</ix:nonNumeric></span>, <span id="xdx_90E_edei--EntityAddressStateOrProvince_c20230401__20230630_zIsTWnIpU0d2"><ix:nonNumeric contextRef="From2023-04-01to2023-06-30" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric></span></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--EntityAddressPostalZipCode_c20230401__20230630_zxnMiRhsS3Hh"><ix:nonNumeric contextRef="From2023-04-01to2023-06-30" name="dei:EntityAddressPostalZipCode">92121</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive offices)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_906_edei--CityAreaCode_c20230401__20230630_zyjNWbLe2zD8"><ix:nonNumeric contextRef="From2023-04-01to2023-06-30" name="dei:CityAreaCode">(619)</ix:nonNumeric></span> <span id="xdx_90D_edei--LocalPhoneNumber_c20230401__20230630_zwGG1okbTG7l"><ix:nonNumeric contextRef="From2023-04-01to2023-06-30" name="dei:LocalPhoneNumber">941-0360</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s telephone number, including
area code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section 12(b)
of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: center; width: 34%; vertical-align: bottom">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-decoration: underline">TITLE OF EACH CLASS</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_900_edei--Security12bTitle_c20230401__20230630" title="Title of 12(b) Security"><ix:nonNumeric contextRef="From2023-04-01to2023-06-30" name="dei:Security12bTitle">COMMON STOCK, $0.001 PAR VALUE</ix:nonNumeric></span></p></td>
    <td style="text-align: center; width: 33%; vertical-align: bottom">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-decoration: underline">TRADING SYMBOL</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_907_edei--TradingSymbol_c20230401__20230630" title="Trading Symbol"><ix:nonNumeric contextRef="From2023-04-01to2023-06-30" name="dei:TradingSymbol">AEMD</ix:nonNumeric></span></p></td>
    <td style="text-align: center; width: 33%; vertical-align: bottom">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-decoration: underline">NAME OF EACH EXCHANGE ON WHICH REGISTERED</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_90A_edei--SecurityExchangeName_c20230401__20230630" title="Security Exchange Name"><ix:nonNumeric contextRef="From2023-04-01to2023-06-30" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> CAPITAL MARKET</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
<span id="xdx_909_edei--EntityCurrentReportingStatus_c20230401__20230630_zdGoD6SpuWEh"><ix:nonNumeric contextRef="From2023-04-01to2023-06-30" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746; No &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <span id="xdx_904_edei--EntityInteractiveDataCurrent_c20230401__20230630_zCVcg2hPjpX4"><ix:nonNumeric contextRef="From2023-04-01to2023-06-30" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span>&#160;&#160;
&#9746; No&#160;&#160;&#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221;,
and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 50%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated Filer &#9744;</span></td>
    <td style="width: 50%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated Filer &#9744;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--EntityFilerCategory_c20230401__20230630_zFqhzBeZyi25"><ix:nonNumeric contextRef="From2023-04-01to2023-06-30" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated Filer</ix:nonNumeric></span> &#9746;</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company <span id="xdx_901_edei--EntitySmallBusiness_c20230401__20230630_zezCNNzhJGyj"><ix:nonNumeric contextRef="From2023-04-01to2023-06-30" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company <span id="xdx_902_edei--EntityEmergingGrowthCompany_c20230401__20230630_z1wbSvplhI9j"><ix:nonNumeric contextRef="From2023-04-01to2023-06-30" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to section 13(a) of the Exchange Act. &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; <span id="xdx_90D_edei--EntityShellCompany_c20230401__20230630_zJTr2jhmYyK8"><ix:nonNumeric contextRef="From2023-04-01to2023-06-30" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span> &#9746;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of August 9, 2023, the registrant had outstanding
<span id="xdx_900_edei--EntityCommonStockSharesOutstanding_iI_c20230809_z68B8Sp7tPOj" title="Entity Common Stock, Shares Outstanding"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2023-08-09" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,835,321</ix:nonFraction></span> shares of common stock, $0.001 par value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="q1_002"></span>TABLE OF CONTENTS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART I.</span></td>
    <td style="width: 86%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#q1_003">FINANCIAL INFORMATION</a></span></td>
    <td style="width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 1.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#q1_004">FINANCIAL STATEMENTS</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#q1_005">CONDENSED CONSOLIDATED BALANCE SHEETS AT JUNE 30, 2023 (UNAUDITED) AND MARCH&#160;31, 2023</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#q1_006">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE MONTHS ENDED JUNE 30, 2023 AND 2022 (UNAUDITED)</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#q1_007">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY FOR THE THREE MONTHS ENDED JUNE 30, 2023 AND 2022 (UNAUDITED)</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#q1_008">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE THREE MONTHS ENDED JUNE 30, 2023 AND 2022 (UNAUDITED)</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#q1_009">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 2.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#q1_010">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></td>
    <td style="text-align: center">17</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 3.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#q1_011">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></td>
    <td style="text-align: center">22</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 4.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#q1_012">CONTROLS AND PROCEDURES</a></span></td>
    <td style="text-align: center">22</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART II.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#q1_013">OTHER INFORMATION</a></span></td>
    <td style="text-align: center">23</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 1.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#q1_014">LEGAL PROCEEDINGS</a></span></td>
    <td style="text-align: center">23</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 1A.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#q1_015">RISK FACTORS</a></span></td>
    <td style="text-align: center">23</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 2.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#q1_016">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</a></span></td>
    <td style="text-align: center">24</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 3.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#q1_017">DEFAULTS UPON SENIOR SECURITIES</a></span></td>
    <td style="text-align: center">24</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 4.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#q1_018">MINE SAFETY DISCLOSURES</a></span></td>
    <td style="text-align: center">24</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 5.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#q1_019">OTHER INFORMATION</a></span></td>
    <td style="text-align: center">24</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 6.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#q1_020">EXHIBITS</a></span></td>
    <td style="text-align: center">25</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#q1_021">SIGNATURES</a></span></td>
    <td style="text-align: center">26</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CAUTIONARY NOTICE REGARDING FORWARD LOOKING STATEMENTS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Quarterly Report on Form 10-Q, or Quarterly Report, contains &#8220;forward-looking
statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, or Securities Act, and Section 21E of the
Securities Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the safe harbor created by those sections.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may, in some cases, use words such as &#8220;anticipate,&#8221;
&#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221;
&#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or
the negative of these terms, and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking
statements. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements
and are based upon our current expectations, beliefs, estimates and projections, and various assumptions, many of which, by their nature,
are inherently uncertain and beyond our control. Such statements, include, but are not limited to, statements contained in this Quarterly
Report relating to our business, business strategy, products and services we may offer in the future, the timing and results of future
clinical trials, and capital outlook, successful completion of our clinical trials, our ability to raise additional capital, our ability
to maintain our Nasdaq listing, U.S. Food and Drug Administration, or FDA, approval of our products candidates, our ability to comply
with changing government regulations, patent protection of our proprietary technology, product liability exposure, uncertainty of market
acceptance, competition, technological change, and other risk factors detailed herein and in other of our filings with the Securities
and Exchange Commission, or the SEC. Forward-looking statements are based on our current expectations and assumptions regarding our business,
the economy and other future conditions. Because forward looking statements relate to the future, they are subject to inherent uncertainties,
risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by
the forward-looking statements. They are neither statement of historical fact nor guarantees of assurance of future performance. We caution
you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ
materially from those in the forward looking statements include, but are not limited to, a decline in general economic conditions nationally
and internationally, the ability to protect our intellectual property rights, competition from other providers and products, risks in
product development, inability to raise capital to fund continuing operations, changes in government regulation, and other factors (including
the risks contained in Item 1A of our most recent Annual Report on Form 10-K under the heading &#8220;Risk Factors&#8221;) relating to
our industry, our operations and results of operations and any businesses that may be acquired by us. Should one or more of these risks
or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those
anticipated, believed, estimated, expected, intended or planned.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Factors or events that could cause our actual results to differ may
emerge from time to time, and it is not possible for us to predict all of them, nor can we assess the impact of all factors on our business
or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any
forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these forward-looking statements.
We cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, we undertake
no obligation to and do not intend to update any of the forward-looking statements to conform these statements to actual results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="q1_003"></span>PART I. FINANCIAL INFORMATION</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="q1_004"></span>ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AETHLON MEDICAL, INC. AND SUBSIDIARY</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="q1_005"></span>CONDENSED CONSOLIDATED BALANCE SHEETS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_111_zAqjCt9lcqe6" summary="xdx: Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_491_20230630" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_497_20230331" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, <br /> 2023</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">March 31, <br /> 2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AssetsAbstract_iB_zCAKtvPEEt9h" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AssetsCurrentAbstract_i01B_zWks5bOSIjCl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--Cash_i02I_maCz22E_zooo2rFBXoGl" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; width: 66%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,897,734</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,532,943</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maCz22E_zStLopPja3yc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">410,223</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">557,623</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AssetsCurrent_i02TI_mtCz22E_maCzbgw_zlCaUoUhpSu3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; text-align: left">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,307,957</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,090,566</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maCzbgw_z84XS1Uazbid" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,284,200</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,144,004</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maCzbgw_zxQm4L4ATym" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Right-of-use lease asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,086,108</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,151,909</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsNet_i01I_maCzbgw_zcfiRunYgic9" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Patents, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,513</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,650</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--RestrictedCash_i01I_maCzbgw_z5MEpgH7TKrf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,506</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,506</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DepositsAssetsNoncurrent_i01I_maCzbgw_zyZf210IMSPg" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt">Deposits</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepositsAssetsNoncurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,305</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepositsAssetsNoncurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,305</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--Assets_i01TI_mtCzbgw_zB6hEm6yFsme" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,800,589</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,508,940</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesCurrentAbstract_i01B_zYq7GbZNrra3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AccountsPayableCurrent_i02I_maCznLz_zyaC96LqX9yk" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">844,536</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">432,890</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--DueToRelatedParties_i02I_maCznLz_z4sjHL5Keq36" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Due to related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="aemd:DueToRelatedParties" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">191,314</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="aemd:DueToRelatedParties" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">214,221</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maCznLz_zP2RNNlXueW2" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Lease liability, current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">274,520</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">269,386</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherLiabilitiesCurrent_i02I_maCznLz_zvwwEoE5LeR1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other current liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">511,377</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">588,592</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesCurrent_i02TI_mtCznLz_maCzb9E_znq8XcGYTlR" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; text-align: left">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,821,747</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,505,089</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_maCzb9E_zHyvZFfHMllb" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Lease liability, less current portion</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">869,945</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">939,642</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--Liabilities_i02TI_mtCzb9E_maCzV2n_maLASEzHxZ_zEkeeeMVj3Rl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,691,692</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,444,731</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--StockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CommonStockValue_i01I_pp0p0_maSEIPAzug8_zMGSys7g9JE" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 20pt">Common stock, par value $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_c20230630_pdd" title="Common stock par value (in dollars per share)"><span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_c20230331_pdd" title="Common stock par value (in dollars per share)"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> per share; <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_c20230630_pdd" title="Common stock shares authorized"><span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_c20230331_pdd" title="Common stock shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized as of June 30, 2023 and March 31, 2023; <span id="xdx_905_eus-gaap--CommonStockSharesIssued_c20230630_pdd" title="Common stock issued"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_c20230630_pdd" title="Common stock outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,835,321</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_907_eus-gaap--CommonStockSharesIssued_c20230331_pdd" title="Common stock issued"><span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_c20230331_pdd" title="Common stock outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">22,992,466</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as of June 30, 2023 and March 31, 2023, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,837</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">22,994</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AdditionalPaidInCapital_i01I_maCz37f_maSEIPAzug8_z2L452Fl9yWj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">158,731,929</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">157,405,911</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i01I_maSEIPAzug8_zznnCkSZZgbb" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Accumulated other comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,135</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,141</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_maSEIPAzug8_z6sLeE3ZSjvl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Accumulated deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">145,640,734</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">142,358,555</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--StockholdersEquity_i01TI_pp0p0_mtSEIPAzug8_maLASEzHxZ_zY0qhsp68nHi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total stockholders&#8217; equity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,108,897</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,064,209</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_pp0p0_mtLASEzHxZ_z5RmWcVtVH4b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders&#8217; equity</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,800,589</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">17,508,940</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AETHLON MEDICAL, INC. AND SUBSIDIARY</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="q1_006"></span>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the Three Month Periods Ended June 30, 2023
and 2022</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_305_113_zekvk3QoAlCc" summary="xdx: Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_499_20230401_20230630" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49F_20220401__20220630_zHAQwILMXPxa" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Three Months <br /> Ended <br /> June 30, <br /> 2023</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Three Months <br /> Ended <br /> June 30, <br /> 2022</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingExpensesAbstract_iB_zSOgNUR9CJKj" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">OPERATING EXPENSES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ProfessionalFees_i01_maCzhGK_zSpnl2XzKX2l" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; width: 66%; text-align: left">Professional fees</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">976,638</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">844,028</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LaborAndRelatedExpense_i01_maCzhGK_zA7dCRjLOB2g" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Payroll and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LaborAndRelatedExpense" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,123,239</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LaborAndRelatedExpense" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,029,686</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--GeneralAndAdministrativeExpense_i01_maCzhGK_zQCdK1l1oA3i" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,308,283</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,032,367</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingExpenses_i01T_mtCzhGK_msCzPdT_z8d3FKtZXowa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,408,160</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,906,081</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingIncomeLoss_i01T_mtCzPdT_maCzHN9_zMLwPpI4ntHe" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">OPERATING LOSS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,408,160</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,906,081</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NoninterestIncomeOtherAbstract_iB_zr9nnJQLemz5" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">OTHER INCOME</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--InterestAndOtherIncome_d0_maCzHN9_zHxQKsPidKae" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Interest income</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InterestAndOtherIncome" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,981</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InterestAndOtherIncome" contextRef="From2022-04-012022-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProfitLoss_iT_mtCzHN9_maCzbFG_zLcEIVPEIR1g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">NET LOSS</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,282,179</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,906,081</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_d0_msCzbFG_zmA8R7KguR3e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">LOSS ATTRIBUTABLE TO NONCONTROLLING INTERESTS</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2023-04-01to2023-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">413</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_iT_mtCzbFG_msOCILTza5t_zCTzr8sFkPcj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">NET LOSS ATTRIBUTABLE TO AETHLON MEDICAL, INC.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,282,179</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,905,668</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_iN_di0_maOCILTza5t_zVwryxQv8r11" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">OTHER COMPREHENSIVE LOSS</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">994</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" contextRef="From2022-04-012022-06-30" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherComprehensiveIncomeLossTax_iN_di_mtOCILTza5t_zvFxjaeC4Kid" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">COMPREHENSIVE LOSS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,283,173</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,905,668</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Basic and diluted net loss per share attributable to common stockholders</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--EarningsPerShareBasic_c20230401__20230630_pdd" title="Basic loss per share"><span id="xdx_902_eus-gaap--EarningsPerShareDiluted_c20230401__20230630_zEcNlt0N0oA3" title="Diluted loss per share">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.14</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--EarningsPerShareBasic_c20220401__20220630_zTkywiOIsVTa" title="Basic loss per share"><span id="xdx_909_eus-gaap--EarningsPerShareDiluted_c20220401__20220630_zQG39RRy2888" title="Diluted loss per share">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.19</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted average number of common shares outstanding &#8211; basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230401__20230630_zVPKZ4z7sDpb" title="Weighted average number of common shares outstanding basic"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230401__20230630_zBK5P918zPX6" title="Weighted average number of common shares outstanding diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,314,759</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220401__20220630_zzujz16Rwpk3" title="Weighted average number of common shares outstanding basic"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220401__20220630_zVbmB65NH894" title="Weighted average number of common shares outstanding diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,486,621</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AETHLON MEDICAL, INC. AND SUBSIDIARY</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="q1_007"></span>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217;
EQUITY</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the Three Months Ended June 30, 2023 and 2022</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_114_zMGUH9oWQsh5" summary="xdx: Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; EQUITY (Unaudited)" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zhHGTTxp7HCc" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zDfUZHdWjnud" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_z4okwJ9gu5Ub" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zz92Ck6mjlpd" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--NoncontrollingInterestMember_zsbYthKAz2pd" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" id="xdx_4B4_zvWBalKzLxX7" style="text-align: center; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">ATTRIBUTABLE TO AETHLON MEDICAL, INC.</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">COMMON STOCK</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">ADDITIONAL <br /> PAID IN</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">ACCUMULATED</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">ACCUMULATED <br /> COMPREHENSIVE</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">NON-<br /> CONTROLLING</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">TOTAL</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">SHARES</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">AMOUNT</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">CAPITAL</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">DEFICIT</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">LOSS</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">INTERESTS</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">EQUITY</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_43A_c20230401__20230630_eus-gaap--StockholdersEquity_iS_zDtK2WZbgOb9" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -5pt; padding-left: 5pt; width: 30%">BALANCE - MARCH 31, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zu6NIMYQ6YHc" title="Beginning balance, shares" style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">22,992,466</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,994</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">157,405,911</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">142,358,555</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,141</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0199">&#8211;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,064,209</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zB5kb3xlO3uc" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -5pt; padding-left: 5pt">Issuances of common stock for cash under at the market program</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zusQM9JZv2xa" title="Issuances of common stock for cash under at the market program, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,778,901</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,779</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,084,340</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0206">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0207">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0208">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,086,119</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExercise_zfQWAfNPEBN4" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -5pt; padding-left: 5pt">Issuance of common shares upon vesting of restricted stock units and net stock option exercises</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExerciseShares_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYM4qXio8fU6" title="Issuance of common shares upon vesting of restricted stock units and net stock option exercise, shares" style="text-align: right"><ix:nonFraction name="aemd:IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExerciseShares" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">63,954</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="aemd:IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExercise" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="aemd:IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExercise" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,436</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0215">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0216">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0217">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="aemd:IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExercise" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,372</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zn7IlxuY2uNf" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -5pt; padding-left: 5pt">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0222">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,114</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0224">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0225">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0226">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,114</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ProfitLoss_ze6rlaj5f2Qg" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -5pt; padding-left: 5pt">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0229">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0230">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,282,179</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0232">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0233">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,282,179</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherComprehensiveIncomeLossNetOfTax_iN_di_z92GFIQjW3Vf" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -5pt; padding-left: 5pt">Other comprehensive loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0236">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0237">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0238">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">994</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0240">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">994</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43F_c20230401__20230630_eus-gaap--StockholdersEquity_iE_z8HV2FuxQDAg" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -5pt; padding-left: 5pt">BALANCE &#8211; JUNE 30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iE_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvYluwfHXSY7" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,835,321</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,837</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">158,731,929</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">145,640,734</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,135</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0247">&#8211;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,108,897</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_438_c20220401__20220630_eus-gaap--StockholdersEquity_iS_zte98qGNnytc" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -5pt; padding-left: 5pt">BALANCE - MARCH 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvairzICa0w7" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,419,163</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,421</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">147,446,868</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">130,329,181</ix:nonFraction></td><td style="text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0255">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">141,708</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,991,400</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueNewIssues_z8NC1mpQCr7c" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -5pt; padding-left: 5pt">Issuances of common stock for cash under at the market program</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSRIbbDqqp7e" title="Issuances of common stock for cash under at the market program, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">574,560</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">575</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">618,867</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0263">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0264">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0265">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">619,442</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zEDG1ZnbinCg" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -5pt; padding-left: 5pt">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0270">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">215,437</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0272">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0273">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0274">&#8211;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">215,437</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ProfitLoss_zyKC0338diZ5" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -5pt; padding-left: 5pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0277">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0278">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,905,668</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0280">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-04-012022-06-30_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">413</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,906,081</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_432_c20220401__20220630_eus-gaap--StockholdersEquity_iE_zQ7uHCIkEbO" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -5pt; padding-left: 5pt">BALANCE &#8211; JUNE 30, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iE_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzkpz5uhxQw5" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,993,723</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,996</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,281,172</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">133,234,849</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0287">&#8211;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">142,121</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,920,198</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AETHLON MEDICAL, INC. AND SUBSIDIARY</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="q1_008"></span>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the Three Months Ended June 30, 2023 and 2022</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</p>

<table cellpadding="0" cellspacing="0" id="xdx_308_112_zA6HUraIKw02" summary="xdx: Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_495_20230401__20230630_zQSdEQpcOgv9" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_499_20220401__20220630_zYSpnGwqpbRa" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Three months <br /> Ended <br /> June 30, 2023</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Three months <br /> Ended <br /> June 30, 2022</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zFzhuQE7Unn5" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Cash flows used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ProfitLoss_i01_maCz0OW_zgFs8MJURuP9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 66%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,282,179</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,906,081</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zAJ480hX9loa" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DepreciationDepletionAndAmortization_i02_maCz0OW_zypxwx4P0O53" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,325</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,650</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ShareBasedCompensation_i02_maCz0OW_z7WJwNZdSwqh" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,114</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">215,437</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--AccretionOfRightofuseLeaseAsset_i02N_di_msCz0OW_z1fHxnfgKAK7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accretion of right-of-use lease asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="aemd:AccretionOfRightofuseLeaseAsset" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,238</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="aemd:AccretionOfRightofuseLeaseAsset" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,800</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_i01B_z9xNtJmckQK1" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i02N_di_msCz0OW_zkaWP64lWFH4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">146,409</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">99,336</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncreaseDecreaseInAccountsReceivable_i02N_di0_msCz0OW_zcuNQ8DACKWa" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; text-align: left">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2023-04-01to2023-06-30" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,116</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i02_maCz0OW_zhRPMAm9FDz8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Accounts payable and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">334,613</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">310,327</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInDeferredRevenue_i02_d0_maCz0OW_znpHBYm19Gs3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; text-align: left">Deferred revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="From2023-04-01to2023-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">114,849</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInAccountsPayableRelatedParties_i02_maCz0OW_zlnzNrGQlow1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Due to related parties</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">22,907</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,303</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i02T_mtCz0OW_maCzNRt_zp8WsvIne6b9" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Net cash used in operating activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,482,387</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,728,917</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zsrxjGfUoFjh" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Cash flows used in investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msCzCH0_zpHM0cXWRSGg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Purchases of property and equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">230,383</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,169</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtCzCH0_maCzNRt_zp8Tre7GF11e" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Net cash used in investing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">230,383</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">41,169</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_z9QDtRK56VS5" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Cash flows provided by financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maCzUKO_zO7wMOYuGbad" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from the issuance of common stock, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,086,119</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">619,442</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PaymentsRelatedToTaxWithholdingForShareBasedCompensation_i01N_di0_msCzUKO_zT5LI44SHlfj" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: left; padding-bottom: 1pt">Tax withholding payments or tax equivalent payments for net share settlement of restricted stock units and net stock option expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,372</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2022-04-012022-06-30" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_mtCzUKO_maCzNRt_z6RgX4QYW8T1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net cash provided by financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,077,747</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">619,442</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d0_maCzNRt_zpaISUzNQhp9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Effect of exchange rate on changes on cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">186</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="From2022-04-012022-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_pp0p0_mtCzNRt_zXSa3Qu4TdVc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net decrease in cash and restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,635,209</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,150,644</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_zJMpRdGWneo7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Cash and restricted cash at beginning of period</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,620,449</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,159,925</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_zTyawKtnf2D" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Cash and restricted cash at end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,985,240</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,009,281</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--SupplementalCashFlowInformationAbstract_iB_ziapHZLbVcxa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Supplemental disclosures of cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_zaudZ9FDflOl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Supplemental disclosures of non-cash investing and financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise_i01_d0_zZ88faINWQL2" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Par value of shares issued for vested restricted stock units and net stock option exercise</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="aemd:ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="aemd:ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise" contextRef="From2022-04-012022-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--RestrictedCashAndCashEquivalentsAbstract_i01B_zCA7zK1rAJL8" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: left">Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02E_zw8Qwmz4WQhe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,897,734</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,921,775</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RestrictedCash_i02E_zw8O0llyRfzj" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Restricted cash</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,506</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,506</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_i01E_zUEg1pNLolt3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Cash and restricted cash</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,985,240</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,009,281</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 7 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AETHLON MEDICAL, INC. AND SUBSIDIARY</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="q1_009"></span>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">June 30, 2023</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<ix:nonNumeric contextRef="From2023-04-01to2023-06-30" escape="true" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"><p id="xdx_803_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zqEBwHCHaTPa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1. <span id="xdx_821_zAHfOn9GSmqd">NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Aethlon Medical, Inc., or Aethlon, the Company,
we or us, is a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases. The
Aethlon Hemopurifier is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. In
cancer, the Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression, seed
the spread of metastasis and inhibit the benefit of leading cancer therapies. The U.S. Food and Drug Administration, or FDA, has designated
the Hemopurifier as a &#8220;Breakthrough Device&#8221; for two independent indications:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the treatment of life-threatening viruses that are not addressed with approved therapies.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe the Hemopurifier can be a substantial
advance in the treatment of patients with advanced and metastatic cancer through the clearance of exosomes that promote the growth and
spread of tumors through multiple mechanisms. We are currently working with our new contract research organization, or CRO, on preparations
to conduct a clinical trial in Australia in patients with solid tumors, including head and neck cancer, gastrointestinal cancers and other
cancers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2023, we entered into an agreement
with North American Science Associates, LLC, or NAMSA, a world leading MedTech CRO offering global end-to-end development services, to
oversee our clinical trials investigating the Hemopurifier for oncology indications. Pursuant to the agreement, NAMSA will manage our
clinical trials of the Hemopurifier for patients in the United States and Australia with various types of cancer tumors. We anticipate
that the initial clinical trials will begin in Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also believe the Hemopurifier can be part of
the broad-spectrum treatment of life-threatening highly glycosylated, or carbohydrate coated, viruses that are not addressed with an already
approved treatment. In small-scale or early feasibility human studies, the Hemopurifier has been used in the past to treat individuals
infected with human immunodeficiency virus, or HIV, hepatitis-C and Ebola.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, <i>in vitro,</i> the Hemopurifier
has been demonstrated to capture Zika virus, Lassa virus, MERS-CoV, cytomegalovirus, Epstein-Barr virus, Herpes simplex virus, Chikungunya
virus, Dengue virus, West Nile virus, smallpox-related viruses, H1N1 swine flu virus, H5N1 bird flu virus, Monkeypox virus and the reconstructed
Spanish flu virus of 1918. In several cases, these studies were conducted in collaboration with leading government or non-government research
institutes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 17, 2020, the FDA approved a supplement
to our open Investigational Device Exemption, or IDE, for the Hemopurifier in viral disease to allow for the testing of the Hemopurifier
in patients with SARS-CoV-2/COVID-19, or COVID-19, in a New Feasibility Study. <span style="background-color: white">That study was designed
to enroll up to 40 subjects at up to 20 centers in the United States. Subjects were to have established laboratory diagnosis of COVID-19,
be admitted to an intensive care unit, or ICU, and have acute lung injury and/or severe or life-threatening disease, among other criteria.
Endpoints for this study, in addition to safety, included reduction in circulating virus as well as clinical outcomes (NCT # 04595903).
</span>In June 2022, the first patient in this study was enrolled and completed the Hemopurifier treatment phase of the protocol. Due
to lack of COVID-19 patients in the ICUs of our trial sites, we terminated this study in 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23F_zZDietQFGsAk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_236_zTysOBKHJqKl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_238_zGwpDHMdiq1f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 8 -->
    <div id="xdx_236_zVyJUxB50e9g" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_231_zt2oLYWZHhU8" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_236_zhjtywDXP4Kf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under Single Patient Emergency Use regulations,
the Company has treated two patients with COVID-19 with the Hemopurifier, in addition to the COVID-19 patient treated with our Hemopurifier
in our COVID-19 clinical trial discussed above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently are experiencing a disruption in
our Hemopurifier supply, as our existing supply of Hemopurifiers expired on September 30, 2022 and, as previously disclosed, we are dependent
on FDA approval of qualified suppliers to manufacture our Hemopurifier. Our intended transition to a new supplier for galanthus nivalis
agglutinin, or GNA, a component of our Hemopurifier, is delayed as we work with the FDA for approval of our supplement to our IDE, which
is required to make this manufacturing change.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2022, we launched a wholly owned subsidiary
in Australia, formed to conduct clinical research, seek regulatory approval and commercialize our Hemopurifier in that country. The subsidiary
will initially focus on the oncology trials in Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also obtained ethics review board,
or ERB approval, from and entered into a clinical trial agreement with Medanta Medicity Hospital, a multi-specialty hospital in Delhi
NCR, India, for a COVID-19 clinical trial at that location. One patient has completed participation in the Indian COVID-19 study. The
relevant authorities in India have accepted the use of our Hemopurifiers made with the GNA from our new supplier.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2023, we also received ERB approval from
the Maulana Azad Medical College, or MAMC, for a second site for our clinical trial in India to treat severe COVID-19. MAMC was established
in 1958 and is located in New Delhi, India. MMAC is affiliated with the University of Delhi and is operated by the Delhi government.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also recently announced that we also have begun
investigating the use of our Hemopurifier in the organ transplant setting. Our objective is to confirm that the Hemopurifier, in our translational
studies, when incorporated into a machine perfusion organ preservation circuit, can remove harmful viruses and exosomes from recovered
organs. We initially are focused on recovered kidneys, in a research collaboration with 34 Lives, PBC. We have previously demonstrated
the removal of multiple viruses and exosomes from buffer solutions, in vitro, utilizing a scaled-down version of our Hemopurifier. This
process potentially may reduce complications following transplantation of the recovered organ, which can include viral infection, delayed
graft function and rejection. We believe this new approach could be additive to existing technologies that currently are in place to increase
the number of viable kidneys for transplant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Successful outcomes of human trials will also
be required by the regulatory agencies of certain foreign countries where we plan to market and sell the Hemopurifier. Some of our patents
may expire before FDA approval or approval in a foreign country, if any, is obtained. However, we believe that certain patent applications
and/or other patents issued to us more recently will help protect the proprietary nature of our Hemopurifier treatment technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the foregoing, we are monitoring
closely the impact of inflation, recent bank failures and the war in Ukraine on our business. Given the level of uncertainty regarding
the duration and impact of these events on capital markets and the U.S. economy, we are unable to assess the impact on our timelines and
future access to capital. The full extent to which inflation, recent bank failures and the war in Ukraine will impact our business, results
of operations, financial condition, clinical trials and preclinical research will depend on future developments, as well as the economic
impact on national and international markets that are highly uncertain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We incorporated in Nevada on March 10, 1999. Our
executive offices are located at 11555 Sorrento Valley Road, Suite 203, San Diego, California 92121. Our telephone number is (619) 941-0360.
Our website address is www.aethlonmedical.com.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common stock is listed on the Nasdaq Capital Market under the symbol
&#8220;AEMD.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:exclude><p id="xdx_230_z8aWlIjLGRaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_239_z37u3mYZAVJ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_237_zmHDCJb1fyeg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 9 -->
    <div id="xdx_23F_zrWKurO8dZj3" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23F_zmtGms7Rlg44" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_zgfeuNukODuc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended June 30, 2023, there
were no changes to our significant accounting policies as described in our Annual Report on Form 10-K for the fiscal year ended March
31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-04-01to2023-06-30" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_84D_eus-gaap--UseOfEstimates_z5zSVHVKBcxd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_866_zhHe5IOoqnyh">Basis of Presentation and Use of Estimates</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited condensed consolidated
financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for
interim financial information and with the instructions to Form 10-Q and Article 8 of the Securities and Exchange Commission, or SEC,
Regulation S-X. Accordingly, they should be read in conjunction with the audited financial statements and notes thereto for the fiscal
year ended March 31, 2023, included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on June 28, 2023. The accompanying
unaudited condensed consolidated financial statements include the accounts of Aethlon Medical, Inc. and its wholly owned subsidiary, Aethlon
Medical Australia Pty Ltd, as well as its previously majority-owned subsidiary, Exosome Sciences, Inc., which dissolved in September 2022.
All significant inter-company transactions and balances have been eliminated in consolidation. The unaudited condensed consolidated financial
statements contain all normal recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the
condensed consolidated financial statements as of and for the three months ended June 30, 2023, and the condensed consolidated statement
of cash flows for the three months ended June 30, 2023. Estimates were made relating to useful lives of fixed assets, impairment of assets,
share-based compensation expense and accruals for clinical trial and research and development expenses. Actual results could differ materially
from those estimates. The accompanying condensed consolidated balance sheet at March 31, 2023 has been derived from the audited consolidated
balance sheet at March 31, 2023, contained in the above referenced 10-K. The results of operations for the three months ended June 30,
2023 are not necessarily indicative of the results to be expected for the full year or any future interim periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-04-01to2023-06-30" escape="true" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription"><p id="xdx_844_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zPYjSofJx4X2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_867_zQFOIPS2Bxpk">Reclassifications</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain prior year balances within the unaudited
condensed consolidated financial statements have been reclassified to conform to the current year presentation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-04-01to2023-06-30" escape="true" name="aemd:LiquidityAndGoingConcernPolicyTextBlock"><p id="xdx_845_ecustom--LiquidityAndGoingConcernPolicyTextBlock_zSKGnONx7Zhi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_864_zldIEJHyTHNe">LIQUIDITY AND GOING CONCERN</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management expects existing cash as of June 30,
2023 to be sufficient to fund the Company&#8217;s operations for at least twelve months from the issuance date of these condensed consolidated
financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-04-01to2023-06-30" escape="true" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"><p id="xdx_84F_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zB8s2iKOa4sl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_86D_zFHX4mGOcFc">Restricted Cash</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To comply with the terms of our laboratory and
office lease and our lease for our manufacturing space, see Note 10, we caused our bank to issue two standby letters of credit, or L/Cs,
in the aggregate amount of $<span id="xdx_90B_eus-gaap--SecurityDeposit_c20220630__us-gaap--BalanceSheetLocationAxis__custom--RestrictedCashMember_pp0p0" title="Security deposit"><ix:nonFraction name="us-gaap:SecurityDeposit" contextRef="AsOf2022-06-30_custom_RestrictedCashMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">87,506</ix:nonFraction></span> in favor of the landlord. The L/Cs are in lieu of a security deposit. In order to support the L/Cs,
we agreed to have our bank withdraw $87,506 from our operating accounts and to place that amount in a restricted certificate of deposit.
We have classified that amount as restricted cash, a long-term asset, on our balance sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2023-04-01to2023-06-30" escape="true" name="us-gaap:EarningsPerShareTextBlock"><p id="xdx_805_eus-gaap--EarningsPerShareTextBlock_zQ8ymf3531b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2. <span id="xdx_825_zz9TCCGCHjE6">LOSS PER COMMON SHARE</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic loss per share is computed by dividing net
loss by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is computed
similar to basic loss per share, except that the denominator is increased to include the number of additional dilutive common shares that
would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive. Since we had net
losses for all periods presented, basic and diluted loss per share are the same, and additional potential common shares have been excluded,
as their effect would be antidilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2023 and 2022, an aggregate of
<span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230401__20230630_z8c1hk8ml2le" title="Antidilutive shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,291,234</ix:nonFraction></span> and <span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220401__20220630_zSjr9Inh5QU1" title="Antidilutive shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,227,286</ix:nonFraction></span> potential common shares, respectively, consisting of shares underlying outstanding stock options, warrants, and
restricted stock units were excluded, as their inclusion would be antidilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:exclude><p id="xdx_230_z9wu10wsul7j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_230_zoCEb655cunh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23F_zHEBqhJTiksa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 10 -->
    <div id="xdx_231_zvmF8hBKFZp1" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_236_zLKkifFA2jm1" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_233_zPP9n8Gtq8qc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-04-01to2023-06-30" escape="true" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"><p id="xdx_80F_eus-gaap--ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_zJkQvXRuWjnf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3. <span id="xdx_82A_zJdffVmSIG2i">RESEARCH AND DEVELOPMENT EXPENSES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our research and development costs are expensed
as incurred. We incurred research and development expenses during the three month periods ended June 30, 2023 and 2022, which are included
in various operating expense line items in the accompanying condensed consolidated statements of operations. Our research and development
expenses in those periods were as follows:</p>

<ix:nonNumeric contextRef="From2023-04-01to2023-06-30" escape="true" name="us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_ziCjsKHdpPu6" summary="xdx: Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;<span id="xdx_8B6_zxOMOTo6NeUl" style="display: none">Research and development expenses</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">June 30,</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">June 30,</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; width: 66%; text-align: center">&#160;</td><td style="text-align: center; width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: center">2023</td><td style="width: 1%; padding-bottom: 1pt; text-align: center">&#160;</td><td style="text-align: center; width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: center">2022</td><td style="width: 1%; padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three months ended</span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230401__20230630_zCmEpxkSGW01" title="Research and development expense" style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">678,922</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220401__20220630_zhhYNp2g0ZZg" title="Research and development expense" style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">858,347</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p id="xdx_8A4_zxWbjXIzjpb4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-04-01to2023-06-30" escape="true" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"><p id="xdx_802_eus-gaap--NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_zrEKyKFsn9C1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4. <span style="text-transform: uppercase"><span id="xdx_82B_zB8RcpZFh4m6">RECENT ACCOUNTING PRONOUNCEMENTS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-04-01to2023-06-30" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_80B_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zS0eteueYr6k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5. <span id="xdx_820_zKowBRU3e1Jf">EQUITY TRANSACTIONS IN THE THREE MONTHS ENDED JUNE 30, 2023</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>2022 At The Market Offering Agreement with H.C. Wainwright &amp;
Co., LLC</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 24, 2022, we entered into an At The Market
Offering Agreement, or the 2022 ATM Agreement, with H.C. Wainwright &amp; Co., LLC, or Wainwright, which established an at-the-market
equity program pursuant to which we may offer and sell shares of our common stock from time to time as set forth in the 2022 ATM Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The offering was registered under the Securities
Act of 1933, as amended, or the Securities Act, pursuant to our shelf registration statement on Form S-3 (Registration Statement No. 333-259909),
as previously filed with the SEC and declared effective on October 21, 2021. We filed a prospectus supplement, dated March 24, 2022, with
the SEC that provides for the sale of shares of our common stock having an aggregate offering price of up to $15,000,000, or the 2022
ATM Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the 2022 ATM Agreement, Wainwright may sell
the 2022 ATM Shares by any method permitted by law and deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415 promulgated
under the Securities Act, including sales made directly on the Nasdaq Capital Market, or on any other existing trading market for the
2022 ATM Shares. In addition, under the 2022 ATM Agreement, Wainwright may sell the 2022 ATM Shares in privately negotiated transactions
with our consent and in block transactions. Under certain circumstances, we may instruct Wainwright not to sell the 2022 ATM Shares if
the sales cannot be effected at or above the price designated by us from time to time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are not obligated to make any sales of the
2022 ATM Shares under the 2022 ATM Agreement. The offering of the 2022 ATM Shares pursuant to the 2022 ATM Agreement will terminate upon
the termination of the 2022 ATM Agreement by Wainwright or us, as permitted therein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2022 ATM Agreement contains customary representations,
warranties and agreements by us, and customary indemnification and contribution rights and obligations of the parties. We agreed to pay
Wainwright a placement fee of up to 3.0% of the aggregate gross proceeds from each sale of the 2022 ATM Shares. We also agreed to reimburse
Wainwright for certain specified expenses in connection with entering into the 2022 ATM Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended June 30, 2023, we
raised net proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20230401__20230630__us-gaap--SecuritiesFinancingTransactionAxis__custom--OfferingAgreementMember_pp0p0" title="Proceeds from issuance of equity"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2023-04-012023-06-30_custom_OfferingAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,086,119</ix:nonFraction></span>, net of $<span id="xdx_90C_eus-gaap--PaymentsForCommissions_c20230401__20230630__srt--CounterpartyNameAxis__custom--HcWainwrightMember__us-gaap--SecuritiesFinancingTransactionAxis__custom--OfferingAgreementMember_pp0p0" title="Payment of commissions"><ix:nonFraction name="us-gaap:PaymentsForCommissions" contextRef="From2023-04-012023-06-30_custom_HcWainwrightMember_custom_OfferingAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">27,999</ix:nonFraction></span> in commissions to Wainwright and $<span id="xdx_90B_eus-gaap--PaymentsOfStockIssuanceCosts_c20230401__20230630__us-gaap--SecuritiesFinancingTransactionAxis__custom--OfferingAgreementMember__us-gaap--TransactionTypeAxis__custom--OtherOfferingExpenseMember_pp0p0" title="Payment of stock issuance costs"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2023-04-012023-06-30_custom_OfferingAgreementMember_custom_OtherOfferingExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,846</ix:nonFraction></span> in other offering expense, through the sale
of, <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230401__20230630__us-gaap--SecuritiesFinancingTransactionAxis__custom--OfferingAgreementMember_pdd" title="Stock issued new, shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-04-012023-06-30_custom_OfferingAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,778,901</ix:nonFraction></span> shares of our common stock at an average price of $0.61 per share under the 2022 ATM Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_237_zsMAL8HTh6V6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_zMnr2OiHNKE7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23D_zRQPKdZNtN6j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 11 -->
    <div id="xdx_236_zNvgCsXpqyok" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_230_zTwTt8rAuDv6" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23C_z3gGTUaiTg24" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Restricted Stock Unit Grants </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 28, 2023, the Board approved, pursuant
to the terms of the Amended and Restated Non-Employee Director Compensation Policy, or the Director Compensation Policy, the grant of
the annual restricted stock units, or RSUs, under the Director Compensation Policy to each of the three non-employee directors of the
Company then serving on the Board. The Director Compensation Policy provides for a grant of stock options or $50,000 worth of RSUs at
the beginning of each fiscal year for current directors then serving on the Board, and for a grant of stock options or $75,000 worth of
RSUs for a newly elected director, with each RSU priced at the average for the closing prices for the five days preceding and including
the date of grant, or $0.43 per share for the RSUs granted in April 2023. As a result, in April 2023 the three eligible directors each
were granted an RSU in the amount of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230401__20230630__srt--CounterpartyNameAxis__custom--EligibleDirectorsEachMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVypdjt567xe" title="Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2023-04-012023-06-30_custom_EligibleDirectorsEachMember_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">116,279</ix:nonFraction></span> shares under the Company&#8217;s 2020 Equity Incentive Plan, or the 2020 Plan. The RSUs are
subject to vesting in four equal installments, with 25% of the restricted stock units vesting on each of June 30, 2023, September 30,
2023, December 31, 2023, and March 31, 2024, subject in each case to the director&#8217;s Continuous Service (as defined in the 2020 Plan),
through such dates. Vesting will terminate upon the director&#8217;s termination of Continuous Service prior to any vesting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-04-01to2023-06-30" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_80F_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zh4Of6uKfiV6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">6. <span id="xdx_821_zXza0wTgkuxi">RELATED PARTY TRANSACTIONS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended June 30, 2023, we
accrued unpaid fees of $<span id="xdx_90B_ecustom--AccruedDirectorFees_c20230630_pp0p0" title="Accrued director fees"><ix:nonFraction name="aemd:AccruedDirectorFees" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">57,000</ix:nonFraction></span> owed to our non-employee directors. Amounts due to related parties were comprised of the following items:</p>

<ix:nonNumeric contextRef="From2023-04-01to2023-06-30" escape="true" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zfxWkxhgBzxj" summary="xdx: Disclosure -  RELATED PARTY TRANSACTIONS (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;<span id="xdx_8B7_zFQUqfZCc5Ea" style="display: none">Due to related parties</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, <br /> 2023</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">March 31, <br /> 2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Accrued Board fees</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--DueToRelatedPartiesCurrent1_c20230630__us-gaap--RelatedPartyTransactionAxis__custom--AccruedBoardFeesMember_pp0p0" title="Due to related parties" style="width: 13%; text-align: right"><ix:nonFraction name="aemd:DueToRelatedPartiesCurrent1" contextRef="AsOf2023-06-30_custom_AccruedBoardFeesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">57,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--DueToRelatedPartiesCurrent1_iI_pp0p0_c20230331__us-gaap--RelatedPartyTransactionAxis__custom--AccruedBoardFeesMember_z3Zz2UjwkKN6" title="Due to related parties" style="width: 13%; text-align: right"><ix:nonFraction name="aemd:DueToRelatedPartiesCurrent1" contextRef="AsOf2023-03-31_custom_AccruedBoardFeesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">57,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Accrued vacation to all employees</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--DueToRelatedPartiesCurrent1_c20230630__us-gaap--RelatedPartyTransactionAxis__custom--AccruedVacationMember_pp0p0" title="Due to related parties" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="aemd:DueToRelatedPartiesCurrent1" contextRef="AsOf2023-06-30_custom_AccruedVacationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">134,314</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_ecustom--DueToRelatedPartiesCurrent1_iI_pp0p0_c20230331__us-gaap--RelatedPartyTransactionAxis__custom--AccruedVacationMember_zcnZNuBXvfhi" title="Due to related parties" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="aemd:DueToRelatedPartiesCurrent1" contextRef="AsOf2023-03-31_custom_AccruedVacationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">157,221</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total due to related parties</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--DueToRelatedPartiesCurrent1_c20230630_pp0p0" title="Due to related parties" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="aemd:DueToRelatedPartiesCurrent1" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">191,314</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--DueToRelatedPartiesCurrent1_iI_pp0p0_c20230331_zqlhTr7UOLje" title="Due to related parties" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="aemd:DueToRelatedPartiesCurrent1" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">214,221</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p id="xdx_8A5_zrmPlp9dot9a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-04-01to2023-06-30" escape="true" name="us-gaap:OtherLiabilitiesDisclosureTextBlock"><p id="xdx_800_eus-gaap--OtherLiabilitiesDisclosureTextBlock_z3kwzUfWljNb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">7. <span id="xdx_828_z0TAQbGAXDR5">OTHER CURRENT LIABILITIES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other current liabilities were comprised of the following items:</p>

<ix:nonNumeric contextRef="From2023-04-01to2023-06-30" escape="true" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_zXcTSEyQ5Mi1" summary="xdx: Disclosure - OTHER CURRENT LIABILITIES (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><b style="display: none">&#160;<span id="xdx_8BA_zXYdGoNH7Hhc">Schedule of other current liabilities</span></b></td><td>&#160;</td>
    <td colspan="2" id="xdx_496_20230630_zEH6GLdHbBAh" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_494_20230331_zQ957KJvXEmb" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">June 30,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">March 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maOLCzQ3w_zPZRgFpIl6l2" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left; padding-bottom: 1pt">Accrued professional fees</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">511,377</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">588,592</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OtherLiabilitiesCurrent_iTI_pp0p0_mtOLCzQ3w_zOXzui78EuN6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total other current liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">511,377</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">588,592</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p id="xdx_8A1_zs2gpAoUZyNi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:exclude><p id="xdx_237_zMkqTl6YXAo" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_231_z4l8QKuuZ7a9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_237_zPfCdF1eTELb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 12 -->
    <div id="xdx_23E_zxzpZXoBDqRh" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_235_zKHuGlJWSf63" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_239_zoHe86EMnkHb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-04-01to2023-06-30" escape="true" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock"><p id="xdx_801_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zuldErmVJz5e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">8. <span id="xdx_828_zHlX2EKmNST">STOCK COMPENSATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following tables summarize share-based compensation
expenses relating to RSUs and stock options and the effect on basic and diluted loss per common share during the three month periods ended
June 30, 2023 and 2022:</p>

<ix:nonNumeric contextRef="From2023-04-01to2023-06-30" escape="true" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zGurrYfR5HYj" summary="xdx: Disclosure - STOCK COMPENSATION (Details - Stock compensation)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B7_zLlfHkJvLm6b" style="display: none">Schedule of share-based compensation expense</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_492_20230401__20230630_zTPPbrMJoBDk" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_499_20220401__20220630_z9iNGfWe6rri" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, <br /> 2023</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, <br /> 2022</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_zKJQPqFYtrE7" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left; padding-bottom: 1pt">Vesting of stock options and restricted stock units</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,114</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">215,437</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ShareBasedCompensation_z5ejZmZOPirc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,114</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">215,437</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Weighted average number of common shares outstanding &#8211; basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230401__20230630_zPnUc9bvkZo2" title="Weighted Average Number of Shares Outstanding, Basic"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230401__20230630_zpmVNJyN3tn9" title="Weighted Average Number of Shares Outstanding, Diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,314,759</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220401__20220630_zzXzg3Go3Ia6" title="Weighted Average Number of Shares Outstanding, Basic"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220401__20220630_zCAWDsHqTi2h" title="Weighted Average Number of Shares Outstanding, Diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,486,621</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Basic and diluted loss per common share attributable to stock-based compensation expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20230401__20230630__us-gaap--TransactionTypeAxis__custom--StockBasedCompensationMember_zR6l4AGdErhf" title="Earnings Per Share, Basic"><span id="xdx_905_eus-gaap--EarningsPerShareDiluted_c20230401__20230630__us-gaap--TransactionTypeAxis__custom--StockBasedCompensationMember_zf0SAlcFLh03" title="Earnings Per Share, Diluted">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-04-012023-06-30_custom_StockBasedCompensationMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-04-012023-06-30_custom_StockBasedCompensationMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--EarningsPerShareBasic_c20220401__20220630__us-gaap--TransactionTypeAxis__custom--StockBasedCompensationMember_z6RqknH9NQ8h" title="Earnings Per Share, Basic"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_c20220401__20220630__us-gaap--TransactionTypeAxis__custom--StockBasedCompensationMember_zFYuWmwJwh54" title="Earnings Per Share, Diluted">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-04-012022-06-30_custom_StockBasedCompensationMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-04-012022-06-30_custom_StockBasedCompensationMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_z0m3BW9VrZf2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All of the stock-based compensation expense recorded
during the three months ended June 30, 2023 and 2022, an aggregate of $<span id="xdx_905_eus-gaap--ShareBasedCompensation_pp0p0_c20230401__20230630_zm6msLBzMNAf" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,114</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--ShareBasedCompensation_pp0p0_c20220401__20220630_zTc9NqgLfgMa" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">215,437</ix:nonFraction></span>, respectively, is included in payroll and
related expense in the accompanying condensed consolidated statements of operations. Stock-based compensation expense recorded during
each of the three months ended June 30, 2023 and 2022 represented an impact on basic and diluted loss per common share of $(0.01) in each
period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We review share-based compensation on a quarterly
basis for changes to the estimate of expected award forfeitures based on actual forfeiture experience. The cumulative effect of adjusting
the forfeiture rate for all expense amortization is recognized in the period the forfeiture estimate is changed. The effect of forfeiture
adjustments for the three months ended June 30, 2023 was insignificant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Stock Option Activity</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We did not issue any stock options during the three months ended June
30, 2023 and 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stock options outstanding that have vested as
of June 30, 2023 and stock options that are expected to vest subsequent to June 30, 2023 are as follows:</p>

<ix:nonNumeric contextRef="From2023-04-01to2023-06-30" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_zPxYiqdu59v5" summary="xdx: Disclosure - STOCK COMPENSATION (Details - Options vested and expected to vest)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B4_zlWPl0Lg8kQ8" style="display: none">Schedule of options outstanding that have vested and are expected to vest</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br /> Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br /> Average<br /> Exercise<br /> Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br /> Average<br /> Remaining<br /> Contractual<br /> Term in<br /> Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 55%">Vested</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_znw6ZxLH8uyc" title="Options vested" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2023-04-012023-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">842,610</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z898JzduWEz" title="Weighted average exercise price options vested" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.44</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zi2naYs42RUh" title="Weighted average remaining contractual term options vested"><ix:nonNumeric contextRef="From2023-04-012023-06-30_us-gaap_StockOptionMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">7.68</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Expected to vest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zkYpWV7RMHh5" title="Options expected to vest" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2023-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">860,243</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zG2gi0sDRvi4" title="Weighted average exercise price options expected to vest" style="padding-bottom: 1pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.06</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zHFw2Ra7oCP9" title="Weighted average remaining contractual term options expected to vest"><ix:nonNumeric contextRef="From2023-04-012023-06-30_us-gaap_StockOptionMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">8.24</ix:nonNumeric></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zdDfdmkzR0Lb" title="Total options outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,702,853</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zA99rQN4stca" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<ix:exclude><p id="xdx_23F_zDVe14IJVCQ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_230_z41ChcUpauf3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_237_zaFAcLTfdqx7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 13 -->
    <div id="xdx_234_zXJwpuoUJyXl" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23B_z4piUsNvoxgj" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23C_zlfYhR50iKKb" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23C_zNDtDBJ3bS33" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of stock option activity during the
three months ended June 30, 2023 is presented below:</p>

<ix:nonNumeric contextRef="From2023-04-01to2023-06-30" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" summary="xdx: Disclosure - STOCK COMPENSATION (Details - Option activity)" id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zpeyqAuknZUa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;<span id="xdx_8BF_zRzgQXvZi0ec" style="display: none">Schedule of stock option activity</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Range of<br /> Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br /> Average <br /> Exercise<br /> Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 52%; text-align: left">Stock options outstanding at March 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_z3pOEl44lBc3" title="Stock options Outstanding, beginning balance" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-03-31_us-gaap_OptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,718,253</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.<span id="xdx_90F_ecustom--RangeOfExercisePricesOptionBeginning_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember" title="Range of exercise prices, Option beginning"><ix:nonNumeric contextRef="From2023-04-012023-06-30_us-gaap_OptionMember" name="aemd:RangeOfExercisePricesOptionBeginning">69 - 142.50</ix:nonNumeric></span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_z2JUJH9ay0rd" title="Outstanding, Weighted Average Exercise Price, beginning price" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-03-31_us-gaap_OptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.31</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zgL3fFC96Xa9" title="Stock options exercised" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-04-012023-06-30_us-gaap_OptionMember" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_z2i1Rs0mwySc" title="Exercised, Weighted Average Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2023-04-012023-06-30_us-gaap_OptionMember" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zp0WfYMCMOkj" title="Stock options granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2023-04-012023-06-30_us-gaap_OptionMember" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_905_ecustom--RangeOfExercisePricesOptionGranted_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zvVKIdRqSxCb" title="Range of exercise prices, Option Granted"><span style="-sec-ix-hidden: xdx2ixbrl0538">&#8211;</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zGm19iob5Qua" title="Granted, Weighted Average Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-04-012023-06-30_us-gaap_OptionMember" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Cancelled/Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zE2KTIKrnx1e" title="Stock options cancelled/forfeited" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2023-04-012023-06-30_us-gaap_OptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,400</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_901_ecustom--RangeOfExercisePricesOptionCancelledexpired_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember" title="Range of exercise prices, Option cancelled/expired"><ix:nonNumeric contextRef="From2023-04-012023-06-30_us-gaap_OptionMember" name="aemd:RangeOfExercisePricesOptionCancelledexpired">1.21</ix:nonNumeric></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_z8BkxuQwIyQ5" title="Cancelled/Forfeited, Weighted Average Exercise Price" style="padding-bottom: 1pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2023-04-012023-06-30_us-gaap_OptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.21</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Stock options outstanding at June 30, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zup67D97zlbc" title="Stock options outstanding, ending balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-06-30_us-gaap_OptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,702,853</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.<span id="xdx_903_ecustom--RangeOfExercisePricesOptionEnding_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember" title="Range of exercise prices, Option ending"><ix:nonNumeric contextRef="From2023-04-012023-06-30_us-gaap_OptionMember" name="aemd:RangeOfExercisePricesOptionEnding">69 - 142.50</ix:nonNumeric></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zZFqik4v6IZf" title="Outstanding Weighted Average Exercise Price, ending price" style="padding-bottom: 1pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-06-30_us-gaap_OptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.25</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock options exercisable at June 30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zqsaEtlrvuld" title="Stock options exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2023-06-30_us-gaap_OptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">842,610</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_ecustom--RangeOfExercisePricesOptionExercisable_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember" title="Range of exercise prices, Option exercisable"><ix:nonNumeric contextRef="From2023-04-012023-06-30_us-gaap_OptionMember" name="aemd:RangeOfExercisePricesOptionExercisable">1.28 - 142.50</ix:nonNumeric></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zLuv9sYiaHIh" title="Exercisable, Weighted Average Exercise Price" style="padding-bottom: 2.5pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-06-30_us-gaap_OptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.44</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zx9AOH1eomBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 30, 2023, our outstanding stock options
had no intrinsic value since the closing share price on that date of $<span id="xdx_904_eus-gaap--SharePrice_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zzGmAYmf6dCh" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-06-30_us-gaap_OptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.36</ix:nonFraction></span> per share was below the weighted average exercise price of
our outstanding stock options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At June 30, 2023, there was approximately $<span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pp0p0_c20230630_z3ac1kRDRaLh" title="Unrecognized compensation costs"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,719,000</ix:nonFraction></span>
of unrecognized compensation cost related to share-based payments, which is expected to be recognized over a weighted average period of
<span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230401__20230630_zI2ReLzaQR42" title="Unrecognized compensation cost amortization period"><ix:nonNumeric contextRef="From2023-04-01to2023-06-30" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">1.84</ix:nonNumeric></span> years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-04-01to2023-06-30" escape="true" name="aemd:WarrantsTextBlock"><p id="xdx_80E_ecustom--WarrantsTextBlock_zSByTrxnjJrk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">9. <span id="xdx_82C_z2ZUIz3WD1e5">WARRANTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended June 30, 2023 and
2022, we did not issue any warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of warrant activity during the three
months ended June 30, 2023 is presented below:</p>

<ix:nonNumeric contextRef="From2023-04-01to2023-06-30" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zVXbLadZcZF1" summary="xdx: Disclosure - Warrant (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;<span id="xdx_8BB_za3QfCelP4vb" style="display: none">Schedule of warrant activity</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Range of<br /> Exercise<br /> Price</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br /> Average<br /> Exercise<br /> Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 52%">Warrants outstanding at March 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zWNsfZCtHYsc" title="Number of Warrants Outstanding, Beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-03-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">326,753</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zSRXugrKKOO6" title="Range of Exercise Price Outstanding, Beginning"><ix:nonNumeric contextRef="From2023-04-012023-06-30_us-gaap_WarrantMember" name="aemd:RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">1.50 &#8211; 2.75</ix:nonNumeric></span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zRNuM9uEtTyk" title="Weighted Average Exercise Price Outstanding, Beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-03-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.01</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zeJLxO6WH7Rk" title="Number of Warrants Exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2023-04-012023-06-30_us-gaap_WarrantMember" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zj6W3O0zGRz4" title="Weighted Average Exercise Price, Exercised" style="text-align: right"><ix:nonFraction name="aemd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" contextRef="From2023-04-012023-06-30_us-gaap_WarrantMember" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt">Cancelled/Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z8VwIxOdpkCg" title="Number of Warrants Cancelled/Expired" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2023-04-012023-06-30_us-gaap_WarrantMember" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_903_ecustom--RangeOfExercisePriceCancelledExpired_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zW2BXRxcebO2" title="Range of Exercise Price Cancelled Expired"><span style="-sec-ix-hidden: xdx2ixbrl0582">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zQ85u3WPAGxa" title="Weighted Average Exercise Price Cancelled/Expired" style="padding-bottom: 1pt; text-align: right"><ix:nonFraction name="aemd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2023-04-012023-06-30_us-gaap_WarrantMember" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Warrants outstanding at June 30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zN9SeW3qrN71" title="Number of Warrants Outstanding, Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-06-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">326,753</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z1GO87z1Iip4" title="Range of Exercise Price Outstanding, Ending"><ix:nonNumeric contextRef="From2023-04-012023-06-30_us-gaap_WarrantMember" name="aemd:RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2">1.50 &#8211; 2.75</ix:nonNumeric></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zZgFv6xD2Khb" title="Weighted Average Exercise Price Outstanding, Ending" style="padding-bottom: 2.5pt; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-06-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.01</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">Warrants exercisable at June 30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zcgM8KbVIsYh" title="Number of Warrants Exercisable, Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="aemd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" contextRef="AsOf2023-06-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">326,753</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--RangeOfWeightedAverageExercisePriceExercisable_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zYDtsUiuVKf" title="Range of Exercise Price Exercisable"><ix:nonNumeric contextRef="From2023-04-012023-06-30_us-gaap_WarrantMember" name="aemd:RangeOfWeightedAverageExercisePriceExercisable">1.50 &#8211; 2.75</ix:nonNumeric></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z5kdpqMiJhQg" title="Weighted Average Exercise Price Exercisable" style="padding-bottom: 2.5pt; text-align: right"><ix:nonFraction name="aemd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-06-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.01</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p id="xdx_8A6_zCpxlDF1liT4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<ix:exclude><p id="xdx_23B_z4SsEBQhKPX4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23D_zPMb8KmKkHW2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_zRjkVh4YRs33" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 14 -->
    <div id="xdx_238_zltcQFUcToO8" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_236_zqDCtdJmooj8" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_236_zRUVzEAZE4el" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-04-01to2023-06-30" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_80D_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z63ZiPipM6tf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">10. <span id="xdx_821_zAI29AWVPZOl">COMMITMENTS AND CONTINGENCIES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LEASE COMMITMENTS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Office, Lab and Manufacturing Space Leases</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2020, we entered into an agreement
to lease approximately 2,823 square feet of office space and 1,807 square feet of laboratory space located at 11555 Sorrento Valley Road,
Suite 203, San Diego, California 92121 and 11575 Sorrento Valley Road, Suite 200, San Diego, California 92121, respectively. The agreement
carries a term of 63 months and we took possession of the office space effective October 1, 2021. We took possession of the laboratory
space effective January 1, 2022. In October 2021, we entered into another lease for approximately 2,655 square feet of space to house
our manufacturing operations located at 11588 Sorrento Valley Road, San Diego, California 92121. The term is for <span id="xdx_90E_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtM_c20220831_z0G5iFq60q5f" title="Lease term"><ix:nonNumeric contextRef="AsOf2022-08-31" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm">55</ix:nonNumeric></span> months and we took
possession of the manufacturing space in August 2022. The current monthly base rent under the office and laboratory component of the lease
is $<span id="xdx_90C_ecustom--MonthlyBaseRent_pp0p0_c20230401__20230630__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--OfficeAndLaboratoryMember_zhE6WvDJjb6h" title="Monthly base rent"><ix:nonFraction name="aemd:MonthlyBaseRent" contextRef="From2023-04-012023-06-30_custom_OfficeAndLaboratoryMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,772</ix:nonFraction></span>. The current monthly base rent under the manufacturing component of the lease is $<span id="xdx_90D_ecustom--MonthlyBaseRent_pp0p0_c20230401__20230630__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--ManufacturingMember_z5EHKGyZIRl7" title="Monthly base rent"><ix:nonFraction name="aemd:MonthlyBaseRent" contextRef="From2023-04-012023-06-30_custom_ManufacturingMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,080</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The office, lab and manufacturing leases are coterminous
with a remaining term of <span id="xdx_907_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20230630__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--OfficeLabAndManufacturingLeasesMember_zdW5HSWLbN28" title="Lease term"><ix:nonNumeric contextRef="AsOf2023-06-30_custom_OfficeLabAndManufacturingLeasesMember" format="ixt-sec:durmonth" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">45</ix:nonNumeric></span> months. The weighted average discount rate is <span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20230630__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--OfficeLabAndManufacturingLeasesMember_z7Yo9e7WhLPd" title="Weighted average discount rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2023-06-30_custom_OfficeLabAndManufacturingLeasesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.25</ix:nonFraction>%</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of our June 30, 2023 balance sheet, we have
a right-of-use lease asset of $<span id="xdx_90E_eus-gaap--OperatingLeaseRightOfUseAsset_c20230630_pp0p0" title="Right of use lease asset"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,086,108</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the lease agreements for the new
office, lab and manufacturing space required us to post a standby L/C in favor of the landlord in the aggregate amount of $<span id="xdx_906_eus-gaap--LettersOfCreditOutstandingAmount_iI_pp0p0_c20230630__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--NewOfficeAndLabSpaceMember_zDvYTQHYHJE7" title="Line of credit"><ix:nonFraction name="us-gaap:LettersOfCreditOutstandingAmount" contextRef="AsOf2023-06-30_custom_NewOfficeAndLabSpaceMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">87,506</ix:nonFraction></span> in lieu
of a security deposit. We arranged for our bank to issue standby L/Cs for the new office and lab in the amounts of $46,726 in the fiscal
year ended March 31, 2021 and for the manufacturing space in the amount of $40,780 in the fiscal year ended March 31, 2022. We transferred
like amounts to a restricted certificate of deposit which secured the bank&#8217;s risk in issuing those L/Cs. We have classified those
restricted certificates of deposit on our balance sheet as restricted cash with a balance of $<span id="xdx_904_eus-gaap--RestrictedCash_iI_c20230630_zcriddthYLmj"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,506</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Mobile Clean Room</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we rented a mobile clean room on
a short term, month-to-month basis, where we housed our manufacturing operations until our permanent manufacturing space was completed.
The mobile clean room was located on leased land near our office and lab and we paid $<span id="xdx_901_ecustom--PaymentForRentPerMonth_c20230401__20230630_pp0p0" title="Payment for rent per month"><ix:nonFraction name="aemd:PaymentForRentPerMonth" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,000</ix:nonFraction></span> per month for the right to locate it there.
The arrangement was terminated in September 2022 and the mobile clean room was returned to the vendor that leased it to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Overall, our rent expense, which is included in
general and administrative expenses, approximated $<span id="xdx_90F_eus-gaap--OperatingLeaseExpense_c20230401__20230630_pp0p0" title="Operating Lease, Expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2023-04-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">105,000</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--OperatingLeaseExpense_c20220401__20220630_pp0p0" title="Operating Lease, Expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">140,000</ix:nonFraction></span> for the three month periods ended June 30, 2023 and 2022, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LEGAL MATTERS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may be involved from time to time in various
claims, lawsuits, and/or disputes with third parties or breach of contract actions incidental to the normal course of our business operations.
We are currently not involved in any litigation or any pending legal proceedings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_231_znUrh1hogeBl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_235_znYpsb2rHyce" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zRHeJhtCLGig" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 15 -->
    <div id="xdx_237_zE0zsBoDyHKa" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23F_zGyshf55KDI5" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_230_z6P5ctn2VxJl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-04-01to2023-06-30" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80C_eus-gaap--SubsequentEventsTextBlock_zZLApxorVNP6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">11. <span id="xdx_82C_zF59TVWfnzp3">SUBSEQUENT EVENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management has evaluated events subsequent to
June 30, 2023 through the date that the accompanying consolidated financial statements were filed with the Securities and Exchange Commission
for transactions and other events which may require adjustment of and/or disclosure in such financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July 2023, Mr. Nikolas Gikakis was appointed
as a member our Board of Directors and as a member of the Nominating and Corporate Governance Committee of the Board, or the N&amp;CG
Committee. Pursuant to the Director Compensation Policy, upon his appointment to the Board, Mr. Gikakis (i) will receive an (a) annual
cash retainer of $40,000 for his service on the Board, and (b) an additional annual cash retainer of $5,000 for his service as a member
of the N&amp;CG Committee, and (ii) was granted, on the date of his appointment to the Board, restricted stock units for 195,414 shares
of our common stock under the 2020 Plan, which will vest in equal quarterly installments over one year from the date of grant, in each
case subject to Mr. Gikakis&#8217;s Continuous Service (as defined in the 2020 Plan) as of each such vesting date. The Director Compensation
Policy also provides for further annual grants to its independent directors, at the beginning of each fiscal year, of restricted stock
units with a grant date fair value of $50,000 or, at the option of our Board, options to purchase shares of our common stock, subject
to vesting as determined by our Board. Mr. Gikakis has also entered into our standard form of indemnification agreement for directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><p id="xdx_815_zMNwV28Po2u3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 16 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="q1_010"></span>ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following discussion of our financial condition
and results of operations should be read in conjunction with, and is qualified in its entirety by, the condensed consolidated financial
statements and notes thereto included in Item 1 in this Quarterly Report on Form 10-Q. Some of the information contained in this discussion
and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business,
includes forward-looking statements that involve risks and uncertainties. For a complete discussion of forward-looking statements, see
the section above entitled &#8220;Cautionary Notice Regarding Forward Looking Statements.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Aethlon Medical, Inc., or Aethlon, the Company,
we or us, is a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases. The
Aethlon Hemopurifier is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. In
cancer, the Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression, seed
the spread of metastasis and inhibit the benefit of leading cancer therapies. The FDA has designated the Hemopurifier as a &#8220;Breakthrough
Device&#8221; for two independent indications:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the treatment of life-threatening viruses that are not addressed with approved therapies.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe the Hemopurifier can be a substantial
advance in the treatment of patients with advanced and metastatic cancer through the clearance of exosomes that promote the growth and
spread of tumors through multiple mechanisms. We are currently working with our new contract research organization, or CRO, on preparations
to conduct a clinical trial in Australia in patients with solid tumors, including head and neck cancer, gastrointestinal cancers and other
cancers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2023, we entered into an agreement
with North American Science Associates, LLC, or NAMSA, a world leading MedTech CRO offering global end-to-end development services, to
oversee our clinical trials investigating the Hemopurifier for oncology indications. Pursuant to the agreement, NAMSA will manage our
clinical trials of the Hemopurifier for patients in the United States and Australia with various types of cancer tumors. We anticipate
that the initial clinical trials will begin in Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also believe the Hemopurifier can be part of
the broad-spectrum treatment of life-threatening highly glycosylated, or carbohydrate coated, viruses that are not addressed with an already
approved treatment. In small-scale or early feasibility human studies, the Hemopurifier has been used in the past to treat individuals
infected with human immunodeficiency virus, or HIV, hepatitis-C and Ebola.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, <i>in vitro,</i> the Hemopurifier
has been demonstrated to capture Zika virus, Lassa virus, MERS-CoV, cytomegalovirus, Epstein-Barr virus, Herpes simplex virus, Chikungunya
virus, Dengue virus, West Nile virus, smallpox-related viruses, H1N1 swine flu virus, H5N1 bird flu virus, Monkeypox virus and the reconstructed
Spanish flu virus of 1918. In several cases, these studies were conducted in collaboration with leading government or non-government research
institutes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 17, 2020, the FDA approved a supplement
to our open Investigational Device Exemption, or IDE, for the Hemopurifier in viral disease to allow for the testing of the Hemopurifier
in patients with SARS-CoV-2/COVID-19, or COVID-19, in a New Feasibility Study. <span style="background-color: white">That study was designed
to enroll up to 40 subjects at up to 20 centers in the United States. Subjects were to have established laboratory diagnosis of COVID-19,
be admitted to an intensive care unit, or ICU, and have acute lung injury and/or severe or life-threatening disease, among other criteria.
Endpoints for this study, in addition to safety, included reduction in circulating virus as well as clinical outcomes (NCT # 04595903).
</span>In June 2022, the first patient in this study was enrolled and completed the Hemopurifier treatment phase of the protocol. Due
to lack of COVID-19 patients in the ICUs of our trial sites, we terminated this study in 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 17 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under Single Patient Emergency Use regulations,
the Company has treated two patients with COVID-19 with the Hemopurifier, in addition to the COVID-19 patient treated with our Hemopurifier
in our COVID-19 clinical trial discussed above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently are experiencing a disruption in
our Hemopurifier supply, as our existing supply of Hemopurifiers expired on September 30, 2022 and, as previously disclosed, we are dependent
on FDA approval of qualified suppliers to manufacture our Hemopurifier. Our intended transition to a new supplier for galanthus nivalis
agglutinin, or GNA, a component of our Hemopurifier, is delayed as we work with the FDA for approval of our supplement to our IDE, which
is required to make this manufacturing change.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2022, we launched a wholly owned subsidiary
in Australia, formed to conduct clinical research, seek regulatory approval and commercialize our Hemopurifier in that country. The subsidiary
will initially focus on the oncology trials in Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also obtained ethics review board, or ERB,
approval from and entered into a clinical trial agreement with Medanta Medicity Hospital, a multi-specialty hospital in Delhi NCR, India,
for a COVID-19 clinical trial at that location. One patient has completed participation in the Indian COVID-19 study. The relevant authorities
in India have accepted the use of our Hemopurifiers made with the GNA from our new supplier.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2023, we also received ERB approval from
the Maulana Azad Medical College, or MAMC, for a second site for our clinical trial in India to treat severe COVID-19. MAMC was established
in 1958 and is located in New Delhi, India. MMAC is affiliated with the University of Delhi and is operated by the Delhi government.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also recently announced that we also have begun
investigating the use of our Hemopurifier in the organ transplant setting. Our objective is to confirm that the Hemopurifier, in our translational
studies, when incorporated into a machine perfusion organ preservation circuit, can remove harmful viruses and exosomes from recovered
organs. We initially are focused on recovered kidneys, in a research collaboration with 34 Lives, PBC. We have previously demonstrated
the removal of multiple viruses and exosomes from buffer solutions, in vitro, utilizing a scaled-down version of our Hemopurifier. This
process potentially may reduce complications following transplantation of the recovered organ, which can include viral infection, delayed
graft function and rejection. We believe this new approach could be additive to existing technologies that currently are in place to increase
the number of viable kidneys for transplant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Successful outcomes of human trials will also
be required by the regulatory agencies of certain foreign countries where we plan to market and sell the Hemopurifier. Some of our patents
may expire before FDA approval or approval in a foreign country, if any, is obtained. However, we believe that certain patent applications
and/or other patents issued to us more recently will help protect the proprietary nature of our Hemopurifier treatment technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the foregoing, we are monitoring
closely the impact of inflation, recent bank failures and the war in Ukraine on our business. Given the level of uncertainty regarding
the duration and impact of these events on capital markets and the U.S. economy, we are unable to assess the impact on our timelines and
future access to capital. The full extent to which inflation, recent bank failures and the war in Ukraine will impact our business, results
of operations, financial condition, clinical trials and preclinical research will depend on future developments, as well as the economic
impact on national and international markets that are highly uncertain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We incorporated in Nevada on March 10, 1999. Our
executive offices are located at 11555 Sorrento Valley Road, Suite 203, San Diego, California 92121. Our telephone number is (619) 941-0360.
Our website address is www.aethlonmedical.com.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common stock is listed on the Nasdaq Capital Market under the symbol
&#8220;AEMD.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">WHERE YOU CAN FIND MORE INFORMATION</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are subject to the informational requirements
of the Exchange Act, and must file reports, proxy statements and other information with the SEC. The SEC maintains a web site (http://www.sec.gov)
that contains reports, proxy and information statements and other information regarding registrants, like us, which file electronically
with the SEC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">RESULTS OF OPERATIONS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THREE MONTHS ENDED JUNE 30, 2023 COMPARED TO THE THREE MONTHS ENDED
JUNE 30, 2022</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Operating Expenses</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Consolidated operating expenses for the three
months ended June 30, 2023 were $3,408,160, compared to $2,906,081 for the three months ended June 30, 2022. This increase of $502,079,
or 17.3%, in the 2023 period was due to increases in our general and administrative expenses of $275,916, professional fees of $132,610
and in our payroll and related expenses of $93,553.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The $275,916 increase in general and administrative
expenses was primarily due to the combination of a $343,853 increase in purchase of raw materials for production of our Hemopurifier,
$132,546 increase related to our Australian subsidiary&#8217;s activities, $104,908 increase in depreciation and equipment maintenance
associated with leasehold improvements and new equipment for our manufacturing and lab facilities and an increase of $14,224 in insurance
expense. The increases were offset by a $160,290 decrease in clinical trial expenses, $139,752 decrease in subcontract expense associated
with government contracts and a net decrease of $28,564 in expenses related to the previously rented mobile cleanroom.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The $132,610 increase in our professional fees
was due to an increase of $123,077 in investor relations associated with facilitating investor awareness and assistance with more widespread
dissemination of Company news, an increase of $36,623 associated with accounting and legal services for our Australian subsidiary and
$86,410 of legal expenses associated with year-end filings and general corporate matters. Increases were offset by decreases in regulatory
services of $85,037, recruiting expense of $27,525 and $5,994 in consulting services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The $93,553 increase in payroll expense was due
to $58,876 in salary expense related to increase in headcount and $34,677 increase in stock based compensation related to employee stock
option grants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Net Loss</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the changes in revenues and expenses
noted above, our net loss increased to $3,282,179 in the three months ended June 30, 2023, from approximately $2,906,081 in the three
months ended June 30, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic and diluted loss attributable to common
stockholders was ($0.14) for the three months ended June 30, 2023, compared to ($0.19) for the three month period ended June 30, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LIQUIDITY AND CAPITAL RESOURCES</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2023, we had a cash balance of
$12,897,734 and working capital of $11,486,210. This compares to a cash balance of $14,532,943 and working capital of $13,585,477 at March
31, 2023. We expect our existing cash as of June 30, 2023 to be sufficient to fund our operations for at least twelve months from the
issuance date of these financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 19 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>2022 At The Market Offering Agreement with H.C. Wainwright &amp;
Co., LLC</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 24, 2022, we entered into an At The Market
Offering Agreement, or the 2022 ATM Agreement, with H.C. Wainwright &amp; Co., LLC, or Wainwright, which established an at-the-market
equity program pursuant to which we may offer and sell shares of our common stock from time to time as set forth in the 2022 ATM Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The offering was registered under the Securities
Act of 1933, as amended, or the Securities Act, pursuant to our shelf registration statement on Form S-3 (Registration Statement No. 333-259909),
as previously filed with the SEC and declared effective on October 21, 2021. We filed a prospectus supplement, dated March 24, 2022, with
the SEC that provides for the sale of shares of our common stock having an aggregate offering price of up to $15,000,000, or the 2022
ATM Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the 2022 ATM Agreement, Wainwright may sell
the 2022 ATM Shares by any method permitted by law and deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415 promulgated
under the Securities Act, including sales made directly on the Nasdaq Capital Market, or on any other existing trading market for the
2022 ATM Shares. In addition, under the 2022 ATM Agreement, Wainwright may sell the 2022 ATM Shares in privately negotiated transactions
with our consent and in block transactions. Under certain circumstances, we may instruct Wainwright not to sell the 2022 ATM Shares if
the sales cannot be effected at or above the price designated by us from time to time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are not obligated to make any sales of the
2022 ATM Shares under the 2022 ATM Agreement. The offering of the 2022 ATM Shares pursuant to the 2022 ATM Agreement will terminate upon
the termination of the 2022 ATM Agreement by Wainwright or us, as permitted therein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2022 ATM Agreement contains customary representations,
warranties and agreements by us, and customary indemnification and contribution rights and obligations of the parties. We agreed to pay
Wainwright a placement fee of up to 3.0% of the aggregate gross proceeds from each sale of the 2022 ATM Shares. We also agreed to reimburse
Wainwright for certain specified expenses in connection with entering into the 2022 ATM Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended June 30, 2023, we
raised net proceeds of $1,086,119, net of $27,999 in commissions to Wainwright and $5,846 in other offering expense, through the sale
of, 1,778,901 shares of our common stock at an average price of $0.61 per share under the 2022 ATM Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Cash Flows</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash flows from operating, investing and financing
activities, as reflected in the accompanying Condensed Consolidated Statements of Cash Flows, are summarized as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">(In thousands) <br /> For the three months ended</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30,<br /> 2023</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30,<br /> 2022</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Cash (used in) provided by:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: left">Operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(2,482</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(2,729</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(230</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(41</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,077</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">619</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net decrease in cash and restricted cash</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,635</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,151</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 20 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NET CASH USED IN OPERATING ACTIVITIES. We used
cash in our operating activities due to our losses from operations. Net cash used in operating activities was approximately $2,482,000
in the three months ended June 30, 2023, compared to approximately $2,729,000 in the three months ended June 30, 2022. The primary components
in the $247,000 decrease in cash used in our operating activities in the 2023 period was an increase in accounts payable and other current
liabilities of $645,000, offset by an increase in our net loss of $376,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NET CASH USED IN INVESTING ACTIVITIES. We used
approximately $230,000 of cash in investing activities in the three months ended June 30, 2023, compared to approximately $41,000 in the
three months ended June 30, 2022. The $189,000 increase in the 2023 period was primarily a result of equipment purchase for our laboratory
to facilitate and enhance our research and development activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NET CASH PROVIDED BY FINANCING ACTIVITIES. During
the three months ended June 30, 2023, we raised approximately $1,086,000 from the issuance of our common stock under our at the market
facility. That source of cash from our financing activities was partially offset by the use of approximately $8,000 to pay for the tax
withholding on restricted stock units, for a net aggregate amount of cash provided by financing activities of approximately $1,077,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended June 30, 2022, we
raised approximately $619,000 from the issuance of our common stock under our at the market facility.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Material Cash Requirements </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As noted above in the results of operations, our
clinical trial expense decreased by $160,290 in the three months ended June 30, 2023, compared to the three-month period ended June 30,
2022. However, we expect our clinical trial expenses will increase over the foreseeable future as we continue to expand our clinical trials
both in the United States and internationally.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Future capital requirements will depend upon many
factors, including progress with pre-clinical testing and clinical trials for our Hemopurifier, the number and breadth of our clinical
programs, the time and costs involved in preparing, filing, prosecuting, maintaining and enforcing patent claims and other proprietary
rights, the time and costs involved in obtaining regulatory approvals, competing technological and market developments, as well as our
ability to establish collaborative arrangements, effective commercialization, marketing activities and other arrangements. We expect to
continue to incur increasing negative cash flows and net losses for the foreseeable future. We will continue to need to raise additional
capital either through equity and/or debt financing for the foreseeable future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CRITICAL ACCOUNTING ESTIMATES</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Use of Estimates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial statements
in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires us to make a number of
estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities
at the date of the financial statements. These estimates and assumptions affect the reported amounts of expenses during the reporting
period. On an ongoing basis, we evaluate estimates and assumptions based upon historical experience and various other factors and circumstances.
We believe our estimates and assumptions are reasonable in the circumstances; however, actual results may differ from these estimates
under different future conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that the estimates and assumptions
that are most important to the portrayal of our financial condition and results of operations, in that they require the most difficult,
subjective or complex judgments, form the basis for the accounting policies deemed to be most critical to us. These critical accounting
estimates relate to revenue recognition, impairment of intangible assets and long lived assets, stock compensation, deferred tax asset
valuation allowance and contingencies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There have been no changes to our critical accounting
estimates as disclosed in our Form 10-K for the year ended March 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 21 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="q1_011"></span>ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a smaller reporting company, as defined by
Item 10(f)(1) of Regulation S-K, we are not required to provide the information required by this item.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="q1_012"></span>ITEM 4. CONTROLS AND PROCEDURES.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">DISCLOSURE CONTROLS AND PROCEDURES</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the supervision and with the participation
of our management, including our Chief Executive Officer and our Chief Financial Officer, we evaluated the effectiveness of the design
and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of the end
of the period covered by this Quarterly Report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on such evaluation, our Chief Executive
Officer and Chief Financial Officer concluded that, as of the end of such period, our disclosure controls and procedures are effective
in recording, processing, summarizing and reporting, on a timely basis, information required to be disclosed by us in the reports that
we file or submit under the Exchange Act and are effective in ensuring that information required to be disclosed by us in the reports
that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer
and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There have been no changes in our internal control
over financial reporting during the last fiscal quarter that have materially affected, or are reasonably likely to materially affect,
our internal control over financial reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 22 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="q1_013"></span>PART II. OTHER INFORMATION</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="q1_014"></span>ITEM 1. LEGAL PROCEEDINGS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, claims are made against us
in the ordinary course of business, which could result in litigation. Claims and associated litigation are subject to inherent uncertainties
and unfavorable outcomes could occur, such as monetary damages, fines, penalties or injunctions prohibiting us from selling one or more
products or engaging in other activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The occurrence of an unfavorable outcome in any
specific period could have a material adverse effect on our results of operations for that period or future periods. We are not presently
a party to any pending or threatened legal proceedings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="q1_015"></span>ITEM 1A. RISK FACTORS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">RISK FACTOR SUMMARY</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Below is a summary of the principal factors that
make an investment in our securities speculative or risky. This summary does not address all of the risks that we face. Additional discussion
of the risks summarized in this risk factor summary, and other risks that we face, can be found under the heading &#8220;Risk Factors&#8221;
in our Annual Report on Form 10-K for the fiscal year ended March 31, 2023, filed with the SEC on June 28, 2023, or Annual Report, and
should be carefully considered, together with other information in this Quarterly Report on Form 10-Q and our other filings with the SEC
before making investment decisions regarding our securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have incurred significant losses and expect to continue to incur losses for the foreseeable future.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will require additional financing to sustain our operations, achieve our business objectives and satisfy our cash obligations, which may dilute the ownership of our existing stockholders.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have limited experience in identifying and working with large-scale contracts with medical device manufacturers; manufacture of our devices must comply with good manufacturing practices in the United States.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delays, interruptions or the cessation of production by our third-party suppliers
of important materials or delays in qualifying new materials, has and may continue to prevent or delay our ability to manufacture our Hemopurifier.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Hemopurifier technology may become obsolete.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we fail to comply with extensive regulations of U.S. and foreign regulatory agencies, the commercialization of our products could be delayed or prevented entirely.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we are unable to regain compliance with the listing requirements of the Nasdaq Capital Market, our common stock may be delisted from the Nasdaq Capital Market which could have a material adverse effect on our financial condition and could make it more difficult for you to sell your shares.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a public company with limited financial resources undertaking the launch of new medical technologies, we may have difficulty attracting and retaining executive management and directors.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We plan to expand our operations, which may strain our resources; our inability to manage our growth could delay or derail implementation of our business objectives.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delays in successfully completing our planned clinical trials could jeopardize our ability to obtain regulatory approval.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 23 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There have been no material changes to the risk
factors previously disclosed under the heading &#8220;Risk Factors&#8221; in our Annual Report. The risks described in our Annual Report
are not the only risks facing our company. Additional risks and uncertainties not currently known to us or that we currently deem to be
immaterial also may materially adversely affect our business, financial condition or future results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="q1_016"></span>ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We did not issue or sell any unregistered securities during the three
months ended June 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="q1_017"></span>ITEM 3. DEFAULTS UPON SENIOR SECURITIES.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="q1_018"></span>ITEM 4. MINE SAFETY DISCLOSURES.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="q1_019"></span>ITEM 5. OTHER INFORMATION.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have no disclosure applicable to this item.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="q1_020"></span>ITEM 6. EXHIBITS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) Exhibits. The following documents are filed
as part of this report:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="7"><p style="border-bottom: black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Incorporated
                    by Reference</p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 8%"><p style="border-bottom: black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exhibit<br />
                          Number</p></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 45%"><p style="border-bottom: black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exhibit
                           Description</p></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 5%"><p style="border-bottom: black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form</p></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%"><p style="border-bottom: black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SEC
                           File No.</p></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 5%"><p style="border-bottom: black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exhibit<br />
                          Number</p></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 16%"><p style="border-bottom: black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date</p></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 5%"><p style="border-bottom: black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Filed<br />
                          Herewith</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/882291/000168316822006480/aethlon_ex0301.htm" style="-sec-extract: exhibit">Articles of Incorporation, as amended.</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37487</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 19, 2022</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/882291/000168316819002910/aethlon_8k-ex0301.htm" style="-sec-extract: exhibit">Amended and Restated Bylaws of the Company.</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37487</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 12, 2019</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/882291/000101968714004876/aethlon_s1-ex0401.htm" style="-sec-extract: exhibit">Form of Common Stock Certificate.</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-201334</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2014</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/882291/000168316819003944/aethlon_ex0414.htm" style="-sec-extract: exhibit">Form of Warrant to Purchase
    Common Stock.</a></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-234712</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    11, 2019</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3 </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/882291/000168316819003944/aethlon_ex0415.htm" style="-sec-extract: exhibit">Form of Underwriter Warrant.</a></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-234712</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    11, 2019</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/882291/000168316820000188/aethlon_ex0401.htm" style="-sec-extract: exhibit">Form of Common Stock Purchase
    Warrant.</a></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37487</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    17, 2020</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">10.1++</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/882291/000168316823004487/aethlon_ex1018.htm" style="-sec-extract: exhibit">Amendment No. 1 to Executive Employment Agreement, by and between Aethlon
Medical, Inc. and Lee D. Arnold, Ph.D., dated May 1, 2023.</a></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">10-K</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">001-37487</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">10.18</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">June 28, 2023</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="aethlon_ex3101.htm">Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.</a></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="aethlon_ex3102.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="aethlon_ex3201.htm">Certification of the Principal Executive Officer pursuant to Rule 13a-14(b) or 15d-14(b) of the Exchange Act and 18 U.S.C. Section 1350.</a></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="aethlon_ex3202.htm">Certification of the Principal Financial Officer pursuant to Rule 13a-14(b) or 15d-14(b) of the Exchange Act and 18 U.S.C. Section 1350.</a></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Instance Document </span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="3">&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Schema Document</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="3">&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase
    Document</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="3">&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase
    Document</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="3">&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="2">&#160;</td>
    <td colspan="2">&#160;</td>
    <td colspan="2">&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase
    Document</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="2">&#160;</td>
    <td colspan="2">&#160;</td>
    <td colspan="2">&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted in XBRL,
    and included in exhibit 101)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%; font-size: 10pt"><span style="font-size: 10pt">++</span></td>
    <td style="width: 97%; font-size: 10pt"><span style="font-size: 10pt">Indicates management contract or compensatory plan.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 25 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="q1_021"></span>SIGNATURES</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AETHLON MEDICAL, INC.</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 51%">&#160;</td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 43%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: August 10, 2023</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ JAMES B. FRAKES</span></td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">JAMES B. FRAKES</span></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHIEF FINANCIAL OFFICER</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHIEF ACCOUNTING OFFICER</span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 26; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>aethlon_ex3101.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EXHIBIT 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a),
AS ADOPTED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY
ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Charles J. Fisher, Jr., M.D. certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.&nbsp;&nbsp;&nbsp;I have reviewed this Quarterly
Report on Form 10-Q of Aethlon Medical, Inc.;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.&nbsp;&nbsp;&nbsp;Based on my knowledge, this
report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,
in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.&nbsp;&nbsp;&nbsp;Based on my knowledge, the
financial statements, and other financial information included in this report, fairly present in all material respects the financial condition,
results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.&nbsp;&nbsp;&nbsp;The registrant&rsquo;s other
certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange
Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))
for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.&nbsp;&nbsp;&nbsp;The registrant&rsquo;s other
certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s
auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: August 10, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 34%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&nbsp;CHARLES J. FISHER</FONT></TD>
    <TD STYLE="width: 65%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHARLES J. FISHER, JR., M.D.</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHIEF EXECUTIVE OFFICER</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(PRINCIPAL EXECUTIVE OFFICER)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>aethlon_ex3102.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EXHIBIT 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a),
AS ADOPTED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY
ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, James B. Frakes, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.&nbsp;&nbsp;&nbsp;I have reviewed this Quarterly
Report on Form 10-Q of Aethlon Medical, Inc.;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.&nbsp;&nbsp;&nbsp;Based on my knowledge, this
report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,
in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.&nbsp;&nbsp;&nbsp;Based on my knowledge, the
financial statements, and other financial information included in this report, fairly present in all material respects the financial condition,
results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.&nbsp;&nbsp;&nbsp;The registrant&rsquo;s other
certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange
Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))
for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.&nbsp;&nbsp;&nbsp;The registrant&rsquo;s other
certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s
auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: August 10, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&nbsp;JAMES B. FRAKES</FONT></TD>
    <TD STYLE="width: 63%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JAMES B. FRAKES</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHIEF FINANCIAL OFFICER</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(PRINCIPAL FINANCIAL OFFICER)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>aethlon_ex3201.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EXHIBIT 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO RULE 13a-14(b) OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AND SECTION 1350 OF CHAPTER 63 OF TITLE 18 OF
THE UNITED STATES CODE (18 U.S.C. SECTION 1350),</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY
ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the Quarterly
Report of Aethlon Medical, Inc., or the Registrant, on Form 10-Q for the period ended June 30, 2023 as filed with the Securities and Exchange
Commission on the date hereof, I, Charles J. Fisher, Jr., MD, Chief Executive Officer of the Registrant, certify, pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1. The Quarterly Report on
Form 10-Q, to which this Certification is attached as Exhibit 32.1, fully complies with the requirements of Section 13(a) or 15(d) of
the Securities Exchange Act of 1934, as amended, and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2. The information contained
in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of
the Registrant.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: August 10, 2023</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ CHARLES J. FISHER</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Charles J. Fisher, Jr., M.D.</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aethlon Medical, Inc.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This certification accompanies the Form 10-Q to
which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any
filing of Aethlon Medical, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether
made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>aethlon_ex3202.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EXHIBIT 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO RULE 13a-14(b) OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AND SECTION 1350 OF CHAPTER 63 OF TITLE 18 OF
THE UNITED STATES CODE (18 U.S.C. SECTION 1350),</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY
ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the Quarterly
Report of Aethlon Medical, Inc., or the Registrant, on Form 10-Q for the period ended June 30, 2023 as filed with the Securities and Exchange
Commission on the date hereof, I, James B. Frakes, Chief Financial Officer of the Registrant, certify, pursuant to 18 U.S.C. Section 1350,
as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1. The Quarterly Report on
Form 10-Q, to which this Certification is attached as Exhibit 32.2, fully complies with the requirements of Section 13(a) or 15(d) of
the Securities Exchange Act of 1934, as amended, and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2. The information contained
in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of
the Registrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: August 10, 2023</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ JAMES B. FRAKES</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James B. Frakes</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aethlon Medical, Inc.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This certification accompanies the Form 10-Q to
which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any
filing of Aethlon Medical, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether
made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>aemd-20230630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +Kopo7xRiXgen8uEbXpMOaKDWaPty552KYkxvmR7fama7ykolFJveCQWhE2mQasG -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:aemd="http://aethlonmedical.com/20230630" elementFormDefault="qualified" targetNamespace="http://aethlonmedical.com/20230630">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://aethlonmedical.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
          <link:definition>00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical" id="CondensedConsolidatedBalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations" id="CondensedConsolidatedStatementsOfOperations">
          <link:definition>00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" id="CondensedConsolidatedStatementsOfOperationsParenthetical">
          <link:definition>00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" id="CondensedConsolidatedStatementsOfStockholdersEquity">
          <link:definition>00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows" id="CondensedConsolidatedStatementsOfCashFlows">
          <link:definition>00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganization" id="NatureOfBusinessAndBasisOfPresentationOrganization">
          <link:definition>00000008 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aethlonmedical.com/role/LossPerCommonShare" id="LossPerCommonShare">
          <link:definition>00000009 - Disclosure - LOSS PER COMMON SHARE</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aethlonmedical.com/role/ResearchAndDevelopmentExpenses" id="ResearchAndDevelopmentExpenses">
          <link:definition>00000010 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aethlonmedical.com/role/RecentAccountingPronouncements" id="RecentAccountingPronouncements">
          <link:definition>00000011 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302023" id="EquityTransactionsInThreeMonthsEndedJune302023">
          <link:definition>00000012 - Disclosure - EQUITY TRANSACTIONS IN THE THREE MONTHS ENDED JUNE 30, 2023</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aethlonmedical.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
          <link:definition>00000013 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aethlonmedical.com/role/OtherCurrentLiabilities" id="OtherCurrentLiabilities">
          <link:definition>00000014 - Disclosure - OTHER CURRENT LIABILITIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aethlonmedical.com/role/StockCompensation" id="StockCompensation">
          <link:definition>00000015 - Disclosure - STOCK COMPENSATION</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aethlonmedical.com/role/Warrants" id="Warrants">
          <link:definition>00000016 - Disclosure - WARRANTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aethlonmedical.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>00000017 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aethlonmedical.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>00000018 - Disclosure - SUBSEQUENT EVENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationPolicies" id="NatureOfBusinessAndBasisOfPresentationOrganizationPolicies">
          <link:definition>00000019 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesTables" id="ResearchAndDevelopmentExpensesTables">
          <link:definition>00000020 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aethlonmedical.com/role/RelatedPartyTransactionsTables" id="RelatedPartyTransactionsTables">
          <link:definition>00000021 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aethlonmedical.com/role/OtherCurrentLiabilitiesTables" id="OtherCurrentLiabilitiesTables">
          <link:definition>00000022 - Disclosure - OTHER CURRENT LIABILITIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aethlonmedical.com/role/StockCompensationTables" id="StockCompensationTables">
          <link:definition>00000023 - Disclosure - STOCK COMPENSATION (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aethlonmedical.com/role/WarrantsTables" id="WarrantsTables">
          <link:definition>00000024 - Disclosure - WARRANTS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationDetailsNarrative" id="NatureOfBusinessAndBasisOfPresentationOrganizationDetailsNarrative">
          <link:definition>00000025 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aethlonmedical.com/role/LossPerCommonShareDetailsNarrative" id="LossPerCommonShareDetailsNarrative">
          <link:definition>00000026 - Disclosure - LOSS PER COMMON SHARE (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesDetails" id="ResearchAndDevelopmentExpensesDetails">
          <link:definition>00000027 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302023DetailsNarrative" id="EquityTransactionsInThreeMonthsEndedJune302023DetailsNarrative">
          <link:definition>00000028 - Disclosure - EQUITY TRANSACTIONS IN THE THREE MONTHS ENDED JUNE 30, 2023 (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aethlonmedical.com/role/RelatedPartyTransactionsDetails" id="RelatedPartyTransactionsDetails">
          <link:definition>00000029 - Disclosure -  RELATED PARTY TRANSACTIONS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aethlonmedical.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
          <link:definition>00000030 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aethlonmedical.com/role/OtherCurrentLiabilitiesDetails" id="OtherCurrentLiabilitiesDetails">
          <link:definition>00000031 - Disclosure - OTHER CURRENT LIABILITIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aethlonmedical.com/role/StockCompensationDetails-StockCompensation" id="StockCompensationDetails-StockCompensation">
          <link:definition>00000032 - Disclosure - STOCK COMPENSATION (Details - Stock compensation)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest" id="StockCompensationDetails-OptionsVestedAndExpectedToVest">
          <link:definition>00000033 - Disclosure - STOCK COMPENSATION (Details - Options vested and expected to vest)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity" id="StockCompensationDetails-OptionActivity">
          <link:definition>00000034 - Disclosure - STOCK COMPENSATION (Details - Option activity)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aethlonmedical.com/role/StockCompensationDetailsNarrative" id="StockCompensationDetailsNarrative">
          <link:definition>00000035 - Disclosure - STOCK COMPENSATION (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aethlonmedical.com/role/WarrantDetails" id="WarrantDetails">
          <link:definition>00000036 - Disclosure - Warrant (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>00000037 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="aemd-20230630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="aemd-20230630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="aemd-20230630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="aemd-20230630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
    <element id="aemd_RestrictedCashMember" name="RestrictedCashMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_OfferingAgreementMember" name="OfferingAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_HcWainwrightMember" name="HcWainwrightMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_OtherOfferingExpenseMember" name="OtherOfferingExpenseMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_EligibleDirectorsEachMember" name="EligibleDirectorsEachMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_AccruedBoardFeesMember" name="AccruedBoardFeesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_AccruedVacationMember" name="AccruedVacationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_StockBasedCompensationMember" name="StockBasedCompensationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_OfficeAndLaboratoryMember" name="OfficeAndLaboratoryMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_ManufacturingMember" name="ManufacturingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_OfficeLabAndManufacturingLeasesMember" name="OfficeLabAndManufacturingLeasesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_NewOfficeAndLabSpaceMember" name="NewOfficeAndLabSpaceMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_DueToRelatedParties" name="DueToRelatedParties" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExercise" name="IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExercise" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExerciseShares" name="IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExerciseShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_AccretionOfRightofuseLeaseAsset" name="AccretionOfRightofuseLeaseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise" name="ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_DisclosureWarrantsAbstract" name="DisclosureWarrantsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_WarrantsTextBlock" name="WarrantsTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_LiquidityAndGoingConcernPolicyTextBlock" name="LiquidityAndGoingConcernPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_DueToRelatedPartiesCurrent1" name="DueToRelatedPartiesCurrent1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_AccruedDirectorFees" name="AccruedDirectorFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_RangeOfExercisePricesOptionBeginning" name="RangeOfExercisePricesOptionBeginning" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_RangeOfExercisePricesOptionGranted" name="RangeOfExercisePricesOptionGranted" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_RangeOfExercisePricesOptionCancelledexpired" name="RangeOfExercisePricesOptionCancelledexpired" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_RangeOfExercisePricesOptionEnding" name="RangeOfExercisePricesOptionEnding" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_RangeOfExercisePricesOptionExercisable" name="RangeOfExercisePricesOptionExercisable" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" name="RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_RangeOfExercisePriceCancelledExpired" name="RangeOfExercisePriceCancelledExpired" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2" name="RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_RangeOfWeightedAverageExercisePriceExercisable" name="RangeOfWeightedAverageExercisePriceExercisable" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_MonthlyBaseRent" name="MonthlyBaseRent" nillable="true" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_PaymentForRentPerMonth" name="PaymentForRentPerMonth" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>aemd-20230630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://aethlonmedical.com/role/Cover" xlink:href="aemd-20230630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets" xlink:href="aemd-20230630.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="aemd-20230630.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="aemd-20230630.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" xlink:href="aemd-20230630.xsd#CondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:href="aemd-20230630.xsd#CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="aemd-20230630.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganization" xlink:href="aemd-20230630.xsd#NatureOfBusinessAndBasisOfPresentationOrganization" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/LossPerCommonShare" xlink:href="aemd-20230630.xsd#LossPerCommonShare" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/ResearchAndDevelopmentExpenses" xlink:href="aemd-20230630.xsd#ResearchAndDevelopmentExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/RecentAccountingPronouncements" xlink:href="aemd-20230630.xsd#RecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302023" xlink:href="aemd-20230630.xsd#EquityTransactionsInThreeMonthsEndedJune302023" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/RelatedPartyTransactions" xlink:href="aemd-20230630.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/OtherCurrentLiabilities" xlink:href="aemd-20230630.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensation" xlink:href="aemd-20230630.xsd#StockCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/Warrants" xlink:href="aemd-20230630.xsd#Warrants" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CommitmentsAndContingencies" xlink:href="aemd-20230630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/SubsequentEvents" xlink:href="aemd-20230630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationPolicies" xlink:href="aemd-20230630.xsd#NatureOfBusinessAndBasisOfPresentationOrganizationPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesTables" xlink:href="aemd-20230630.xsd#ResearchAndDevelopmentExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/RelatedPartyTransactionsTables" xlink:href="aemd-20230630.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/OtherCurrentLiabilitiesTables" xlink:href="aemd-20230630.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationTables" xlink:href="aemd-20230630.xsd#StockCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/WarrantsTables" xlink:href="aemd-20230630.xsd#WarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationDetailsNarrative" xlink:href="aemd-20230630.xsd#NatureOfBusinessAndBasisOfPresentationOrganizationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/LossPerCommonShareDetailsNarrative" xlink:href="aemd-20230630.xsd#LossPerCommonShareDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesDetails" xlink:href="aemd-20230630.xsd#ResearchAndDevelopmentExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302023DetailsNarrative" xlink:href="aemd-20230630.xsd#EquityTransactionsInThreeMonthsEndedJune302023DetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/RelatedPartyTransactionsDetails" xlink:href="aemd-20230630.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="aemd-20230630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/OtherCurrentLiabilitiesDetails" xlink:href="aemd-20230630.xsd#OtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationDetails-StockCompensation" xlink:href="aemd-20230630.xsd#StockCompensationDetails-StockCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest" xlink:href="aemd-20230630.xsd#StockCompensationDetails-OptionsVestedAndExpectedToVest" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity" xlink:href="aemd-20230630.xsd#StockCompensationDetails-OptionActivity" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationDetailsNarrative" xlink:href="aemd-20230630.xsd#StockCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/WarrantDetails" xlink:href="aemd-20230630.xsd#WarrantDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="aemd-20230630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_DueToRelatedParties" xlink:label="loc_aemdDueToRelatedParties" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_aemdDueToRelatedParties" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaapLaborAndRelatedExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapLaborAndRelatedExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndOtherIncome" xlink:label="loc_us-gaapInterestAndOtherIncome" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapInterestAndOtherIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossTax" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossTaxPortionAttributableToParent1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:title="00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; EQUITY (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:title="00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_AccretionOfRightofuseLeaseAsset" xlink:label="loc_aemdAccretionOfRightofuseLeaseAsset" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_aemdAccretionOfRightofuseLeaseAsset" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableRelatedParties" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableRelatedParties" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganization" xlink:title="00000008 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/LossPerCommonShare" xlink:title="00000009 - Disclosure - LOSS PER COMMON SHARE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/ResearchAndDevelopmentExpenses" xlink:title="00000010 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/RecentAccountingPronouncements" xlink:title="00000011 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302023" xlink:title="00000012 - Disclosure - EQUITY TRANSACTIONS IN THE THREE MONTHS ENDED JUNE 30, 2023" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/RelatedPartyTransactions" xlink:title="00000013 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/OtherCurrentLiabilities" xlink:title="00000014 - Disclosure - OTHER CURRENT LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensation" xlink:title="00000015 - Disclosure - STOCK COMPENSATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/Warrants" xlink:title="00000016 - Disclosure - WARRANTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CommitmentsAndContingencies" xlink:title="00000017 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/SubsequentEvents" xlink:title="00000018 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationPolicies" xlink:title="00000019 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesTables" xlink:title="00000020 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/RelatedPartyTransactionsTables" xlink:title="00000021 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000022 - Disclosure - OTHER CURRENT LIABILITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationTables" xlink:title="00000023 - Disclosure - STOCK COMPENSATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/WarrantsTables" xlink:title="00000024 - Disclosure - WARRANTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationDetailsNarrative" xlink:title="00000025 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/LossPerCommonShareDetailsNarrative" xlink:title="00000026 - Disclosure - LOSS PER COMMON SHARE (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesDetails" xlink:title="00000027 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302023DetailsNarrative" xlink:title="00000028 - Disclosure - EQUITY TRANSACTIONS IN THE THREE MONTHS ENDED JUNE 30, 2023 (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/RelatedPartyTransactionsDetails" xlink:title="00000029 - Disclosure -  RELATED PARTY TRANSACTIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000030 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/OtherCurrentLiabilitiesDetails" xlink:title="00000031 - Disclosure - OTHER CURRENT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationDetails-StockCompensation" xlink:title="00000032 - Disclosure - STOCK COMPENSATION (Details - Stock compensation)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest" xlink:title="00000033 - Disclosure - STOCK COMPENSATION (Details - Options vested and expected to vest)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity" xlink:title="00000034 - Disclosure - STOCK COMPENSATION (Details - Option activity)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationDetailsNarrative" xlink:title="00000035 - Disclosure - STOCK COMPENSATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/WarrantDetails" xlink:title="00000036 - Disclosure - Warrant (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000037 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>aemd-20230630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://aethlonmedical.com/role/Cover" xlink:href="aemd-20230630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets" xlink:href="aemd-20230630.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="aemd-20230630.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="aemd-20230630.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" xlink:href="aemd-20230630.xsd#CondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:href="aemd-20230630.xsd#CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="aemd-20230630.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganization" xlink:href="aemd-20230630.xsd#NatureOfBusinessAndBasisOfPresentationOrganization" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/LossPerCommonShare" xlink:href="aemd-20230630.xsd#LossPerCommonShare" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/ResearchAndDevelopmentExpenses" xlink:href="aemd-20230630.xsd#ResearchAndDevelopmentExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/RecentAccountingPronouncements" xlink:href="aemd-20230630.xsd#RecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302023" xlink:href="aemd-20230630.xsd#EquityTransactionsInThreeMonthsEndedJune302023" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/RelatedPartyTransactions" xlink:href="aemd-20230630.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/OtherCurrentLiabilities" xlink:href="aemd-20230630.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensation" xlink:href="aemd-20230630.xsd#StockCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/Warrants" xlink:href="aemd-20230630.xsd#Warrants" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CommitmentsAndContingencies" xlink:href="aemd-20230630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/SubsequentEvents" xlink:href="aemd-20230630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationPolicies" xlink:href="aemd-20230630.xsd#NatureOfBusinessAndBasisOfPresentationOrganizationPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesTables" xlink:href="aemd-20230630.xsd#ResearchAndDevelopmentExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/RelatedPartyTransactionsTables" xlink:href="aemd-20230630.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/OtherCurrentLiabilitiesTables" xlink:href="aemd-20230630.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationTables" xlink:href="aemd-20230630.xsd#StockCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/WarrantsTables" xlink:href="aemd-20230630.xsd#WarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationDetailsNarrative" xlink:href="aemd-20230630.xsd#NatureOfBusinessAndBasisOfPresentationOrganizationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/LossPerCommonShareDetailsNarrative" xlink:href="aemd-20230630.xsd#LossPerCommonShareDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesDetails" xlink:href="aemd-20230630.xsd#ResearchAndDevelopmentExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302023DetailsNarrative" xlink:href="aemd-20230630.xsd#EquityTransactionsInThreeMonthsEndedJune302023DetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/RelatedPartyTransactionsDetails" xlink:href="aemd-20230630.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="aemd-20230630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/OtherCurrentLiabilitiesDetails" xlink:href="aemd-20230630.xsd#OtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationDetails-StockCompensation" xlink:href="aemd-20230630.xsd#StockCompensationDetails-StockCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest" xlink:href="aemd-20230630.xsd#StockCompensationDetails-OptionsVestedAndExpectedToVest" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity" xlink:href="aemd-20230630.xsd#StockCompensationDetails-OptionActivity" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationDetailsNarrative" xlink:href="aemd-20230630.xsd#StockCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/WarrantDetails" xlink:href="aemd-20230630.xsd#WarrantDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="aemd-20230630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:title="00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; EQUITY (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaapNoncontrollingInterestMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapNoncontrollingInterestMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExercise" xlink:label="loc_aemdIssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExercise_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdIssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExercise_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExerciseShares" xlink:label="loc_aemdIssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExerciseShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdIssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExerciseShares_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax_70" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:title="00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganization" xlink:title="00000008 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/LossPerCommonShare" xlink:title="00000009 - Disclosure - LOSS PER COMMON SHARE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/ResearchAndDevelopmentExpenses" xlink:title="00000010 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/RecentAccountingPronouncements" xlink:title="00000011 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302023" xlink:title="00000012 - Disclosure - EQUITY TRANSACTIONS IN THE THREE MONTHS ENDED JUNE 30, 2023" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/RelatedPartyTransactions" xlink:title="00000013 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/OtherCurrentLiabilities" xlink:title="00000014 - Disclosure - OTHER CURRENT LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensation" xlink:title="00000015 - Disclosure - STOCK COMPENSATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/Warrants" xlink:title="00000016 - Disclosure - WARRANTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CommitmentsAndContingencies" xlink:title="00000017 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/SubsequentEvents" xlink:title="00000018 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationPolicies" xlink:title="00000019 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesTables" xlink:title="00000020 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/RelatedPartyTransactionsTables" xlink:title="00000021 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000022 - Disclosure - OTHER CURRENT LIABILITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationTables" xlink:title="00000023 - Disclosure - STOCK COMPENSATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/WarrantsTables" xlink:title="00000024 - Disclosure - WARRANTS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationDetailsNarrative" xlink:title="00000025 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaapBalanceSheetLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBalanceSheetLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_RestrictedCashMember" xlink:label="loc_aemdRestrictedCashMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_aemdRestrictedCashMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSecurityDeposit_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/LossPerCommonShareDetailsNarrative" xlink:title="00000026 - Disclosure - LOSS PER COMMON SHARE (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesDetails" xlink:title="00000027 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302023DetailsNarrative" xlink:title="00000028 - Disclosure - EQUITY TRANSACTIONS IN THE THREE MONTHS ENDED JUNE 30, 2023 (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuritiesFinancingTransactionLineItems" xlink:label="loc_us-gaapSecuritiesFinancingTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuritiesFinancingTransactionTable" xlink:label="loc_us-gaapSecuritiesFinancingTransactionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSecuritiesFinancingTransactionLineItems" xlink:to="loc_us-gaapSecuritiesFinancingTransactionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuritiesFinancingTransactionAxis" xlink:label="loc_us-gaapSecuritiesFinancingTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSecuritiesFinancingTransactionTable" xlink:to="loc_us-gaapSecuritiesFinancingTransactionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuritiesFinancingTransactionTypeDomain" xlink:label="loc_us-gaapSecuritiesFinancingTransactionTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSecuritiesFinancingTransactionAxis" xlink:to="loc_us-gaapSecuritiesFinancingTransactionTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuritiesFinancingTransactionTypeDomain" xlink:label="loc_us-gaapSecuritiesFinancingTransactionTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSecuritiesFinancingTransactionAxis" xlink:to="loc_us-gaapSecuritiesFinancingTransactionTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_OfferingAgreementMember" xlink:label="loc_aemdOfferingAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSecuritiesFinancingTransactionTypeDomain" xlink:to="loc_aemdOfferingAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSecuritiesFinancingTransactionTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_HcWainwrightMember" xlink:label="loc_aemdHcWainwrightMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_aemdHcWainwrightMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_EligibleDirectorsEachMember" xlink:label="loc_aemdEligibleDirectorsEachMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_aemdEligibleDirectorsEachMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaapTransactionTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSecuritiesFinancingTransactionTable" xlink:to="loc_us-gaapTransactionTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_OtherOfferingExpenseMember" xlink:label="loc_aemdOtherOfferingExpenseMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_aemdOtherOfferingExpenseMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSecuritiesFinancingTransactionTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSecuritiesFinancingTransactionLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForCommissions" xlink:label="loc_us-gaapPaymentsForCommissions_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSecuritiesFinancingTransactionLineItems" xlink:to="loc_us-gaapPaymentsForCommissions_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSecuritiesFinancingTransactionLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSecuritiesFinancingTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSecuritiesFinancingTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_50" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/RelatedPartyTransactionsDetails" xlink:title="00000029 - Disclosure -  RELATED PARTY TRANSACTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_AccruedBoardFeesMember" xlink:label="loc_aemdAccruedBoardFeesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_aemdAccruedBoardFeesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_AccruedVacationMember" xlink:label="loc_aemdAccruedVacationMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_aemdAccruedVacationMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_DueToRelatedPartiesCurrent1" xlink:label="loc_aemdDueToRelatedPartiesCurrent1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_aemdDueToRelatedPartiesCurrent1_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000030 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/OtherCurrentLiabilitiesDetails" xlink:title="00000031 - Disclosure - OTHER CURRENT LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationDetails-StockCompensation" xlink:title="00000032 - Disclosure - STOCK COMPENSATION (Details - Stock compensation)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaapTransactionTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapTransactionTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_StockBasedCompensationMember" xlink:label="loc_aemdStockBasedCompensationMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_aemdStockBasedCompensationMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensation_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted_50" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest" xlink:title="00000033 - Disclosure - STOCK COMPENSATION (Details - Options vested and expected to vest)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity" xlink:title="00000034 - Disclosure - STOCK COMPENSATION (Details - Option activity)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_RangeOfExercisePricesOptionBeginning" xlink:label="loc_aemdRangeOfExercisePricesOptionBeginning_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_aemdRangeOfExercisePricesOptionBeginning_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_RangeOfExercisePricesOptionGranted" xlink:label="loc_aemdRangeOfExercisePricesOptionGranted_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_aemdRangeOfExercisePricesOptionGranted_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_RangeOfExercisePricesOptionCancelledexpired" xlink:label="loc_aemdRangeOfExercisePricesOptionCancelledexpired_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_aemdRangeOfExercisePricesOptionCancelledexpired_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_RangeOfExercisePricesOptionEnding" xlink:label="loc_aemdRangeOfExercisePricesOptionEnding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_aemdRangeOfExercisePricesOptionEnding_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_RangeOfExercisePricesOptionExercisable" xlink:label="loc_aemdRangeOfExercisePricesOptionExercisable_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_aemdRangeOfExercisePricesOptionExercisable_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_40" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationDetailsNarrative" xlink:title="00000035 - Disclosure - STOCK COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapOptionMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharePrice_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_50" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/WarrantDetails" xlink:title="00000036 - Disclosure - Warrant (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_aemdRangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_aemdRangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="loc_aemdShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_aemdShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_RangeOfExercisePriceCancelledExpired" xlink:label="loc_aemdRangeOfExercisePriceCancelledExpired_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_aemdRangeOfExercisePriceCancelledExpired_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_aemdShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_aemdShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2" xlink:label="loc_aemdRangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_aemdRangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" xlink:label="loc_aemdShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_aemdShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_RangeOfWeightedAverageExercisePriceExercisable" xlink:label="loc_aemdRangeOfWeightedAverageExercisePriceExercisable_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_aemdRangeOfWeightedAverageExercisePriceExercisable_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_aemdShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_aemdShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_40" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000037 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_OfficeAndLaboratoryMember" xlink:label="loc_aemdOfficeAndLaboratoryMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="loc_aemdOfficeAndLaboratoryMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_ManufacturingMember" xlink:label="loc_aemdManufacturingMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="loc_aemdManufacturingMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_OfficeLabAndManufacturingLeasesMember" xlink:label="loc_aemdOfficeLabAndManufacturingLeasesMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="loc_aemdOfficeLabAndManufacturingLeasesMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_NewOfficeAndLabSpaceMember" xlink:label="loc_aemdNewOfficeAndLabSpaceMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="loc_aemdNewOfficeAndLabSpaceMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_MonthlyBaseRent" xlink:label="loc_aemdMonthlyBaseRent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdMonthlyBaseRent_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="loc_us-gaapLettersOfCreditOutstandingAmount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLettersOfCreditOutstandingAmount_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRestrictedCash_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_PaymentForRentPerMonth" xlink:label="loc_aemdPaymentForRentPerMonth_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdPaymentForRentPerMonth_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense_90" xlink:type="arc" order="8" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>aemd-20230630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_RestrictedCashMember" xlink:label="aemd_RestrictedCashMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RestrictedCashMember" xlink:to="aemd_RestrictedCashMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_RestrictedCashMember_lbl" xml:lang="en-US">Restricted Cash [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuritiesFinancingTransactionAxis" xlink:label="us-gaap_SecuritiesFinancingTransactionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuritiesFinancingTransactionAxis" xlink:to="us-gaap_SecuritiesFinancingTransactionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuritiesFinancingTransactionAxis_lbl" xml:lang="en-US">Securities Financing Transaction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_OfferingAgreementMember" xlink:label="aemd_OfferingAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_OfferingAgreementMember" xlink:to="aemd_OfferingAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_OfferingAgreementMember_lbl" xml:lang="en-US">Offering Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_HcWainwrightMember" xlink:label="aemd_HcWainwrightMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_HcWainwrightMember" xlink:to="aemd_HcWainwrightMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_HcWainwrightMember_lbl" xml:lang="en-US">Hc Wainwright [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransactionTypeAxis_lbl" xml:lang="en-US">Transaction Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_OtherOfferingExpenseMember" xlink:label="aemd_OtherOfferingExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_OtherOfferingExpenseMember" xlink:to="aemd_OtherOfferingExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_OtherOfferingExpenseMember_lbl" xml:lang="en-US">Other Offering Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_EligibleDirectorsEachMember" xlink:label="aemd_EligibleDirectorsEachMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_EligibleDirectorsEachMember" xlink:to="aemd_EligibleDirectorsEachMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_EligibleDirectorsEachMember_lbl" xml:lang="en-US">Eligible Directors Each [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_AccruedBoardFeesMember" xlink:label="aemd_AccruedBoardFeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_AccruedBoardFeesMember" xlink:to="aemd_AccruedBoardFeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_AccruedBoardFeesMember_lbl" xml:lang="en-US">Accrued Board Fees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_AccruedVacationMember" xlink:label="aemd_AccruedVacationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_AccruedVacationMember" xlink:to="aemd_AccruedVacationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_AccruedVacationMember_lbl" xml:lang="en-US">Accrued Vacation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_StockBasedCompensationMember" xlink:label="aemd_StockBasedCompensationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_StockBasedCompensationMember" xlink:to="aemd_StockBasedCompensationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_StockBasedCompensationMember_lbl" xml:lang="en-US">Stock Based Compensation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionMember" xlink:label="us-gaap_OptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionMember" xlink:to="us-gaap_OptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionMember_lbl" xml:lang="en-US">Options Held [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_lbl" xml:lang="en-US">Property Subject to or Available for Operating Lease [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_OfficeAndLaboratoryMember" xlink:label="aemd_OfficeAndLaboratoryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_OfficeAndLaboratoryMember" xlink:to="aemd_OfficeAndLaboratoryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_OfficeAndLaboratoryMember_lbl" xml:lang="en-US">Office And Laboratory [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_ManufacturingMember" xlink:label="aemd_ManufacturingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ManufacturingMember" xlink:to="aemd_ManufacturingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_ManufacturingMember_lbl" xml:lang="en-US">Manufacturing [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_OfficeLabAndManufacturingLeasesMember" xlink:label="aemd_OfficeLabAndManufacturingLeasesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_OfficeLabAndManufacturingLeasesMember" xlink:to="aemd_OfficeLabAndManufacturingLeasesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_OfficeLabAndManufacturingLeasesMember_lbl" xml:lang="en-US">Office Lab And Manufacturing Leases [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_NewOfficeAndLabSpaceMember" xlink:label="aemd_NewOfficeAndLabSpaceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_NewOfficeAndLabSpaceMember" xlink:to="aemd_NewOfficeAndLabSpaceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_NewOfficeAndLabSpaceMember_lbl" xml:lang="en-US">New Office And Lab Space [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use lease asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Patents, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US">Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_DueToRelatedParties" xlink:label="aemd_DueToRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_DueToRelatedParties" xlink:to="aemd_DueToRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_DueToRelatedParties_lbl" xml:lang="en-US">Due to related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Lease liability, current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Lease liability, less current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, par value $0.001 per share; 60,000,000 shares authorized as of June 30, 2023 and March 31, 2023; 24,835,321 and 22,992,466 shares issued and outstanding as of June 30, 2023 and March 31, 2023, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock par value (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">OPERATING EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xml:lang="en-US">Payroll and related expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">OPERATING LOSS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoninterestIncomeOtherAbstract" xlink:label="us-gaap_NoninterestIncomeOtherAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoninterestIncomeOtherAbstract" xlink:to="us-gaap_NoninterestIncomeOtherAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoninterestIncomeOtherAbstract_lbl" xml:lang="en-US">OTHER INCOME</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">NET LOSS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">LOSS ATTRIBUTABLE TO NONCONTROLLING INTERESTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS ATTRIBUTABLE TO AETHLON MEDICAL, INC.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_lbl" xml:lang="en-US">OTHER COMPREHENSIVE LOSS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossTax_lbl" xml:lang="en-US">COMPREHENSIVE LOSS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average number of common shares outstanding basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average number of common shares outstanding diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">BALANCE - MARCH 31, 2022</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuances of common stock for cash under at the market program</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuances of common stock for cash under at the market program, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExercise" xlink:label="aemd_IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExercise" xlink:to="aemd_IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExercise_lbl" xml:lang="en-US">Issuance of common shares upon vesting of restricted stock units and net stock option exercises</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExerciseShares" xlink:label="aemd_IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExerciseShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExerciseShares" xlink:to="aemd_IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExerciseShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExerciseShares_lbl" xml:lang="en-US">Issuance of common shares upon vesting of restricted stock units and net stock option exercise, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Other comprehensive loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">BALANCE &#8211; JUNE 30, 2022</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_AccretionOfRightofuseLeaseAsset" xlink:label="aemd_AccretionOfRightofuseLeaseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_AccretionOfRightofuseLeaseAsset" xlink:to="aemd_AccretionOfRightofuseLeaseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="aemd_AccretionOfRightofuseLeaseAsset_lbl" xml:lang="en-US">Accretion of right-of-use lease asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl" xml:lang="en-US">Due to related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows used in investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows provided by financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from the issuance of common stock, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US">Tax withholding payments or tax equivalent payments for net share settlement of restricted stock units and net stock option expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Effect of exchange rate on changes on cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net decrease in cash and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and restricted cash at beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosures of cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Supplemental disclosures of non-cash investing and financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise" xlink:label="aemd_ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise" xlink:to="aemd_ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise_lbl" xml:lang="en-US">Par value of shares issued for vested restricted stock units and net stock option exercise</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_RestrictedCash_2_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">LOSS PER COMMON SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xml:lang="en-US">Research and Development [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xml:lang="en-US">RECENT ACCOUNTING PRONOUNCEMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">EQUITY TRANSACTIONS IN THE THREE MONTHS ENDED JUNE 30, 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCK COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_DisclosureWarrantsAbstract" xlink:label="aemd_DisclosureWarrantsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_DisclosureWarrantsAbstract" xlink:to="aemd_DisclosureWarrantsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_DisclosureWarrantsAbstract_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_WarrantsTextBlock" xlink:label="aemd_WarrantsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WarrantsTextBlock" xlink:to="aemd_WarrantsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_WarrantsTextBlock_lbl" xml:lang="en-US">WARRANTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Basis of Presentation and Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Reclassifications</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_LiquidityAndGoingConcernPolicyTextBlock" xlink:label="aemd_LiquidityAndGoingConcernPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_LiquidityAndGoingConcernPolicyTextBlock" xlink:to="aemd_LiquidityAndGoingConcernPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_LiquidityAndGoingConcernPolicyTextBlock_lbl" xml:lang="en-US">LIQUIDITY AND GOING CONCERN</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Restricted Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Due to related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US">Schedule of share-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_lbl" xml:lang="en-US">Schedule of options outstanding that have vested and are expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of stock option activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of warrant activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuritiesFinancingTransactionTable" xlink:label="us-gaap_SecuritiesFinancingTransactionTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuritiesFinancingTransactionTable" xlink:to="us-gaap_SecuritiesFinancingTransactionTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuritiesFinancingTransactionTable_lbl" xml:lang="en-US">Securities Financing Transaction [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuritiesFinancingTransactionLineItems" xlink:label="us-gaap_SecuritiesFinancingTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuritiesFinancingTransactionLineItems" xlink:to="us-gaap_SecuritiesFinancingTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuritiesFinancingTransactionLineItems_lbl" xml:lang="en-US">Securities Financing Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from issuance of equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForCommissions" xlink:label="us-gaap_PaymentsForCommissions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForCommissions" xlink:to="us-gaap_PaymentsForCommissions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForCommissions_lbl" xml:lang="en-US">Payment of commissions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Payment of stock issuance costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Stock issued new, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_DueToRelatedPartiesCurrent1" xlink:label="aemd_DueToRelatedPartiesCurrent1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_DueToRelatedPartiesCurrent1" xlink:to="aemd_DueToRelatedPartiesCurrent1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aemd_DueToRelatedPartiesCurrent1_lbl" xml:lang="en-US">Due to related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_AccruedDirectorFees" xlink:label="aemd_AccruedDirectorFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_AccruedDirectorFees" xlink:to="aemd_AccruedDirectorFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_AccruedDirectorFees_lbl" xml:lang="en-US">Accrued director fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued professional fees</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_2_lbl" xml:lang="en-US">Total other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffsettingAssetsTable" xlink:label="us-gaap_OffsettingAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsTable" xlink:to="us-gaap_OffsettingAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsTable_lbl" xml:lang="en-US">Offsetting Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="us-gaap_OffsettingAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsLineItems" xlink:to="us-gaap_OffsettingAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsLineItems_lbl" xml:lang="en-US">Offsetting Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Vesting of stock options and restricted stock units</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Total stock-based compensation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_2_lbl" xml:lang="en-US">Earnings Per Share, Basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_2_lbl" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Options vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price options vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual term options vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Options expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price options expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual term options expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Total options outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Stock options Outstanding, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_RangeOfExercisePricesOptionBeginning" xlink:label="aemd_RangeOfExercisePricesOptionBeginning" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RangeOfExercisePricesOptionBeginning" xlink:to="aemd_RangeOfExercisePricesOptionBeginning_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_RangeOfExercisePricesOptionBeginning_lbl" xml:lang="en-US">Range of exercise prices, Option beginning</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Outstanding, Weighted Average Exercise Price, beginning price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Stock options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercised, Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Stock options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_RangeOfExercisePricesOptionGranted" xlink:label="aemd_RangeOfExercisePricesOptionGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RangeOfExercisePricesOptionGranted" xlink:to="aemd_RangeOfExercisePricesOptionGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_RangeOfExercisePricesOptionGranted_lbl" xml:lang="en-US">Range of exercise prices, Option Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted, Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Stock options cancelled/forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_RangeOfExercisePricesOptionCancelledexpired" xlink:label="aemd_RangeOfExercisePricesOptionCancelledexpired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RangeOfExercisePricesOptionCancelledexpired" xlink:to="aemd_RangeOfExercisePricesOptionCancelledexpired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_RangeOfExercisePricesOptionCancelledexpired_lbl" xml:lang="en-US">Range of exercise prices, Option cancelled/expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Cancelled/Forfeited, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Stock options outstanding, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_RangeOfExercisePricesOptionEnding" xlink:label="aemd_RangeOfExercisePricesOptionEnding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RangeOfExercisePricesOptionEnding" xlink:to="aemd_RangeOfExercisePricesOptionEnding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_RangeOfExercisePricesOptionEnding_lbl" xml:lang="en-US">Range of exercise prices, Option ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Outstanding Weighted Average Exercise Price, ending price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Stock options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_RangeOfExercisePricesOptionExercisable" xlink:label="aemd_RangeOfExercisePricesOptionExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RangeOfExercisePricesOptionExercisable" xlink:to="aemd_RangeOfExercisePricesOptionExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_RangeOfExercisePricesOptionExercisable_lbl" xml:lang="en-US">Range of exercise prices, Option exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercisable, Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized compensation costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Unrecognized compensation cost amortization period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Number of Warrants Outstanding, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="aemd_RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="aemd_RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Range of Exercise Price Outstanding, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of Warrants Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="aemd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:to="aemd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xml:lang="en-US">Number of Warrants Cancelled/Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_RangeOfExercisePriceCancelledExpired" xlink:label="aemd_RangeOfExercisePriceCancelledExpired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RangeOfExercisePriceCancelledExpired" xlink:to="aemd_RangeOfExercisePriceCancelledExpired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_RangeOfExercisePriceCancelledExpired_lbl" xml:lang="en-US">Range of Exercise Price Cancelled Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="aemd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="aemd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Cancelled/Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xml:lang="en-US">Number of Warrants Outstanding, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2" xlink:label="aemd_RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2" xlink:to="aemd_RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2_lbl" xml:lang="en-US">Range of Exercise Price Outstanding, Ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" xlink:label="aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" xlink:to="aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Warrants Exercisable, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_RangeOfWeightedAverageExercisePriceExercisable" xlink:label="aemd_RangeOfWeightedAverageExercisePriceExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RangeOfWeightedAverageExercisePriceExercisable" xlink:to="aemd_RangeOfWeightedAverageExercisePriceExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_RangeOfWeightedAverageExercisePriceExercisable_lbl" xml:lang="en-US">Range of Exercise Price Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:label="aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:to="aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xml:lang="en-US">Lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_MonthlyBaseRent" xlink:label="aemd_MonthlyBaseRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_MonthlyBaseRent" xlink:to="aemd_MonthlyBaseRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_MonthlyBaseRent_lbl" xml:lang="en-US">Monthly base rent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Right of use lease asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LettersOfCreditOutstandingAmount" xlink:to="us-gaap_LettersOfCreditOutstandingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xml:lang="en-US">Line of credit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCash_3_lbl" xml:lang="en-US">Restricted Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_PaymentForRentPerMonth" xlink:label="aemd_PaymentForRentPerMonth" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_PaymentForRentPerMonth" xlink:to="aemd_PaymentForRentPerMonth_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_PaymentForRentPerMonth_lbl" xml:lang="en-US">Payment for rent per month</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating Lease, Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RangeOfExercisePricesOptionBeginning" xlink:to="aemd_RangeOfExercisePricesOptionBeginning_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_RangeOfExercisePricesOptionBeginning_doc" xml:lang="en-US">Range of exercise prices, Option beginning</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RangeOfExercisePricesOptionCancelledexpired" xlink:to="aemd_RangeOfExercisePricesOptionCancelledexpired_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_RangeOfExercisePricesOptionCancelledexpired_doc" xml:lang="en-US">Range of exercise prices, Option cancelled/expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RangeOfExercisePricesOptionEnding" xlink:to="aemd_RangeOfExercisePricesOptionEnding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_RangeOfExercisePricesOptionEnding_doc" xml:lang="en-US">Range of exercise prices, Option ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RangeOfExercisePricesOptionExercisable" xlink:to="aemd_RangeOfExercisePricesOptionExercisable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_RangeOfExercisePricesOptionExercisable_doc" xml:lang="en-US">Range of exercise prices, Option exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_2_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossTax_2_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_2_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_AccretionOfRightofuseLeaseAsset" xlink:to="aemd_AccretionOfRightofuseLeaseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_AccretionOfRightofuseLeaseAsset_2_lbl" xml:lang="en-US">AccretionOfRightofuseLeaseAsset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Related Parties</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2_lbl" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_2_lbl" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_DueToRelatedPartiesCurrent1" xlink:to="aemd_DueToRelatedPartiesCurrent1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_DueToRelatedPartiesCurrent1_2_lbl" xml:lang="en-US">Due to related parties [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_3_lbl" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2_lbl" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>aemd-20230630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://aethlonmedical.com/role/Cover" xlink:href="aemd-20230630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets" xlink:href="aemd-20230630.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="aemd-20230630.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="aemd-20230630.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" xlink:href="aemd-20230630.xsd#CondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:href="aemd-20230630.xsd#CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="aemd-20230630.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganization" xlink:href="aemd-20230630.xsd#NatureOfBusinessAndBasisOfPresentationOrganization" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/LossPerCommonShare" xlink:href="aemd-20230630.xsd#LossPerCommonShare" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/ResearchAndDevelopmentExpenses" xlink:href="aemd-20230630.xsd#ResearchAndDevelopmentExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/RecentAccountingPronouncements" xlink:href="aemd-20230630.xsd#RecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302023" xlink:href="aemd-20230630.xsd#EquityTransactionsInThreeMonthsEndedJune302023" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/RelatedPartyTransactions" xlink:href="aemd-20230630.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/OtherCurrentLiabilities" xlink:href="aemd-20230630.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensation" xlink:href="aemd-20230630.xsd#StockCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/Warrants" xlink:href="aemd-20230630.xsd#Warrants" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CommitmentsAndContingencies" xlink:href="aemd-20230630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/SubsequentEvents" xlink:href="aemd-20230630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationPolicies" xlink:href="aemd-20230630.xsd#NatureOfBusinessAndBasisOfPresentationOrganizationPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesTables" xlink:href="aemd-20230630.xsd#ResearchAndDevelopmentExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/RelatedPartyTransactionsTables" xlink:href="aemd-20230630.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/OtherCurrentLiabilitiesTables" xlink:href="aemd-20230630.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationTables" xlink:href="aemd-20230630.xsd#StockCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/WarrantsTables" xlink:href="aemd-20230630.xsd#WarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationDetailsNarrative" xlink:href="aemd-20230630.xsd#NatureOfBusinessAndBasisOfPresentationOrganizationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/LossPerCommonShareDetailsNarrative" xlink:href="aemd-20230630.xsd#LossPerCommonShareDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesDetails" xlink:href="aemd-20230630.xsd#ResearchAndDevelopmentExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302023DetailsNarrative" xlink:href="aemd-20230630.xsd#EquityTransactionsInThreeMonthsEndedJune302023DetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/RelatedPartyTransactionsDetails" xlink:href="aemd-20230630.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="aemd-20230630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/OtherCurrentLiabilitiesDetails" xlink:href="aemd-20230630.xsd#OtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationDetails-StockCompensation" xlink:href="aemd-20230630.xsd#StockCompensationDetails-StockCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest" xlink:href="aemd-20230630.xsd#StockCompensationDetails-OptionsVestedAndExpectedToVest" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity" xlink:href="aemd-20230630.xsd#StockCompensationDetails-OptionActivity" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationDetailsNarrative" xlink:href="aemd-20230630.xsd#StockCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/WarrantDetails" xlink:href="aemd-20230630.xsd#WarrantDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="aemd-20230630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_DueToRelatedParties" xlink:label="loc_aemdDueToRelatedParties" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_aemdDueToRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaapLaborAndRelatedExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapLaborAndRelatedExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoninterestIncomeOtherAbstract" xlink:label="loc_us-gaapNoninterestIncomeOtherAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNoninterestIncomeOtherAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndOtherIncome" xlink:label="loc_us-gaapInterestAndOtherIncome" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInterestAndOtherIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossTaxPortionAttributableToParent1" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossTax" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:title="00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; EQUITY (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaapNoncontrollingInterestMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapNoncontrollingInterestMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExercise" xlink:label="loc_aemdIssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExercise" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdIssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExercise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExerciseShares" xlink:label="loc_aemdIssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExerciseShares" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdIssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExerciseShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:title="00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_AccretionOfRightofuseLeaseAsset" xlink:label="loc_aemdAccretionOfRightofuseLeaseAsset" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_aemdAccretionOfRightofuseLeaseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableRelatedParties" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableRelatedParties" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise" xlink:label="loc_aemdParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_aemdParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsAbstract" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestrictedCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestrictedCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganization" xlink:title="00000008 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/LossPerCommonShare" xlink:title="00000009 - Disclosure - LOSS PER COMMON SHARE">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/ResearchAndDevelopmentExpenses" xlink:title="00000010 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="loc_us-gaapResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/RecentAccountingPronouncements" xlink:title="00000011 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302023" xlink:title="00000012 - Disclosure - EQUITY TRANSACTIONS IN THE THREE MONTHS ENDED JUNE 30, 2023">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/RelatedPartyTransactions" xlink:title="00000013 - Disclosure - RELATED PARTY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/OtherCurrentLiabilities" xlink:title="00000014 - Disclosure - OTHER CURRENT LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapOtherLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensation" xlink:title="00000015 - Disclosure - STOCK COMPENSATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapShareholdersEquityAndShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/Warrants" xlink:title="00000016 - Disclosure - WARRANTS">
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_DisclosureWarrantsAbstract" xlink:label="loc_aemdDisclosureWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_WarrantsTextBlock" xlink:label="loc_aemdWarrantsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdDisclosureWarrantsAbstract" xlink:to="loc_aemdWarrantsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CommitmentsAndContingencies" xlink:title="00000017 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/SubsequentEvents" xlink:title="00000018 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationPolicies" xlink:title="00000019 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_LiquidityAndGoingConcernPolicyTextBlock" xlink:label="loc_aemdLiquidityAndGoingConcernPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_aemdLiquidityAndGoingConcernPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesTables" xlink:title="00000020 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:label="loc_us-gaapScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/RelatedPartyTransactionsTables" xlink:title="00000021 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000022 - Disclosure - OTHER CURRENT LIABILITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="loc_us-gaapOtherCurrentLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapOtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationTables" xlink:title="00000023 - Disclosure - STOCK COMPENSATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaapScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/WarrantsTables" xlink:title="00000024 - Disclosure - WARRANTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_DisclosureWarrantsAbstract" xlink:label="loc_aemdDisclosureWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdDisclosureWarrantsAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationDetailsNarrative" xlink:title="00000025 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaapBalanceSheetLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBalanceSheetLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_RestrictedCashMember" xlink:label="loc_aemdRestrictedCashMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_aemdRestrictedCashMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSecurityDeposit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/LossPerCommonShareDetailsNarrative" xlink:title="00000026 - Disclosure - LOSS PER COMMON SHARE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesDetails" xlink:title="00000027 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302023DetailsNarrative" xlink:title="00000028 - Disclosure - EQUITY TRANSACTIONS IN THE THREE MONTHS ENDED JUNE 30, 2023 (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuritiesFinancingTransactionTable" xlink:label="loc_us-gaapSecuritiesFinancingTransactionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSecuritiesFinancingTransactionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuritiesFinancingTransactionLineItems" xlink:label="loc_us-gaapSecuritiesFinancingTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSecuritiesFinancingTransactionTable" xlink:to="loc_us-gaapSecuritiesFinancingTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuritiesFinancingTransactionAxis" xlink:label="loc_us-gaapSecuritiesFinancingTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSecuritiesFinancingTransactionTable" xlink:to="loc_us-gaapSecuritiesFinancingTransactionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuritiesFinancingTransactionTypeDomain" xlink:label="loc_us-gaapSecuritiesFinancingTransactionTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSecuritiesFinancingTransactionAxis" xlink:to="loc_us-gaapSecuritiesFinancingTransactionTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_OfferingAgreementMember" xlink:label="loc_aemdOfferingAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSecuritiesFinancingTransactionTypeDomain" xlink:to="loc_aemdOfferingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSecuritiesFinancingTransactionTable" xlink:to="loc_srtCounterpartyNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_HcWainwrightMember" xlink:label="loc_aemdHcWainwrightMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_aemdHcWainwrightMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_EligibleDirectorsEachMember" xlink:label="loc_aemdEligibleDirectorsEachMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_aemdEligibleDirectorsEachMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaapTransactionTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSecuritiesFinancingTransactionTable" xlink:to="loc_us-gaapTransactionTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_OtherOfferingExpenseMember" xlink:label="loc_aemdOtherOfferingExpenseMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_aemdOtherOfferingExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSecuritiesFinancingTransactionTable" xlink:to="loc_us-gaapAwardTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSecuritiesFinancingTransactionLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForCommissions" xlink:label="loc_us-gaapPaymentsForCommissions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSecuritiesFinancingTransactionLineItems" xlink:to="loc_us-gaapPaymentsForCommissions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSecuritiesFinancingTransactionLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSecuritiesFinancingTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSecuritiesFinancingTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/RelatedPartyTransactionsDetails" xlink:title="00000029 - Disclosure -  RELATED PARTY TRANSACTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_AccruedBoardFeesMember" xlink:label="loc_aemdAccruedBoardFeesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_aemdAccruedBoardFeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_AccruedVacationMember" xlink:label="loc_aemdAccruedVacationMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_aemdAccruedVacationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_DueToRelatedPartiesCurrent1" xlink:label="loc_aemdDueToRelatedPartiesCurrent1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_aemdDueToRelatedPartiesCurrent1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000030 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_AccruedDirectorFees" xlink:label="loc_aemdAccruedDirectorFees" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_aemdAccruedDirectorFees" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/OtherCurrentLiabilitiesDetails" xlink:title="00000031 - Disclosure - OTHER CURRENT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationDetails-StockCompensation" xlink:title="00000032 - Disclosure - STOCK COMPENSATION (Details - Stock compensation)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaapTransactionTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapTransactionTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_StockBasedCompensationMember" xlink:label="loc_aemdStockBasedCompensationMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_aemdStockBasedCompensationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest" xlink:title="00000033 - Disclosure - STOCK COMPENSATION (Details - Options vested and expected to vest)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity" xlink:title="00000034 - Disclosure - STOCK COMPENSATION (Details - Option activity)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_RangeOfExercisePricesOptionBeginning" xlink:label="loc_aemdRangeOfExercisePricesOptionBeginning" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_aemdRangeOfExercisePricesOptionBeginning" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_RangeOfExercisePricesOptionGranted" xlink:label="loc_aemdRangeOfExercisePricesOptionGranted" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_aemdRangeOfExercisePricesOptionGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_RangeOfExercisePricesOptionCancelledexpired" xlink:label="loc_aemdRangeOfExercisePricesOptionCancelledexpired" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_aemdRangeOfExercisePricesOptionCancelledexpired" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_RangeOfExercisePricesOptionEnding" xlink:label="loc_aemdRangeOfExercisePricesOptionEnding" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_aemdRangeOfExercisePricesOptionEnding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_RangeOfExercisePricesOptionExercisable" xlink:label="loc_aemdRangeOfExercisePricesOptionExercisable" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_aemdRangeOfExercisePricesOptionExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationDetailsNarrative" xlink:title="00000035 - Disclosure - STOCK COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/WarrantDetails" xlink:title="00000036 - Disclosure - Warrant (Details)">
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_DisclosureWarrantsAbstract" xlink:label="loc_aemdDisclosureWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aemdDisclosureWarrantsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_aemdRangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_aemdRangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="loc_aemdShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_aemdShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_RangeOfExercisePriceCancelledExpired" xlink:label="loc_aemdRangeOfExercisePriceCancelledExpired" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_aemdRangeOfExercisePriceCancelledExpired" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_aemdShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_aemdShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2" xlink:label="loc_aemdRangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_aemdRangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" xlink:label="loc_aemdShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_aemdShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_RangeOfWeightedAverageExercisePriceExercisable" xlink:label="loc_aemdRangeOfWeightedAverageExercisePriceExercisable" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_aemdRangeOfWeightedAverageExercisePriceExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_aemdShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_aemdShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000037 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_OfficeAndLaboratoryMember" xlink:label="loc_aemdOfficeAndLaboratoryMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="loc_aemdOfficeAndLaboratoryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_ManufacturingMember" xlink:label="loc_aemdManufacturingMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="loc_aemdManufacturingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_OfficeLabAndManufacturingLeasesMember" xlink:label="loc_aemdOfficeLabAndManufacturingLeasesMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="loc_aemdOfficeLabAndManufacturingLeasesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_NewOfficeAndLabSpaceMember" xlink:label="loc_aemdNewOfficeAndLabSpaceMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="loc_aemdNewOfficeAndLabSpaceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_MonthlyBaseRent" xlink:label="loc_aemdMonthlyBaseRent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdMonthlyBaseRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="loc_us-gaapLettersOfCreditOutstandingAmount" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLettersOfCreditOutstandingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aemd-20230630.xsd#aemd_PaymentForRentPerMonth" xlink:label="loc_aemdPaymentForRentPerMonth" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdPaymentForRentPerMonth" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139908505976256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Aug. 09, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--03-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Aethlon Medical, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000882291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-3632859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11555 SORRENTO VALLEY ROAD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">SUITE 203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">SAN DIEGO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(619)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">941-0360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">COMMON STOCK, $0.001 PAR VALUE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AEMD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,835,321<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139908509918192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 12,897,734<span></span>
</td>
<td class="nump">$ 14,532,943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">410,223<span></span>
</td>
<td class="nump">557,623<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">13,307,957<span></span>
</td>
<td class="nump">15,090,566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,284,200<span></span>
</td>
<td class="nump">1,144,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use lease asset</a></td>
<td class="nump">1,086,108<span></span>
</td>
<td class="nump">1,151,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patents, net</a></td>
<td class="nump">1,513<span></span>
</td>
<td class="nump">1,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">87,506<span></span>
</td>
<td class="nump">87,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits</a></td>
<td class="nump">33,305<span></span>
</td>
<td class="nump">33,305<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">15,800,589<span></span>
</td>
<td class="nump">17,508,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">844,536<span></span>
</td>
<td class="nump">432,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aemd_DueToRelatedParties', window );">Due to related parties</a></td>
<td class="nump">191,314<span></span>
</td>
<td class="nump">214,221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability, current portion</a></td>
<td class="nump">274,520<span></span>
</td>
<td class="nump">269,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">511,377<span></span>
</td>
<td class="nump">588,592<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,821,747<span></span>
</td>
<td class="nump">1,505,089<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, less current portion</a></td>
<td class="nump">869,945<span></span>
</td>
<td class="nump">939,642<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,691,692<span></span>
</td>
<td class="nump">2,444,731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.001 per share; 60,000,000 shares authorized as of June 30, 2023 and March 31, 2023; 24,835,321 and 22,992,466 shares issued and outstanding as of June 30, 2023 and March 31, 2023, respectively</a></td>
<td class="nump">24,837<span></span>
</td>
<td class="nump">22,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">158,731,929<span></span>
</td>
<td class="nump">157,405,911<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(7,135)<span></span>
</td>
<td class="num">(6,141)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(145,640,734)<span></span>
</td>
<td class="num">(142,358,555)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">13,108,897<span></span>
</td>
<td class="nump">15,064,209<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 15,800,589<span></span>
</td>
<td class="nump">$ 17,508,940<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_DueToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_DueToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139908506453504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized</a></td>
<td class="nump">60,000,000<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued</a></td>
<td class="nump">24,835,321<span></span>
</td>
<td class="nump">22,992,466<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding</a></td>
<td class="nump">24,835,321<span></span>
</td>
<td class="nump">22,992,466<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139908505878848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="nump">$ 976,638<span></span>
</td>
<td class="nump">$ 844,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Payroll and related expenses</a></td>
<td class="nump">1,123,239<span></span>
</td>
<td class="nump">1,029,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,308,283<span></span>
</td>
<td class="nump">1,032,367<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">3,408,160<span></span>
</td>
<td class="nump">2,906,081<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING LOSS</a></td>
<td class="num">(3,408,160)<span></span>
</td>
<td class="num">(2,906,081)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestIncomeOtherAbstract', window );"><strong>OTHER INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest income</a></td>
<td class="nump">125,981<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">NET LOSS</a></td>
<td class="num">(3,282,179)<span></span>
</td>
<td class="num">(2,906,081)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">LOSS ATTRIBUTABLE TO NONCONTROLLING INTERESTS</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(413)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS ATTRIBUTABLE TO AETHLON MEDICAL, INC.</a></td>
<td class="num">(3,282,179)<span></span>
</td>
<td class="num">(2,905,668)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">OTHER COMPREHENSIVE LOSS</a></td>
<td class="num">(994)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">COMPREHENSIVE LOSS</a></td>
<td class="num">$ (3,283,173)<span></span>
</td>
<td class="num">$ (2,905,668)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoninterestIncomeOtherAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoninterestIncomeOtherAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139908509976272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share</a></td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share</a></td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding basic</a></td>
<td class="nump">24,314,759<span></span>
</td>
<td class="nump">15,486,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares outstanding diluted</a></td>
<td class="nump">24,314,759<span></span>
</td>
<td class="nump">15,486,621<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139908505990512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Noncontrolling Interest [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">BALANCE - MARCH 31, 2022 at Mar. 31, 2022</a></td>
<td class="nump">$ 15,421<span></span>
</td>
<td class="nump">$ 147,446,868<span></span>
</td>
<td class="num">$ (130,329,181)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (141,708)<span></span>
</td>
<td class="nump">$ 16,991,400<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2022</a></td>
<td class="nump">15,419,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuances of common stock for cash under at the market program</a></td>
<td class="nump">$ 575<span></span>
</td>
<td class="nump">618,867<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">619,442<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuances of common stock for cash under at the market program, shares</a></td>
<td class="nump">574,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">215,437<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">215,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,905,668)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(413)<span></span>
</td>
<td class="num">(2,906,081)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">BALANCE &#8211; JUNE 30, 2022 at Jun. 30, 2022</a></td>
<td class="nump">$ 15,996<span></span>
</td>
<td class="nump">148,281,172<span></span>
</td>
<td class="num">(133,234,849)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(142,121)<span></span>
</td>
<td class="nump">14,920,198<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2022</a></td>
<td class="nump">15,993,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">BALANCE - MARCH 31, 2022 at Mar. 31, 2023</a></td>
<td class="nump">$ 22,994<span></span>
</td>
<td class="nump">157,405,911<span></span>
</td>
<td class="num">(142,358,555)<span></span>
</td>
<td class="num">(6,141)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">15,064,209<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2023</a></td>
<td class="nump">22,992,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuances of common stock for cash under at the market program</a></td>
<td class="nump">$ 1,779<span></span>
</td>
<td class="nump">1,084,340<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,086,119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuances of common stock for cash under at the market program, shares</a></td>
<td class="nump">1,778,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aemd_IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExercise', window );">Issuance of common shares upon vesting of restricted stock units and net stock option exercises</a></td>
<td class="nump">$ 64<span></span>
</td>
<td class="num">(8,436)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,372)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aemd_IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExerciseShares', window );">Issuance of common shares upon vesting of restricted stock units and net stock option exercise, shares</a></td>
<td class="nump">63,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">250,114<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">250,114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,282,179)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,282,179)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(994)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(994)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">BALANCE &#8211; JUNE 30, 2022 at Jun. 30, 2023</a></td>
<td class="nump">$ 24,837<span></span>
</td>
<td class="nump">$ 158,731,929<span></span>
</td>
<td class="num">$ (145,640,734)<span></span>
</td>
<td class="num">$ (7,135)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 13,108,897<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2023</a></td>
<td class="nump">24,835,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExerciseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExerciseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139908505898352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (3,282,179)<span></span>
</td>
<td class="num">$ (2,906,081)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">90,325<span></span>
</td>
<td class="nump">30,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">250,114<span></span>
</td>
<td class="nump">215,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aemd_AccretionOfRightofuseLeaseAsset', window );">Accretion of right-of-use lease asset</a></td>
<td class="nump">1,238<span></span>
</td>
<td class="nump">7,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">146,409<span></span>
</td>
<td class="nump">99,336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and other current liabilities</a></td>
<td class="nump">334,613<span></span>
</td>
<td class="num">(310,327)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">114,849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties', window );">Due to related parties</a></td>
<td class="num">(22,907)<span></span>
</td>
<td class="nump">6,303<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(2,482,387)<span></span>
</td>
<td class="num">(2,728,917)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows used in investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(230,383)<span></span>
</td>
<td class="num">(41,169)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(230,383)<span></span>
</td>
<td class="num">(41,169)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows provided by financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock, net</a></td>
<td class="nump">1,086,119<span></span>
</td>
<td class="nump">619,442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Tax withholding payments or tax equivalent payments for net share settlement of restricted stock units and net stock option expense</a></td>
<td class="num">(8,372)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">1,077,747<span></span>
</td>
<td class="nump">619,442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate on changes on cash</a></td>
<td class="num">(186)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and restricted cash</a></td>
<td class="num">(1,635,209)<span></span>
</td>
<td class="num">(2,150,644)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and restricted cash at beginning of period</a></td>
<td class="nump">14,620,449<span></span>
</td>
<td class="nump">17,159,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and restricted cash</a></td>
<td class="nump">12,985,240<span></span>
</td>
<td class="nump">15,009,281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aemd_ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise', window );">Par value of shares issued for vested restricted stock units and net stock option exercise</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">12,897,734<span></span>
</td>
<td class="nump">14,921,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 87,506<span></span>
</td>
<td class="nump">$ 87,506<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_AccretionOfRightofuseLeaseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_AccretionOfRightofuseLeaseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139908508083312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION</a></td>
<td class="text"><p id="xdx_803_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zqEBwHCHaTPa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1. <span id="xdx_821_zAHfOn9GSmqd">NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Aethlon Medical, Inc., or Aethlon, the Company,
we or us, is a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases. The
Aethlon Hemopurifier is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. In
cancer, the Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression, seed
the spread of metastasis and inhibit the benefit of leading cancer therapies. The U.S. Food and Drug Administration, or FDA, has designated
the Hemopurifier as a &#8220;Breakthrough Device&#8221; for two independent indications:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the treatment of life-threatening viruses that are not addressed with approved therapies.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe the Hemopurifier can be a substantial
advance in the treatment of patients with advanced and metastatic cancer through the clearance of exosomes that promote the growth and
spread of tumors through multiple mechanisms. We are currently working with our new contract research organization, or CRO, on preparations
to conduct a clinical trial in Australia in patients with solid tumors, including head and neck cancer, gastrointestinal cancers and other
cancers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2023, we entered into an agreement
with North American Science Associates, LLC, or NAMSA, a world leading MedTech CRO offering global end-to-end development services, to
oversee our clinical trials investigating the Hemopurifier for oncology indications. Pursuant to the agreement, NAMSA will manage our
clinical trials of the Hemopurifier for patients in the United States and Australia with various types of cancer tumors. We anticipate
that the initial clinical trials will begin in Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also believe the Hemopurifier can be part of
the broad-spectrum treatment of life-threatening highly glycosylated, or carbohydrate coated, viruses that are not addressed with an already
approved treatment. In small-scale or early feasibility human studies, the Hemopurifier has been used in the past to treat individuals
infected with human immunodeficiency virus, or HIV, hepatitis-C and Ebola.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, <i>in vitro,</i> the Hemopurifier
has been demonstrated to capture Zika virus, Lassa virus, MERS-CoV, cytomegalovirus, Epstein-Barr virus, Herpes simplex virus, Chikungunya
virus, Dengue virus, West Nile virus, smallpox-related viruses, H1N1 swine flu virus, H5N1 bird flu virus, Monkeypox virus and the reconstructed
Spanish flu virus of 1918. In several cases, these studies were conducted in collaboration with leading government or non-government research
institutes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 17, 2020, the FDA approved a supplement
to our open Investigational Device Exemption, or IDE, for the Hemopurifier in viral disease to allow for the testing of the Hemopurifier
in patients with SARS-CoV-2/COVID-19, or COVID-19, in a New Feasibility Study. <span style="background-color: white">That study was designed
to enroll up to 40 subjects at up to 20 centers in the United States. Subjects were to have established laboratory diagnosis of COVID-19,
be admitted to an intensive care unit, or ICU, and have acute lung injury and/or severe or life-threatening disease, among other criteria.
Endpoints for this study, in addition to safety, included reduction in circulating virus as well as clinical outcomes (NCT # 04595903).
</span>In June 2022, the first patient in this study was enrolled and completed the Hemopurifier treatment phase of the protocol. Due
to lack of COVID-19 patients in the ICUs of our trial sites, we terminated this study in 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under Single Patient Emergency Use regulations,
the Company has treated two patients with COVID-19 with the Hemopurifier, in addition to the COVID-19 patient treated with our Hemopurifier
in our COVID-19 clinical trial discussed above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently are experiencing a disruption in
our Hemopurifier supply, as our existing supply of Hemopurifiers expired on September 30, 2022 and, as previously disclosed, we are dependent
on FDA approval of qualified suppliers to manufacture our Hemopurifier. Our intended transition to a new supplier for galanthus nivalis
agglutinin, or GNA, a component of our Hemopurifier, is delayed as we work with the FDA for approval of our supplement to our IDE, which
is required to make this manufacturing change.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2022, we launched a wholly owned subsidiary
in Australia, formed to conduct clinical research, seek regulatory approval and commercialize our Hemopurifier in that country. The subsidiary
will initially focus on the oncology trials in Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also obtained ethics review board,
or ERB approval, from and entered into a clinical trial agreement with Medanta Medicity Hospital, a multi-specialty hospital in Delhi
NCR, India, for a COVID-19 clinical trial at that location. One patient has completed participation in the Indian COVID-19 study. The
relevant authorities in India have accepted the use of our Hemopurifiers made with the GNA from our new supplier.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2023, we also received ERB approval from
the Maulana Azad Medical College, or MAMC, for a second site for our clinical trial in India to treat severe COVID-19. MAMC was established
in 1958 and is located in New Delhi, India. MMAC is affiliated with the University of Delhi and is operated by the Delhi government.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also recently announced that we also have begun
investigating the use of our Hemopurifier in the organ transplant setting. Our objective is to confirm that the Hemopurifier, in our translational
studies, when incorporated into a machine perfusion organ preservation circuit, can remove harmful viruses and exosomes from recovered
organs. We initially are focused on recovered kidneys, in a research collaboration with 34 Lives, PBC. We have previously demonstrated
the removal of multiple viruses and exosomes from buffer solutions, in vitro, utilizing a scaled-down version of our Hemopurifier. This
process potentially may reduce complications following transplantation of the recovered organ, which can include viral infection, delayed
graft function and rejection. We believe this new approach could be additive to existing technologies that currently are in place to increase
the number of viable kidneys for transplant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Successful outcomes of human trials will also
be required by the regulatory agencies of certain foreign countries where we plan to market and sell the Hemopurifier. Some of our patents
may expire before FDA approval or approval in a foreign country, if any, is obtained. However, we believe that certain patent applications
and/or other patents issued to us more recently will help protect the proprietary nature of our Hemopurifier treatment technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the foregoing, we are monitoring
closely the impact of inflation, recent bank failures and the war in Ukraine on our business. Given the level of uncertainty regarding
the duration and impact of these events on capital markets and the U.S. economy, we are unable to assess the impact on our timelines and
future access to capital. The full extent to which inflation, recent bank failures and the war in Ukraine will impact our business, results
of operations, financial condition, clinical trials and preclinical research will depend on future developments, as well as the economic
impact on national and international markets that are highly uncertain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We incorporated in Nevada on March 10, 1999. Our
executive offices are located at 11555 Sorrento Valley Road, Suite 203, San Diego, California 92121. Our telephone number is (619) 941-0360.
Our website address is www.aethlonmedical.com.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common stock is listed on the Nasdaq Capital Market under the symbol
&#8220;AEMD.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended June 30, 2023, there
were no changes to our significant accounting policies as described in our Annual Report on Form 10-K for the fiscal year ended March
31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p id="xdx_84D_eus-gaap--UseOfEstimates_z5zSVHVKBcxd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_866_zhHe5IOoqnyh">Basis of Presentation and Use of Estimates</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited condensed consolidated
financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for
interim financial information and with the instructions to Form 10-Q and Article 8 of the Securities and Exchange Commission, or SEC,
Regulation S-X. Accordingly, they should be read in conjunction with the audited financial statements and notes thereto for the fiscal
year ended March 31, 2023, included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on June 28, 2023. The accompanying
unaudited condensed consolidated financial statements include the accounts of Aethlon Medical, Inc. and its wholly owned subsidiary, Aethlon
Medical Australia Pty Ltd, as well as its previously majority-owned subsidiary, Exosome Sciences, Inc., which dissolved in September 2022.
All significant inter-company transactions and balances have been eliminated in consolidation. The unaudited condensed consolidated financial
statements contain all normal recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the
condensed consolidated financial statements as of and for the three months ended June 30, 2023, and the condensed consolidated statement
of cash flows for the three months ended June 30, 2023. Estimates were made relating to useful lives of fixed assets, impairment of assets,
share-based compensation expense and accruals for clinical trial and research and development expenses. Actual results could differ materially
from those estimates. The accompanying condensed consolidated balance sheet at March 31, 2023 has been derived from the audited consolidated
balance sheet at March 31, 2023, contained in the above referenced 10-K. The results of operations for the three months ended June 30,
2023 are not necessarily indicative of the results to be expected for the full year or any future interim periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p id="xdx_844_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zPYjSofJx4X2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_867_zQFOIPS2Bxpk">Reclassifications</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain prior year balances within the unaudited
condensed consolidated financial statements have been reclassified to conform to the current year presentation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p id="xdx_845_ecustom--LiquidityAndGoingConcernPolicyTextBlock_zSKGnONx7Zhi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_864_zldIEJHyTHNe">LIQUIDITY AND GOING CONCERN</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management expects existing cash as of June 30,
2023 to be sufficient to fund the Company&#8217;s operations for at least twelve months from the issuance date of these condensed consolidated
financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p id="xdx_84F_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zB8s2iKOa4sl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_86D_zFHX4mGOcFc">Restricted Cash</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To comply with the terms of our laboratory and
office lease and our lease for our manufacturing space, see Note 10, we caused our bank to issue two standby letters of credit, or L/Cs,
in the aggregate amount of $<span id="xdx_90B_eus-gaap--SecurityDeposit_c20220630__us-gaap--BalanceSheetLocationAxis__custom--RestrictedCashMember_pp0p0" title="Security deposit">87,506</span> in favor of the landlord. The L/Cs are in lieu of a security deposit. In order to support the L/Cs,
we agreed to have our bank withdraw $87,506 from our operating accounts and to place that amount in a restricted certificate of deposit.
We have classified that amount as restricted cash, a long-term asset, on our balance sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139908668732608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER COMMON SHARE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">LOSS PER COMMON SHARE</a></td>
<td class="text"><p id="xdx_805_eus-gaap--EarningsPerShareTextBlock_zQ8ymf3531b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2. <span id="xdx_825_zz9TCCGCHjE6">LOSS PER COMMON SHARE</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic loss per share is computed by dividing net
loss by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is computed
similar to basic loss per share, except that the denominator is increased to include the number of additional dilutive common shares that
would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive. Since we had net
losses for all periods presented, basic and diluted loss per share are the same, and additional potential common shares have been excluded,
as their effect would be antidilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2023 and 2022, an aggregate of
<span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230401__20230630_z8c1hk8ml2le" title="Antidilutive shares">2,291,234</span> and <span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220401__20220630_zSjr9Inh5QU1" title="Antidilutive shares">2,227,286</span> potential common shares, respectively, consisting of shares underlying outstanding stock options, warrants, and
restricted stock units were excluded, as their inclusion would be antidilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>











<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139908511292544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT EXPENSES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">RESEARCH AND DEVELOPMENT EXPENSES</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_zJkQvXRuWjnf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3. <span id="xdx_82A_zJdffVmSIG2i">RESEARCH AND DEVELOPMENT EXPENSES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our research and development costs are expensed
as incurred. We incurred research and development expenses during the three month periods ended June 30, 2023 and 2022, which are included
in various operating expense line items in the accompanying condensed consolidated statements of operations. Our research and development
expenses in those periods were as follows:</p>

<table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_ziCjsKHdpPu6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;<span id="xdx_8B6_zxOMOTo6NeUl" style="display: none">Research and development expenses</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">June 30,</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">June 30,</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; width: 66%; text-align: center">&#160;</td><td style="text-align: center; width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: center">2023</td><td style="width: 1%; padding-bottom: 1pt; text-align: center">&#160;</td><td style="text-align: center; width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: center">2022</td><td style="width: 1%; padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three months ended</span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230401__20230630_zCmEpxkSGW01" style="text-align: right" title="Research and development expense">678,922</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220401__20220630_zhhYNp2g0ZZg" style="text-align: right" title="Research and development expense">858,347</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zxWbjXIzjpb4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 985<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//985-730/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139908509959792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RECENT ACCOUNTING PRONOUNCEMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">RECENT ACCOUNTING PRONOUNCEMENTS</a></td>
<td class="text"><p id="xdx_802_eus-gaap--NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_zrEKyKFsn9C1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4. <span style="text-transform: uppercase"><span id="xdx_82B_zB8RcpZFh4m6">RECENT ACCOUNTING PRONOUNCEMENTS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -Publisher FASB<br> -URI https://asc.fasb.org//250/tableOfContent<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -SubTopic 20<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -SubTopic 20<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139908508361264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY TRANSACTIONS IN THE THREE MONTHS ENDED JUNE 30, 2023<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">EQUITY TRANSACTIONS IN THE THREE MONTHS ENDED JUNE 30, 2023</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zS0eteueYr6k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5. <span id="xdx_820_zKowBRU3e1Jf">EQUITY TRANSACTIONS IN THE THREE MONTHS ENDED JUNE 30, 2023</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>2022 At The Market Offering Agreement with H.C. Wainwright &amp;
Co., LLC</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 24, 2022, we entered into an At The Market
Offering Agreement, or the 2022 ATM Agreement, with H.C. Wainwright &amp; Co., LLC, or Wainwright, which established an at-the-market
equity program pursuant to which we may offer and sell shares of our common stock from time to time as set forth in the 2022 ATM Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The offering was registered under the Securities
Act of 1933, as amended, or the Securities Act, pursuant to our shelf registration statement on Form S-3 (Registration Statement No. 333-259909),
as previously filed with the SEC and declared effective on October 21, 2021. We filed a prospectus supplement, dated March 24, 2022, with
the SEC that provides for the sale of shares of our common stock having an aggregate offering price of up to $15,000,000, or the 2022
ATM Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the 2022 ATM Agreement, Wainwright may sell
the 2022 ATM Shares by any method permitted by law and deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415 promulgated
under the Securities Act, including sales made directly on the Nasdaq Capital Market, or on any other existing trading market for the
2022 ATM Shares. In addition, under the 2022 ATM Agreement, Wainwright may sell the 2022 ATM Shares in privately negotiated transactions
with our consent and in block transactions. Under certain circumstances, we may instruct Wainwright not to sell the 2022 ATM Shares if
the sales cannot be effected at or above the price designated by us from time to time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are not obligated to make any sales of the
2022 ATM Shares under the 2022 ATM Agreement. The offering of the 2022 ATM Shares pursuant to the 2022 ATM Agreement will terminate upon
the termination of the 2022 ATM Agreement by Wainwright or us, as permitted therein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2022 ATM Agreement contains customary representations,
warranties and agreements by us, and customary indemnification and contribution rights and obligations of the parties. We agreed to pay
Wainwright a placement fee of up to 3.0% of the aggregate gross proceeds from each sale of the 2022 ATM Shares. We also agreed to reimburse
Wainwright for certain specified expenses in connection with entering into the 2022 ATM Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended June 30, 2023, we
raised net proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20230401__20230630__us-gaap--SecuritiesFinancingTransactionAxis__custom--OfferingAgreementMember_pp0p0" title="Proceeds from issuance of equity">1,086,119</span>, net of $<span id="xdx_90C_eus-gaap--PaymentsForCommissions_c20230401__20230630__srt--CounterpartyNameAxis__custom--HcWainwrightMember__us-gaap--SecuritiesFinancingTransactionAxis__custom--OfferingAgreementMember_pp0p0" title="Payment of commissions">27,999</span> in commissions to Wainwright and $<span id="xdx_90B_eus-gaap--PaymentsOfStockIssuanceCosts_c20230401__20230630__us-gaap--SecuritiesFinancingTransactionAxis__custom--OfferingAgreementMember__us-gaap--TransactionTypeAxis__custom--OtherOfferingExpenseMember_pp0p0" title="Payment of stock issuance costs">5,846</span> in other offering expense, through the sale
of, <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230401__20230630__us-gaap--SecuritiesFinancingTransactionAxis__custom--OfferingAgreementMember_pdd" title="Stock issued new, shares issued">1,778,901</span> shares of our common stock at an average price of $0.61 per share under the 2022 ATM Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Restricted Stock Unit Grants </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 28, 2023, the Board approved, pursuant
to the terms of the Amended and Restated Non-Employee Director Compensation Policy, or the Director Compensation Policy, the grant of
the annual restricted stock units, or RSUs, under the Director Compensation Policy to each of the three non-employee directors of the
Company then serving on the Board. The Director Compensation Policy provides for a grant of stock options or $50,000 worth of RSUs at
the beginning of each fiscal year for current directors then serving on the Board, and for a grant of stock options or $75,000 worth of
RSUs for a newly elected director, with each RSU priced at the average for the closing prices for the five days preceding and including
the date of grant, or $0.43 per share for the RSUs granted in April 2023. As a result, in April 2023 the three eligible directors each
were granted an RSU in the amount of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230401__20230630__srt--CounterpartyNameAxis__custom--EligibleDirectorsEachMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVypdjt567xe" title="Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period">116,279</span> shares under the Company&#8217;s 2020 Equity Incentive Plan, or the 2020 Plan. The RSUs are
subject to vesting in four equal installments, with 25% of the restricted stock units vesting on each of June 30, 2023, September 30,
2023, December 31, 2023, and March 31, 2024, subject in each case to the director&#8217;s Continuous Service (as defined in the 2020 Plan),
through such dates. Vesting will terminate upon the director&#8217;s termination of Continuous Service prior to any vesting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139908508107408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zh4Of6uKfiV6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">6. <span id="xdx_821_zXza0wTgkuxi">RELATED PARTY TRANSACTIONS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended June 30, 2023, we
accrued unpaid fees of $<span id="xdx_90B_ecustom--AccruedDirectorFees_c20230630_pp0p0" title="Accrued director fees">57,000</span> owed to our non-employee directors. Amounts due to related parties were comprised of the following items:</p>

<table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zfxWkxhgBzxj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure -  RELATED PARTY TRANSACTIONS (Details)">
  <tr style="vertical-align: bottom">
    <td>&#160;<span id="xdx_8B7_zFQUqfZCc5Ea" style="display: none">Due to related parties</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, <br/> 2023</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">March 31, <br/> 2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Accrued Board fees</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--DueToRelatedPartiesCurrent1_c20230630__us-gaap--RelatedPartyTransactionAxis__custom--AccruedBoardFeesMember_pp0p0" style="width: 13%; text-align: right" title="Due to related parties">57,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--DueToRelatedPartiesCurrent1_iI_pp0p0_c20230331__us-gaap--RelatedPartyTransactionAxis__custom--AccruedBoardFeesMember_z3Zz2UjwkKN6" style="width: 13%; text-align: right" title="Due to related parties">57,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Accrued vacation to all employees</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--DueToRelatedPartiesCurrent1_c20230630__us-gaap--RelatedPartyTransactionAxis__custom--AccruedVacationMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Due to related parties">134,314</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_ecustom--DueToRelatedPartiesCurrent1_iI_pp0p0_c20230331__us-gaap--RelatedPartyTransactionAxis__custom--AccruedVacationMember_zcnZNuBXvfhi" style="border-bottom: Black 1pt solid; text-align: right" title="Due to related parties">157,221</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total due to related parties</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--DueToRelatedPartiesCurrent1_c20230630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Due to related parties">191,314</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--DueToRelatedPartiesCurrent1_iI_pp0p0_c20230331_zqlhTr7UOLje" style="border-bottom: Black 2.5pt double; text-align: right" title="Due to related parties">214,221</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zrmPlp9dot9a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139908509503664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">OTHER CURRENT LIABILITIES</a></td>
<td class="text"><p id="xdx_800_eus-gaap--OtherLiabilitiesDisclosureTextBlock_z3kwzUfWljNb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">7. <span id="xdx_828_z0TAQbGAXDR5">OTHER CURRENT LIABILITIES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other current liabilities were comprised of the following items:</p>

<table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_zXcTSEyQ5Mi1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - OTHER CURRENT LIABILITIES (Details)">
  <tr style="vertical-align: bottom">
    <td><b style="display: none">&#160;<span id="xdx_8BA_zXYdGoNH7Hhc">Schedule of other current liabilities</span></b></td><td>&#160;</td>
    <td colspan="2" id="xdx_496_20230630_zEH6GLdHbBAh" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_494_20230331_zQ957KJvXEmb" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">June 30,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">March 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maOLCzQ3w_zPZRgFpIl6l2" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left; padding-bottom: 1pt">Accrued professional fees</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">511,377</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">588,592</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OtherLiabilitiesCurrent_iTI_pp0p0_mtOLCzQ3w_zOXzui78EuN6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total other current liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">511,377</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">588,592</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zs2gpAoUZyNi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>











<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20,24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139908511020304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">STOCK COMPENSATION</a></td>
<td class="text"><p id="xdx_801_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zuldErmVJz5e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">8. <span id="xdx_828_zHlX2EKmNST">STOCK COMPENSATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following tables summarize share-based compensation
expenses relating to RSUs and stock options and the effect on basic and diluted loss per common share during the three month periods ended
June 30, 2023 and 2022:</p>

<table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zGurrYfR5HYj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK COMPENSATION (Details - Stock compensation)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B7_zLlfHkJvLm6b" style="display: none">Schedule of share-based compensation expense</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_492_20230401__20230630_zTPPbrMJoBDk" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_499_20220401__20220630_z9iNGfWe6rri" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, <br/> 2023</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, <br/> 2022</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_zKJQPqFYtrE7" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left; padding-bottom: 1pt">Vesting of stock options and restricted stock units</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">250,114</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">215,437</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ShareBasedCompensation_z5ejZmZOPirc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">250,114</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">215,437</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Weighted average number of common shares outstanding &#8211; basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230401__20230630_zPnUc9bvkZo2" title="Weighted Average Number of Shares Outstanding, Basic"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230401__20230630_zpmVNJyN3tn9" title="Weighted Average Number of Shares Outstanding, Diluted">24,314,759</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220401__20220630_zzXzg3Go3Ia6" title="Weighted Average Number of Shares Outstanding, Basic"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220401__20220630_zCAWDsHqTi2h" title="Weighted Average Number of Shares Outstanding, Diluted">15,486,621</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Basic and diluted loss per common share attributable to stock-based compensation expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20230401__20230630__us-gaap--TransactionTypeAxis__custom--StockBasedCompensationMember_zR6l4AGdErhf" title="Earnings Per Share, Basic"><span id="xdx_905_eus-gaap--EarningsPerShareDiluted_c20230401__20230630__us-gaap--TransactionTypeAxis__custom--StockBasedCompensationMember_zf0SAlcFLh03" title="Earnings Per Share, Diluted">(0.01</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--EarningsPerShareBasic_c20220401__20220630__us-gaap--TransactionTypeAxis__custom--StockBasedCompensationMember_z6RqknH9NQ8h" title="Earnings Per Share, Basic"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_c20220401__20220630__us-gaap--TransactionTypeAxis__custom--StockBasedCompensationMember_zFYuWmwJwh54" title="Earnings Per Share, Diluted">(0.01</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8A4_z0m3BW9VrZf2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All of the stock-based compensation expense recorded
during the three months ended June 30, 2023 and 2022, an aggregate of $<span id="xdx_905_eus-gaap--ShareBasedCompensation_pp0p0_c20230401__20230630_zm6msLBzMNAf" title="Stock based compensation">250,114</span> and $<span id="xdx_904_eus-gaap--ShareBasedCompensation_pp0p0_c20220401__20220630_zTc9NqgLfgMa" title="Stock based compensation">215,437</span>, respectively, is included in payroll and
related expense in the accompanying condensed consolidated statements of operations. Stock-based compensation expense recorded during
each of the three months ended June 30, 2023 and 2022 represented an impact on basic and diluted loss per common share of $(0.01) in each
period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We review share-based compensation on a quarterly
basis for changes to the estimate of expected award forfeitures based on actual forfeiture experience. The cumulative effect of adjusting
the forfeiture rate for all expense amortization is recognized in the period the forfeiture estimate is changed. The effect of forfeiture
adjustments for the three months ended June 30, 2023 was insignificant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Stock Option Activity</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We did not issue any stock options during the three months ended June
30, 2023 and 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stock options outstanding that have vested as
of June 30, 2023 and stock options that are expected to vest subsequent to June 30, 2023 are as follows:</p>

<table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_zPxYiqdu59v5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK COMPENSATION (Details - Options vested and expected to vest)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B4_zlWPl0Lg8kQ8" style="display: none">Schedule of options outstanding that have vested and are expected to vest</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/> Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term in<br/> Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 55%">Vested</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_znw6ZxLH8uyc" style="width: 11%; text-align: right" title="Options vested">842,610</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z898JzduWEz" style="width: 11%; text-align: right" title="Weighted average exercise price options vested">2.44</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zi2naYs42RUh" title="Weighted average remaining contractual term options vested">7.68</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Expected to vest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zkYpWV7RMHh5" style="border-bottom: Black 1pt solid; text-align: right" title="Options expected to vest">860,243</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zG2gi0sDRvi4" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price options expected to vest">2.06</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zHFw2Ra7oCP9" title="Weighted average remaining contractual term options expected to vest">8.24</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zdDfdmkzR0Lb" style="border-bottom: Black 2.5pt double; text-align: right" title="Total options outstanding">1,702,853</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zA99rQN4stca" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of stock option activity during the
three months ended June 30, 2023 is presented below:</p>

<table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zpeyqAuknZUa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK COMPENSATION (Details - Option activity)">
  <tr style="vertical-align: bottom">
    <td>&#160;<span id="xdx_8BF_zRzgQXvZi0ec" style="display: none">Schedule of stock option activity</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Range of<br/> Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average <br/> Exercise<br/> Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 52%; text-align: left">Stock options outstanding at March 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_z3pOEl44lBc3" style="width: 12%; text-align: right" title="Stock options Outstanding, beginning balance">1,718,253</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.<span id="xdx_90F_ecustom--RangeOfExercisePricesOptionBeginning_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember" title="Range of exercise prices, Option beginning">69 - 142.50</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_z2JUJH9ay0rd" style="width: 12%; text-align: right" title="Outstanding, Weighted Average Exercise Price, beginning price">2.31</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zgL3fFC96Xa9" style="text-align: right" title="Stock options exercised">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_z2i1Rs0mwySc" style="text-align: right" title="Exercised, Weighted Average Exercise Price">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zp0WfYMCMOkj" style="text-align: right" title="Stock options granted">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_905_ecustom--RangeOfExercisePricesOptionGranted_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zvVKIdRqSxCb" title="Range of exercise prices, Option Granted"><span style="-sec-ix-hidden: xdx2ixbrl0538">&#8211;</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zGm19iob5Qua" style="text-align: right" title="Granted, Weighted Average Exercise Price">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Cancelled/Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zE2KTIKrnx1e" style="border-bottom: Black 1pt solid; text-align: right" title="Stock options cancelled/forfeited">15,400</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_901_ecustom--RangeOfExercisePricesOptionCancelledexpired_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember" title="Range of exercise prices, Option cancelled/expired">1.21</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_z8BkxuQwIyQ5" style="padding-bottom: 1pt; text-align: right" title="Cancelled/Forfeited, Weighted Average Exercise Price">1.21</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Stock options outstanding at June 30, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zup67D97zlbc" style="border-bottom: Black 1pt solid; text-align: right" title="Stock options outstanding, ending balance">1,702,853</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.<span id="xdx_903_ecustom--RangeOfExercisePricesOptionEnding_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember" title="Range of exercise prices, Option ending">69 - 142.50</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zZFqik4v6IZf" style="padding-bottom: 1pt; text-align: right" title="Outstanding Weighted Average Exercise Price, ending price">2.25</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock options exercisable at June 30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zqsaEtlrvuld" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock options exercisable">842,610</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_ecustom--RangeOfExercisePricesOptionExercisable_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember" title="Range of exercise prices, Option exercisable">1.28 - 142.50</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zLuv9sYiaHIh" style="padding-bottom: 2.5pt; text-align: right" title="Exercisable, Weighted Average Exercise Price">2.44</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zx9AOH1eomBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 30, 2023, our outstanding stock options
had no intrinsic value since the closing share price on that date of $<span id="xdx_904_eus-gaap--SharePrice_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zzGmAYmf6dCh" title="Share price">0.36</span> per share was below the weighted average exercise price of
our outstanding stock options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At June 30, 2023, there was approximately $<span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pp0p0_c20230630_z3ac1kRDRaLh" title="Unrecognized compensation costs">1,719,000</span>
of unrecognized compensation cost related to share-based payments, which is expected to be recognized over a weighted average period of
<span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230401__20230630_zI2ReLzaQR42" title="Unrecognized compensation cost amortization period">1.84</span> years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139908508274256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aemd_DisclosureWarrantsAbstract', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aemd_WarrantsTextBlock', window );">WARRANTS</a></td>
<td class="text"><p id="xdx_80E_ecustom--WarrantsTextBlock_zSByTrxnjJrk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">9. <span id="xdx_82C_z2ZUIz3WD1e5">WARRANTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended June 30, 2023 and
2022, we did not issue any warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of warrant activity during the three
months ended June 30, 2023 is presented below:</p>

<table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zVXbLadZcZF1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Warrant (Details)">
  <tr style="vertical-align: bottom">
    <td>&#160;<span id="xdx_8BB_za3QfCelP4vb" style="display: none">Schedule of warrant activity</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Range of<br/> Exercise<br/> Price</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 52%">Warrants outstanding at March 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zWNsfZCtHYsc" style="width: 12%; text-align: right" title="Number of Warrants Outstanding, Beginning">326,753</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zSRXugrKKOO6" title="Range of Exercise Price Outstanding, Beginning">1.50 &#8211; 2.75</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zRNuM9uEtTyk" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning">2.01</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zeJLxO6WH7Rk" style="text-align: right" title="Number of Warrants Exercised">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zj6W3O0zGRz4" style="text-align: right" title="Weighted Average Exercise Price, Exercised">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt">Cancelled/Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z8VwIxOdpkCg" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants Cancelled/Expired">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_903_ecustom--RangeOfExercisePriceCancelledExpired_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zW2BXRxcebO2" title="Range of Exercise Price Cancelled Expired"><span style="-sec-ix-hidden: xdx2ixbrl0582">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zQ85u3WPAGxa" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price Cancelled/Expired">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Warrants outstanding at June 30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zN9SeW3qrN71" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Outstanding, Ending">326,753</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z1GO87z1Iip4" title="Range of Exercise Price Outstanding, Ending">1.50 &#8211; 2.75</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zZgFv6xD2Khb" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price Outstanding, Ending">2.01</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">Warrants exercisable at June 30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zcgM8KbVIsYh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Exercisable, Ending">326,753</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--RangeOfWeightedAverageExercisePriceExercisable_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zYDtsUiuVKf" title="Range of Exercise Price Exercisable">1.50 &#8211; 2.75</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z5kdpqMiJhQg" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price Exercisable">2.01</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zCpxlDF1liT4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>











<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_DisclosureWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_DisclosureWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_WarrantsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_WarrantsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139908596795136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z63ZiPipM6tf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">10. <span id="xdx_821_zAI29AWVPZOl">COMMITMENTS AND CONTINGENCIES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LEASE COMMITMENTS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Office, Lab and Manufacturing Space Leases</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2020, we entered into an agreement
to lease approximately 2,823 square feet of office space and 1,807 square feet of laboratory space located at 11555 Sorrento Valley Road,
Suite 203, San Diego, California 92121 and 11575 Sorrento Valley Road, Suite 200, San Diego, California 92121, respectively. The agreement
carries a term of 63 months and we took possession of the office space effective October 1, 2021. We took possession of the laboratory
space effective January 1, 2022. In October 2021, we entered into another lease for approximately 2,655 square feet of space to house
our manufacturing operations located at 11588 Sorrento Valley Road, San Diego, California 92121. The term is for <span id="xdx_90E_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtM_c20220831_z0G5iFq60q5f" title="Lease term">55</span> months and we took
possession of the manufacturing space in August 2022. The current monthly base rent under the office and laboratory component of the lease
is $<span id="xdx_90C_ecustom--MonthlyBaseRent_pp0p0_c20230401__20230630__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--OfficeAndLaboratoryMember_zhE6WvDJjb6h" title="Monthly base rent">13,772</span>. The current monthly base rent under the manufacturing component of the lease is $<span id="xdx_90D_ecustom--MonthlyBaseRent_pp0p0_c20230401__20230630__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--ManufacturingMember_z5EHKGyZIRl7" title="Monthly base rent">12,080</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The office, lab and manufacturing leases are coterminous
with a remaining term of <span id="xdx_907_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20230630__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--OfficeLabAndManufacturingLeasesMember_zdW5HSWLbN28" title="Lease term">45</span> months. The weighted average discount rate is <span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20230630__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--OfficeLabAndManufacturingLeasesMember_z7Yo9e7WhLPd" title="Weighted average discount rate">4.25%</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of our June 30, 2023 balance sheet, we have
a right-of-use lease asset of $<span id="xdx_90E_eus-gaap--OperatingLeaseRightOfUseAsset_c20230630_pp0p0" title="Right of use lease asset">1,086,108</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the lease agreements for the new
office, lab and manufacturing space required us to post a standby L/C in favor of the landlord in the aggregate amount of $<span id="xdx_906_eus-gaap--LettersOfCreditOutstandingAmount_iI_pp0p0_c20230630__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--NewOfficeAndLabSpaceMember_zDvYTQHYHJE7" title="Line of credit">87,506</span> in lieu
of a security deposit. We arranged for our bank to issue standby L/Cs for the new office and lab in the amounts of $46,726 in the fiscal
year ended March 31, 2021 and for the manufacturing space in the amount of $40,780 in the fiscal year ended March 31, 2022. We transferred
like amounts to a restricted certificate of deposit which secured the bank&#8217;s risk in issuing those L/Cs. We have classified those
restricted certificates of deposit on our balance sheet as restricted cash with a balance of $<span id="xdx_904_eus-gaap--RestrictedCash_iI_c20230630_zcriddthYLmj">87,506</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Mobile Clean Room</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we rented a mobile clean room on
a short term, month-to-month basis, where we housed our manufacturing operations until our permanent manufacturing space was completed.
The mobile clean room was located on leased land near our office and lab and we paid $<span id="xdx_901_ecustom--PaymentForRentPerMonth_c20230401__20230630_pp0p0" title="Payment for rent per month">2,000</span> per month for the right to locate it there.
The arrangement was terminated in September 2022 and the mobile clean room was returned to the vendor that leased it to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Overall, our rent expense, which is included in
general and administrative expenses, approximated $<span id="xdx_90F_eus-gaap--OperatingLeaseExpense_c20230401__20230630_pp0p0" title="Operating Lease, Expense">105,000</span> and $<span id="xdx_909_eus-gaap--OperatingLeaseExpense_c20220401__20220630_pp0p0" title="Operating Lease, Expense">140,000</span> for the three month periods ended June 30, 2023 and 2022, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LEGAL MATTERS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may be involved from time to time in various
claims, lawsuits, and/or disputes with third parties or breach of contract actions incidental to the normal course of our business operations.
We are currently not involved in any litigation or any pending legal proceedings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139908508534912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--SubsequentEventsTextBlock_zZLApxorVNP6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">11. <span id="xdx_82C_zF59TVWfnzp3">SUBSEQUENT EVENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management has evaluated events subsequent to
June 30, 2023 through the date that the accompanying consolidated financial statements were filed with the Securities and Exchange Commission
for transactions and other events which may require adjustment of and/or disclosure in such financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July 2023, Mr. Nikolas Gikakis was appointed
as a member our Board of Directors and as a member of the Nominating and Corporate Governance Committee of the Board, or the N&amp;CG
Committee. Pursuant to the Director Compensation Policy, upon his appointment to the Board, Mr. Gikakis (i) will receive an (a) annual
cash retainer of $40,000 for his service on the Board, and (b) an additional annual cash retainer of $5,000 for his service as a member
of the N&amp;CG Committee, and (ii) was granted, on the date of his appointment to the Board, restricted stock units for 195,414 shares
of our common stock under the 2020 Plan, which will vest in equal quarterly installments over one year from the date of grant, in each
case subject to Mr. Gikakis&#8217;s Continuous Service (as defined in the 2020 Plan) as of each such vesting date. The Director Compensation
Policy also provides for further annual grants to its independent directors, at the beginning of each fiscal year, of restricted stock
units with a grant date fair value of $50,000 or, at the option of our Board, options to purchase shares of our common stock, subject
to vesting as determined by our Board. Mr. Gikakis has also entered into our standard form of indemnification agreement for directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139908505937424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Basis of Presentation and Use of Estimates</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--UseOfEstimates_z5zSVHVKBcxd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_866_zhHe5IOoqnyh">Basis of Presentation and Use of Estimates</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited condensed consolidated
financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for
interim financial information and with the instructions to Form 10-Q and Article 8 of the Securities and Exchange Commission, or SEC,
Regulation S-X. Accordingly, they should be read in conjunction with the audited financial statements and notes thereto for the fiscal
year ended March 31, 2023, included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on June 28, 2023. The accompanying
unaudited condensed consolidated financial statements include the accounts of Aethlon Medical, Inc. and its wholly owned subsidiary, Aethlon
Medical Australia Pty Ltd, as well as its previously majority-owned subsidiary, Exosome Sciences, Inc., which dissolved in September 2022.
All significant inter-company transactions and balances have been eliminated in consolidation. The unaudited condensed consolidated financial
statements contain all normal recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the
condensed consolidated financial statements as of and for the three months ended June 30, 2023, and the condensed consolidated statement
of cash flows for the three months ended June 30, 2023. Estimates were made relating to useful lives of fixed assets, impairment of assets,
share-based compensation expense and accruals for clinical trial and research and development expenses. Actual results could differ materially
from those estimates. The accompanying condensed consolidated balance sheet at March 31, 2023 has been derived from the audited consolidated
balance sheet at March 31, 2023, contained in the above referenced 10-K. The results of operations for the three months ended June 30,
2023 are not necessarily indicative of the results to be expected for the full year or any future interim periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><p id="xdx_844_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zPYjSofJx4X2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_867_zQFOIPS2Bxpk">Reclassifications</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain prior year balances within the unaudited
condensed consolidated financial statements have been reclassified to conform to the current year presentation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aemd_LiquidityAndGoingConcernPolicyTextBlock', window );">LIQUIDITY AND GOING CONCERN</a></td>
<td class="text"><p id="xdx_845_ecustom--LiquidityAndGoingConcernPolicyTextBlock_zSKGnONx7Zhi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_864_zldIEJHyTHNe">LIQUIDITY AND GOING CONCERN</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management expects existing cash as of June 30,
2023 to be sufficient to fund the Company&#8217;s operations for at least twelve months from the issuance date of these condensed consolidated
financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zB8s2iKOa4sl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_86D_zFHX4mGOcFc">Restricted Cash</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To comply with the terms of our laboratory and
office lease and our lease for our manufacturing space, see Note 10, we caused our bank to issue two standby letters of credit, or L/Cs,
in the aggregate amount of $<span id="xdx_90B_eus-gaap--SecurityDeposit_c20220630__us-gaap--BalanceSheetLocationAxis__custom--RestrictedCashMember_pp0p0" title="Security deposit">87,506</span> in favor of the landlord. The L/Cs are in lieu of a security deposit. In order to support the L/Cs,
we agreed to have our bank withdraw $87,506 from our operating accounts and to place that amount in a restricted certificate of deposit.
We have classified that amount as restricted cash, a long-term asset, on our balance sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_LiquidityAndGoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_LiquidityAndGoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483504/205-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139908505847152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock', window );">Research and development expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_ziCjsKHdpPu6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;<span id="xdx_8B6_zxOMOTo6NeUl" style="display: none">Research and development expenses</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">June 30,</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">June 30,</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; width: 66%; text-align: center">&#160;</td><td style="text-align: center; width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: center">2023</td><td style="width: 1%; padding-bottom: 1pt; text-align: center">&#160;</td><td style="text-align: center; width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: center">2022</td><td style="width: 1%; padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three months ended</span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230401__20230630_zCmEpxkSGW01" style="text-align: right" title="Research and development expense">678,922</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220401__20220630_zhhYNp2g0ZZg" style="text-align: right" title="Research and development expense">858,347</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature and amounts of capitalized costs of a research and development nature that were acquired in a transaction other than a business combination, the amount of such assets charged to expense during the period, and identification of the income statement caption in which the charges are included.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139908505846928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Due to related parties</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zfxWkxhgBzxj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure -  RELATED PARTY TRANSACTIONS (Details)">
  <tr style="vertical-align: bottom">
    <td>&#160;<span id="xdx_8B7_zFQUqfZCc5Ea" style="display: none">Due to related parties</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, <br/> 2023</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">March 31, <br/> 2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Accrued Board fees</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--DueToRelatedPartiesCurrent1_c20230630__us-gaap--RelatedPartyTransactionAxis__custom--AccruedBoardFeesMember_pp0p0" style="width: 13%; text-align: right" title="Due to related parties">57,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--DueToRelatedPartiesCurrent1_iI_pp0p0_c20230331__us-gaap--RelatedPartyTransactionAxis__custom--AccruedBoardFeesMember_z3Zz2UjwkKN6" style="width: 13%; text-align: right" title="Due to related parties">57,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Accrued vacation to all employees</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--DueToRelatedPartiesCurrent1_c20230630__us-gaap--RelatedPartyTransactionAxis__custom--AccruedVacationMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Due to related parties">134,314</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_ecustom--DueToRelatedPartiesCurrent1_iI_pp0p0_c20230331__us-gaap--RelatedPartyTransactionAxis__custom--AccruedVacationMember_zcnZNuBXvfhi" style="border-bottom: Black 1pt solid; text-align: right" title="Due to related parties">157,221</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total due to related parties</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--DueToRelatedPartiesCurrent1_c20230630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Due to related parties">191,314</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--DueToRelatedPartiesCurrent1_iI_pp0p0_c20230331_zqlhTr7UOLje" style="border-bottom: Black 2.5pt double; text-align: right" title="Due to related parties">214,221</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139908508300192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Schedule of other current liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_zXcTSEyQ5Mi1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - OTHER CURRENT LIABILITIES (Details)">
  <tr style="vertical-align: bottom">
    <td><b style="display: none">&#160;<span id="xdx_8BA_zXYdGoNH7Hhc">Schedule of other current liabilities</span></b></td><td>&#160;</td>
    <td colspan="2" id="xdx_496_20230630_zEH6GLdHbBAh" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_494_20230331_zQ957KJvXEmb" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">June 30,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">March 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maOLCzQ3w_zPZRgFpIl6l2" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left; padding-bottom: 1pt">Accrued professional fees</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">511,377</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">588,592</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OtherLiabilitiesCurrent_iTI_pp0p0_mtOLCzQ3w_zOXzui78EuN6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total other current liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">511,377</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">588,592</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139908511264832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of share-based compensation expense</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zGurrYfR5HYj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK COMPENSATION (Details - Stock compensation)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B7_zLlfHkJvLm6b" style="display: none">Schedule of share-based compensation expense</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_492_20230401__20230630_zTPPbrMJoBDk" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_499_20220401__20220630_z9iNGfWe6rri" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, <br/> 2023</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, <br/> 2022</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_zKJQPqFYtrE7" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left; padding-bottom: 1pt">Vesting of stock options and restricted stock units</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">250,114</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">215,437</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ShareBasedCompensation_z5ejZmZOPirc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">250,114</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">215,437</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Weighted average number of common shares outstanding &#8211; basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230401__20230630_zPnUc9bvkZo2" title="Weighted Average Number of Shares Outstanding, Basic"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230401__20230630_zpmVNJyN3tn9" title="Weighted Average Number of Shares Outstanding, Diluted">24,314,759</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220401__20220630_zzXzg3Go3Ia6" title="Weighted Average Number of Shares Outstanding, Basic"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220401__20220630_zCAWDsHqTi2h" title="Weighted Average Number of Shares Outstanding, Diluted">15,486,621</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Basic and diluted loss per common share attributable to stock-based compensation expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20230401__20230630__us-gaap--TransactionTypeAxis__custom--StockBasedCompensationMember_zR6l4AGdErhf" title="Earnings Per Share, Basic"><span id="xdx_905_eus-gaap--EarningsPerShareDiluted_c20230401__20230630__us-gaap--TransactionTypeAxis__custom--StockBasedCompensationMember_zf0SAlcFLh03" title="Earnings Per Share, Diluted">(0.01</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--EarningsPerShareBasic_c20220401__20220630__us-gaap--TransactionTypeAxis__custom--StockBasedCompensationMember_z6RqknH9NQ8h" title="Earnings Per Share, Basic"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_c20220401__20220630__us-gaap--TransactionTypeAxis__custom--StockBasedCompensationMember_zFYuWmwJwh54" title="Earnings Per Share, Diluted">(0.01</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock', window );">Schedule of options outstanding that have vested and are expected to vest</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_zPxYiqdu59v5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK COMPENSATION (Details - Options vested and expected to vest)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B4_zlWPl0Lg8kQ8" style="display: none">Schedule of options outstanding that have vested and are expected to vest</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/> Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term in<br/> Years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 55%">Vested</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_znw6ZxLH8uyc" style="width: 11%; text-align: right" title="Options vested">842,610</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z898JzduWEz" style="width: 11%; text-align: right" title="Weighted average exercise price options vested">2.44</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zi2naYs42RUh" title="Weighted average remaining contractual term options vested">7.68</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Expected to vest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zkYpWV7RMHh5" style="border-bottom: Black 1pt solid; text-align: right" title="Options expected to vest">860,243</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zG2gi0sDRvi4" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price options expected to vest">2.06</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zHFw2Ra7oCP9" title="Weighted average remaining contractual term options expected to vest">8.24</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zdDfdmkzR0Lb" style="border-bottom: Black 2.5pt double; text-align: right" title="Total options outstanding">1,702,853</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zpeyqAuknZUa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK COMPENSATION (Details - Option activity)">
  <tr style="vertical-align: bottom">
    <td>&#160;<span id="xdx_8BF_zRzgQXvZi0ec" style="display: none">Schedule of stock option activity</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Range of<br/> Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average <br/> Exercise<br/> Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 52%; text-align: left">Stock options outstanding at March 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_z3pOEl44lBc3" style="width: 12%; text-align: right" title="Stock options Outstanding, beginning balance">1,718,253</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.<span id="xdx_90F_ecustom--RangeOfExercisePricesOptionBeginning_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember" title="Range of exercise prices, Option beginning">69 - 142.50</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_z2JUJH9ay0rd" style="width: 12%; text-align: right" title="Outstanding, Weighted Average Exercise Price, beginning price">2.31</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zgL3fFC96Xa9" style="text-align: right" title="Stock options exercised">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_z2i1Rs0mwySc" style="text-align: right" title="Exercised, Weighted Average Exercise Price">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zp0WfYMCMOkj" style="text-align: right" title="Stock options granted">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_905_ecustom--RangeOfExercisePricesOptionGranted_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zvVKIdRqSxCb" title="Range of exercise prices, Option Granted"><span style="-sec-ix-hidden: xdx2ixbrl0538">&#8211;</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zGm19iob5Qua" style="text-align: right" title="Granted, Weighted Average Exercise Price">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Cancelled/Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zE2KTIKrnx1e" style="border-bottom: Black 1pt solid; text-align: right" title="Stock options cancelled/forfeited">15,400</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_901_ecustom--RangeOfExercisePricesOptionCancelledexpired_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember" title="Range of exercise prices, Option cancelled/expired">1.21</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_z8BkxuQwIyQ5" style="padding-bottom: 1pt; text-align: right" title="Cancelled/Forfeited, Weighted Average Exercise Price">1.21</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Stock options outstanding at June 30, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zup67D97zlbc" style="border-bottom: Black 1pt solid; text-align: right" title="Stock options outstanding, ending balance">1,702,853</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.<span id="xdx_903_ecustom--RangeOfExercisePricesOptionEnding_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember" title="Range of exercise prices, Option ending">69 - 142.50</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zZFqik4v6IZf" style="padding-bottom: 1pt; text-align: right" title="Outstanding Weighted Average Exercise Price, ending price">2.25</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock options exercisable at June 30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zqsaEtlrvuld" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock options exercisable">842,610</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_ecustom--RangeOfExercisePricesOptionExercisable_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember" title="Range of exercise prices, Option exercisable">1.28 - 142.50</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zLuv9sYiaHIh" style="padding-bottom: 2.5pt; text-align: right" title="Exercisable, Weighted Average Exercise Price">2.44</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139908509265520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aemd_DisclosureWarrantsAbstract', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrant activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zVXbLadZcZF1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Warrant (Details)">
  <tr style="vertical-align: bottom">
    <td>&#160;<span id="xdx_8BB_za3QfCelP4vb" style="display: none">Schedule of warrant activity</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Range of<br/> Exercise<br/> Price</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 52%">Warrants outstanding at March 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zWNsfZCtHYsc" style="width: 12%; text-align: right" title="Number of Warrants Outstanding, Beginning">326,753</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zSRXugrKKOO6" title="Range of Exercise Price Outstanding, Beginning">1.50 &#8211; 2.75</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zRNuM9uEtTyk" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning">2.01</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zeJLxO6WH7Rk" style="text-align: right" title="Number of Warrants Exercised">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zj6W3O0zGRz4" style="text-align: right" title="Weighted Average Exercise Price, Exercised">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt">Cancelled/Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z8VwIxOdpkCg" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants Cancelled/Expired">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_903_ecustom--RangeOfExercisePriceCancelledExpired_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zW2BXRxcebO2" title="Range of Exercise Price Cancelled Expired"><span style="-sec-ix-hidden: xdx2ixbrl0582">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zQ85u3WPAGxa" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price Cancelled/Expired">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Warrants outstanding at June 30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zN9SeW3qrN71" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Outstanding, Ending">326,753</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z1GO87z1Iip4" title="Range of Exercise Price Outstanding, Ending">1.50 &#8211; 2.75</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zZgFv6xD2Khb" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price Outstanding, Ending">2.01</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">Warrants exercisable at June 30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zcgM8KbVIsYh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Exercisable, Ending">326,753</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--RangeOfWeightedAverageExercisePriceExercisable_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zYDtsUiuVKf" title="Range of Exercise Price Exercisable">1.50 &#8211; 2.75</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z5kdpqMiJhQg" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price Exercisable">2.01</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_DisclosureWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_DisclosureWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139908508361264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION (Details Narrative)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=aemd_RestrictedCashMember', window );">Restricted Cash [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">$ 87,506<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=aemd_RestrictedCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=aemd_RestrictedCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139908511095248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER COMMON SHARE (Details Narrative) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares</a></td>
<td class="nump">2,291,234<span></span>
</td>
<td class="nump">2,227,286<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139908508168176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT EXPENSES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 678,922<span></span>
</td>
<td class="nump">$ 858,347<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139908509938224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY TRANSACTIONS IN THE THREE MONTHS ENDED JUNE 30, 2023 (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=aemd_EligibleDirectorsEachMember', window );">Eligible Directors Each [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuritiesFinancingTransactionLineItems', window );"><strong>Securities Financing Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period | shares</a></td>
<td class="nump">116,279<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuritiesFinancingTransactionAxis=aemd_OfferingAgreementMember', window );">Offering Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuritiesFinancingTransactionLineItems', window );"><strong>Securities Financing Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance of equity</a></td>
<td class="nump">$ 1,086,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued new, shares issued | shares</a></td>
<td class="nump">1,778,901<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuritiesFinancingTransactionAxis=aemd_OfferingAgreementMember', window );">Offering Agreement [Member] | Other Offering Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuritiesFinancingTransactionLineItems', window );"><strong>Securities Financing Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of stock issuance costs</a></td>
<td class="nump">$ 5,846<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuritiesFinancingTransactionAxis=aemd_OfferingAgreementMember', window );">Offering Agreement [Member] | Hc Wainwright [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuritiesFinancingTransactionLineItems', window );"><strong>Securities Financing Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForCommissions', window );">Payment of commissions</a></td>
<td class="nump">$ 27,999<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for commissions during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuritiesFinancingTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuritiesFinancingTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=aemd_EligibleDirectorsEachMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=aemd_EligibleDirectorsEachMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuritiesFinancingTransactionAxis=aemd_OfferingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuritiesFinancingTransactionAxis=aemd_OfferingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=aemd_OtherOfferingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=aemd_OtherOfferingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=aemd_HcWainwrightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=aemd_HcWainwrightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139908507435328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aemd_DueToRelatedPartiesCurrent1', window );">Due to related parties</a></td>
<td class="nump">$ 191,314<span></span>
</td>
<td class="nump">$ 214,221<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=aemd_AccruedBoardFeesMember', window );">Accrued Board Fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aemd_DueToRelatedPartiesCurrent1', window );">Due to related parties</a></td>
<td class="nump">57,000<span></span>
</td>
<td class="nump">57,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=aemd_AccruedVacationMember', window );">Accrued Vacation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aemd_DueToRelatedPartiesCurrent1', window );">Due to related parties</a></td>
<td class="nump">$ 134,314<span></span>
</td>
<td class="nump">$ 157,221<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_DueToRelatedPartiesCurrent1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_DueToRelatedPartiesCurrent1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=aemd_AccruedBoardFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=aemd_AccruedBoardFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=aemd_AccruedVacationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=aemd_AccruedVacationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139908508147696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details Narrative)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aemd_AccruedDirectorFees', window );">Accrued director fees</a></td>
<td class="nump">$ 57,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_AccruedDirectorFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_AccruedDirectorFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139908505868928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">$ 511,377<span></span>
</td>
<td class="nump">$ 588,592<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total other current liabilities</a></td>
<td class="nump">$ 511,377<span></span>
</td>
<td class="nump">$ 588,592<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139908506800128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK COMPENSATION (Details - Stock compensation) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Vesting of stock options and restricted stock units</a></td>
<td class="nump">$ 250,114<span></span>
</td>
<td class="nump">$ 215,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 250,114<span></span>
</td>
<td class="nump">$ 215,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Number of Shares Outstanding, Basic</a></td>
<td class="nump">24,314,759<span></span>
</td>
<td class="nump">15,486,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Number of Shares Outstanding, Diluted</a></td>
<td class="nump">24,314,759<span></span>
</td>
<td class="nump">15,486,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings Per Share, Basic</a></td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings Per Share, Diluted</a></td>
<td class="num">(0.14)<span></span>
</td>
<td class="num">(0.19)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=aemd_StockBasedCompensationMember', window );">Stock Based Compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings Per Share, Basic</a></td>
<td class="num">(0.01)<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings Per Share, Diluted</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=aemd_StockBasedCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=aemd_StockBasedCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139908507438784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK COMPENSATION (Details - Options vested and expected to vest) - Equity Option [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Options vested</a></td>
<td class="nump">842,610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price options vested | $ / shares</a></td>
<td class="nump">$ 2.44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term options vested</a></td>
<td class="text">7 years 8 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options expected to vest</a></td>
<td class="nump">860,243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options expected to vest | $ / shares</a></td>
<td class="nump">$ 2.06<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term options expected to vest</a></td>
<td class="text">8 years 2 months 26 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total options outstanding</a></td>
<td class="nump">1,702,853<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139908506298912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK COMPENSATION (Details - Option activity) - Options Held [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options Outstanding, beginning balance | shares</a></td>
<td class="nump">1,718,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aemd_RangeOfExercisePricesOptionBeginning', window );">Range of exercise prices, Option beginning</a></td>
<td class="text">69 - 142.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Weighted Average Exercise Price, beginning price | $ / shares</a></td>
<td class="nump">$ 2.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock options granted | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aemd_RangeOfExercisePricesOptionGranted', window );">Range of exercise prices, Option Granted</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Stock options cancelled/forfeited | shares</a></td>
<td class="nump">15,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aemd_RangeOfExercisePricesOptionCancelledexpired', window );">Range of exercise prices, Option cancelled/expired</a></td>
<td class="text">1.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled/Forfeited, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 1.21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding, ending balance | shares</a></td>
<td class="nump">1,702,853<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aemd_RangeOfExercisePricesOptionEnding', window );">Range of exercise prices, Option ending</a></td>
<td class="text">69 - 142.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding Weighted Average Exercise Price, ending price | $ / shares</a></td>
<td class="nump">$ 2.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock options exercisable | shares</a></td>
<td class="nump">842,610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aemd_RangeOfExercisePricesOptionExercisable', window );">Range of exercise prices, Option exercisable</a></td>
<td class="text">1.28 - 142.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 2.44<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_RangeOfExercisePricesOptionBeginning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Range of exercise prices, Option beginning</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_RangeOfExercisePricesOptionBeginning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_RangeOfExercisePricesOptionCancelledexpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Range of exercise prices, Option cancelled/expired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_RangeOfExercisePricesOptionCancelledexpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_RangeOfExercisePricesOptionEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Range of exercise prices, Option ending</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_RangeOfExercisePricesOptionEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_RangeOfExercisePricesOptionExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Range of exercise prices, Option exercisable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_RangeOfExercisePricesOptionExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_RangeOfExercisePricesOptionGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_RangeOfExercisePricesOptionGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_OptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_OptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139908507446080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK COMPENSATION (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">$ 250,114<span></span>
</td>
<td class="nump">$ 215,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation costs</a></td>
<td class="nump">$ 1,719,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost amortization period</a></td>
<td class="text">1 year 10 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_OptionMember', window );">Options Held [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="nump">$ 0.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_OptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_OptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139908505748880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant (Details) - Warrant [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding, Beginning | shares</a></td>
<td class="nump">326,753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aemd_RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Range of Exercise Price Outstanding, Beginning</a></td>
<td class="text">1.50 &#8211; 2.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price Outstanding, Beginning | $ / shares</a></td>
<td class="nump">$ 2.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Warrants Exercised | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aemd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Number of Warrants Cancelled/Expired | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aemd_RangeOfExercisePriceCancelledExpired', window );">Range of Exercise Price Cancelled Expired</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aemd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Cancelled/Expired | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding, Ending | shares</a></td>
<td class="nump">326,753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aemd_RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2', window );">Range of Exercise Price Outstanding, Ending</a></td>
<td class="text">1.50 &#8211; 2.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price Outstanding, Ending | $ / shares</a></td>
<td class="nump">$ 2.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber', window );">Number of Warrants Exercisable, Ending | shares</a></td>
<td class="nump">326,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aemd_RangeOfWeightedAverageExercisePriceExercisable', window );">Range of Exercise Price Exercisable</a></td>
<td class="text">1.50 &#8211; 2.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercisable | $ / shares</a></td>
<td class="nump">$ 2.01<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_RangeOfExercisePriceCancelledExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_RangeOfExercisePriceCancelledExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_RangeOfWeightedAverageExercisePriceExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_RangeOfWeightedAverageExercisePriceExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139908505691168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">55 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use lease asset</a></td>
<td class="nump">$ 1,086,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,151,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash</a></td>
<td class="nump">87,506<span></span>
</td>
<td class="nump">$ 87,506<span></span>
</td>
<td class="nump">$ 87,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aemd_PaymentForRentPerMonth', window );">Payment for rent per month</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease, Expense</a></td>
<td class="nump">105,000<span></span>
</td>
<td class="nump">$ 140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=aemd_OfficeAndLaboratoryMember', window );">Office And Laboratory [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aemd_MonthlyBaseRent', window );">Monthly base rent</a></td>
<td class="nump">13,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=aemd_ManufacturingMember', window );">Manufacturing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aemd_MonthlyBaseRent', window );">Monthly base rent</a></td>
<td class="nump">$ 12,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=aemd_OfficeLabAndManufacturingLeasesMember', window );">Office Lab And Manufacturing Leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Lease term</a></td>
<td class="text">45 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=aemd_NewOfficeAndLabSpaceMember', window );">New Office And Lab Space [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Line of credit</a></td>
<td class="nump">$ 87,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_MonthlyBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_MonthlyBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_PaymentForRentPerMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_PaymentForRentPerMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=aemd_OfficeAndLaboratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=aemd_OfficeAndLaboratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=aemd_ManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=aemd_ManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=aemd_OfficeLabAndManufacturingLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=aemd_OfficeLabAndManufacturingLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=aemd_NewOfficeAndLabSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=aemd_NewOfficeAndLabSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>aethlon_i10q-063023_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:aemd="http://aethlonmedical.com/20230630"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="aemd-20230630.xsd" xlink:type="simple"/>
    <context id="From2023-04-01to2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-08-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
        </entity>
        <period>
            <instant>2023-08-09</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2022-04-012022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_custom_RestrictedCashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">aemd:RestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_custom_OfferingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">aemd:OfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_custom_HcWainwrightMember_custom_OfferingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">aemd:HcWainwrightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">aemd:OfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_custom_OfferingAgreementMember_custom_OtherOfferingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">aemd:OfferingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">aemd:OtherOfferingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_custom_EligibleDirectorsEachMember_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">aemd:EligibleDirectorsEachMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_AccruedBoardFeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aemd:AccruedBoardFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_AccruedBoardFeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aemd:AccruedBoardFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_AccruedVacationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aemd:AccruedVacationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_AccruedVacationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aemd:AccruedVacationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_custom_StockBasedCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">aemd:StockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_custom_StockBasedCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">aemd:StockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_OptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_OptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_OptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-08-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_custom_OfficeAndLaboratoryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">aemd:OfficeAndLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_custom_ManufacturingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">aemd:ManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_OfficeLabAndManufacturingLeasesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">aemd:OfficeLabAndManufacturingLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_NewOfficeAndLabSpaceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">aemd:NewOfficeAndLabSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2023-04-01to2023-06-30">0000882291</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2023-04-01to2023-06-30">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2023-04-01to2023-06-30">--03-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2023-04-01to2023-06-30">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2023-04-01to2023-06-30">Q1</dei:DocumentFiscalPeriodFocus>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0199"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0206"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0207"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-012023-06-30_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0208"
      unitRef="USD"
      xsi:nil="true"/>
    <aemd:IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExercise
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0215"
      unitRef="USD"
      xsi:nil="true"/>
    <aemd:IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExercise
      contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0216"
      unitRef="USD"
      xsi:nil="true"/>
    <aemd:IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExercise
      contextRef="From2023-04-012023-06-30_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0217"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0222"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0224"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0225"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012023-06-30_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0226"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0229"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0230"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0232"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2023-04-012023-06-30_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0233"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0236"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0237"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0238"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-04-012023-06-30_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0240"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0247"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0255"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0263"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-04-012022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0264"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-04-012022-06-30_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0265"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0270"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0272"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-04-012022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0273"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-04-012022-06-30_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0274"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0277"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0278"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2022-04-012022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0280"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0287"
      unitRef="USD"
      xsi:nil="true"/>
    <aemd:RangeOfExercisePricesOptionGranted
      contextRef="From2023-04-012023-06-30_us-gaap_OptionMember"
      id="xdx2ixbrl0538"
      xsi:nil="true"/>
    <aemd:RangeOfExercisePriceCancelledExpired
      contextRef="From2023-04-012023-06-30_us-gaap_WarrantMember"
      id="xdx2ixbrl0582"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2023-04-01to2023-06-30">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2023-04-01to2023-06-30">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2023-04-01to2023-06-30">2023-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2023-04-01to2023-06-30">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2023-04-01to2023-06-30">001-37487</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2023-04-01to2023-06-30">Aethlon Medical, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-04-01to2023-06-30">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-04-01to2023-06-30">13-3632859</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-04-01to2023-06-30">11555 SORRENTO VALLEY ROAD</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2023-04-01to2023-06-30">SUITE 203</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2023-04-01to2023-06-30">SAN DIEGO</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-04-01to2023-06-30">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-04-01to2023-06-30">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-04-01to2023-06-30">(619)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-04-01to2023-06-30">941-0360</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2023-04-01to2023-06-30">COMMON STOCK, $0.001 PAR VALUE</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-04-01to2023-06-30">AEMD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-04-01to2023-06-30">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2023-04-01to2023-06-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2023-04-01to2023-06-30">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2023-04-01to2023-06-30">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2023-04-01to2023-06-30">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-04-01to2023-06-30">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2023-04-01to2023-06-30">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2023-08-09" decimals="INF" unitRef="Shares">24835321</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Cash contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">12897734</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">14532943</us-gaap:Cash>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">410223</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">557623</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">13307957</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">15090566</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">1284200</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">1144004</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">1086108</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">1151909</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">1513</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">1650</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:RestrictedCash contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">87506</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">87506</us-gaap:RestrictedCash>
    <us-gaap:DepositsAssetsNoncurrent contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">33305</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">33305</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">15800589</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">17508940</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">844536</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">432890</us-gaap:AccountsPayableCurrent>
    <aemd:DueToRelatedParties contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">191314</aemd:DueToRelatedParties>
    <aemd:DueToRelatedParties contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">214221</aemd:DueToRelatedParties>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">274520</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">269386</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">511377</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">588592</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">1821747</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">1505089</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">869945</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">939642</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">2691692</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">2444731</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-06-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-03-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2023-06-30" decimals="INF" unitRef="Shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2023-06-30" decimals="INF" unitRef="Shares">24835321</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2023-06-30" decimals="INF" unitRef="Shares">24835321</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">22992466</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">22992466</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">24837</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">22994</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">158731929</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">157405911</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">-7135</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">-6141</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">-145640734</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">-142358555</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">13108897</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">15064209</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">15800589</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">17508940</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ProfessionalFees
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      unitRef="USD">976638</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">844028</us-gaap:ProfessionalFees>
    <us-gaap:LaborAndRelatedExpense
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      unitRef="USD">1123239</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">1029686</us-gaap:LaborAndRelatedExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      unitRef="USD">1308283</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">1032367</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      unitRef="USD">3408160</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">2906081</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      unitRef="USD">-3408160</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-2906081</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndOtherIncome
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      unitRef="USD">125981</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">0</us-gaap:InterestAndOtherIncome>
    <us-gaap:ProfitLoss
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      unitRef="USD">-3282179</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-2906081</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      unitRef="USD">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-413</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      unitRef="USD">-3282179</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-2905668</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      unitRef="USD">994</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-0</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      unitRef="USD">3283173</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">2905668</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-04-01to2023-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-04-01to2023-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-04-012022-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-04-012022-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-04-01to2023-06-30"
      decimals="INF"
      unitRef="Shares">24314759</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-04-01to2023-06-30"
      decimals="INF"
      unitRef="Shares">24314759</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-04-012022-06-30"
      decimals="INF"
      unitRef="Shares">15486621</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-04-012022-06-30"
      decimals="INF"
      unitRef="Shares">15486621</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">22992466</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">22994</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">157405911</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-142358555</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-6141</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">15064209</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1778901</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1779</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1084340</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      unitRef="USD">1086119</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <aemd:IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExerciseShares
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">63954</aemd:IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExerciseShares>
    <aemd:IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExercise
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">64</aemd:IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExercise>
    <aemd:IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExercise
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-8436</aemd:IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExercise>
    <aemd:IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExercise
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      unitRef="USD">-8372</aemd:IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExercise>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">250114</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      unitRef="USD">250114</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ProfitLoss
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-3282179</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      unitRef="USD">-3282179</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">994</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      unitRef="USD">994</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">24835321</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">24837</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">158731929</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-145640734</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-7135</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">13108897</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">15419163</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">15421</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">147446868</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-130329181</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      unitRef="USD">-141708</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">16991400</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">574560</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">575</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">618867</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">619442</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">215437</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">215437</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ProfitLoss
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-2905668</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-04-012022-06-30_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      unitRef="USD">-413</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-2906081</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">15993723</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">15996</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">148281172</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-133234849</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      unitRef="USD">-142121</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">14920198</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      unitRef="USD">-3282179</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-2906081</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      unitRef="USD">90325</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">30650</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      unitRef="USD">250114</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">215437</us-gaap:ShareBasedCompensation>
    <aemd:AccretionOfRightofuseLeaseAsset
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      unitRef="USD">-1238</aemd:AccretionOfRightofuseLeaseAsset>
    <aemd:AccretionOfRightofuseLeaseAsset
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-7800</aemd:AccretionOfRightofuseLeaseAsset>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      unitRef="USD">-146409</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-99336</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      unitRef="USD">-0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-13116</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      unitRef="USD">334613</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-310327</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      unitRef="USD">0</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">114849</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      unitRef="USD">-22907</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">6303</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      unitRef="USD">-2482387</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-2728917</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      unitRef="USD">230383</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">41169</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      unitRef="USD">-230383</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-41169</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      unitRef="USD">1086119</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">619442</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      unitRef="USD">8372</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      unitRef="USD">1077747</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">619442</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      unitRef="USD">-186</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      unitRef="USD">-1635209</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-2150644</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">14620449</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">17159925</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">12985240</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">15009281</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <aemd:ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      unitRef="USD">64</aemd:ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise>
    <aemd:ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">0</aemd:ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">12897734</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">14921775</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">87506</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">87506</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">12985240</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">15009281</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2023-04-01to2023-06-30">&lt;p id="xdx_803_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zqEBwHCHaTPa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;1. &lt;span id="xdx_821_zAHfOn9GSmqd"&gt;NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Aethlon Medical, Inc., or Aethlon, the Company,
we or us, is a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases. The
Aethlon Hemopurifier is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. In
cancer, the Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression, seed
the spread of metastasis and inhibit the benefit of leading cancer therapies. The U.S. Food and Drug Administration, or FDA, has designated
the Hemopurifier as a &#x201c;Breakthrough Device&#x201d; for two independent indications:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the treatment of life-threatening viruses that are not addressed with approved therapies.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We believe the Hemopurifier can be a substantial
advance in the treatment of patients with advanced and metastatic cancer through the clearance of exosomes that promote the growth and
spread of tumors through multiple mechanisms. We are currently working with our new contract research organization, or CRO, on preparations
to conduct a clinical trial in Australia in patients with solid tumors, including head and neck cancer, gastrointestinal cancers and other
cancers.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In January 2023, we entered into an agreement
with North American Science Associates, LLC, or NAMSA, a world leading MedTech CRO offering global end-to-end development services, to
oversee our clinical trials investigating the Hemopurifier for oncology indications. Pursuant to the agreement, NAMSA will manage our
clinical trials of the Hemopurifier for patients in the United States and Australia with various types of cancer tumors. We anticipate
that the initial clinical trials will begin in Australia.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We also believe the Hemopurifier can be part of
the broad-spectrum treatment of life-threatening highly glycosylated, or carbohydrate coated, viruses that are not addressed with an already
approved treatment. In small-scale or early feasibility human studies, the Hemopurifier has been used in the past to treat individuals
infected with human immunodeficiency virus, or HIV, hepatitis-C and Ebola.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Additionally, &lt;i&gt;in vitro,&lt;/i&gt; the Hemopurifier
has been demonstrated to capture Zika virus, Lassa virus, MERS-CoV, cytomegalovirus, Epstein-Barr virus, Herpes simplex virus, Chikungunya
virus, Dengue virus, West Nile virus, smallpox-related viruses, H1N1 swine flu virus, H5N1 bird flu virus, Monkeypox virus and the reconstructed
Spanish flu virus of 1918. In several cases, these studies were conducted in collaboration with leading government or non-government research
institutes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 17, 2020, the FDA approved a supplement
to our open Investigational Device Exemption, or IDE, for the Hemopurifier in viral disease to allow for the testing of the Hemopurifier
in patients with SARS-CoV-2/COVID-19, or COVID-19, in a New Feasibility Study. &lt;span style="background-color: white"&gt;That study was designed
to enroll up to 40 subjects at up to 20 centers in the United States. Subjects were to have established laboratory diagnosis of COVID-19,
be admitted to an intensive care unit, or ICU, and have acute lung injury and/or severe or life-threatening disease, among other criteria.
Endpoints for this study, in addition to safety, included reduction in circulating virus as well as clinical outcomes (NCT # 04595903).
&lt;/span&gt;In June 2022, the first patient in this study was enrolled and completed the Hemopurifier treatment phase of the protocol. Due
to lack of COVID-19 patients in the ICUs of our trial sites, we terminated this study in 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Under Single Patient Emergency Use regulations,
the Company has treated two patients with COVID-19 with the Hemopurifier, in addition to the COVID-19 patient treated with our Hemopurifier
in our COVID-19 clinical trial discussed above.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We currently are experiencing a disruption in
our Hemopurifier supply, as our existing supply of Hemopurifiers expired on September 30, 2022 and, as previously disclosed, we are dependent
on FDA approval of qualified suppliers to manufacture our Hemopurifier. Our intended transition to a new supplier for galanthus nivalis
agglutinin, or GNA, a component of our Hemopurifier, is delayed as we work with the FDA for approval of our supplement to our IDE, which
is required to make this manufacturing change.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In October 2022, we launched a wholly owned subsidiary
in Australia, formed to conduct clinical research, seek regulatory approval and commercialize our Hemopurifier in that country. The subsidiary
will initially focus on the oncology trials in Australia.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We also obtained ethics review board,
or ERB approval, from and entered into a clinical trial agreement with Medanta Medicity Hospital, a multi-specialty hospital in Delhi
NCR, India, for a COVID-19 clinical trial at that location. One patient has completed participation in the Indian COVID-19 study. The
relevant authorities in India have accepted the use of our Hemopurifiers made with the GNA from our new supplier.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In May 2023, we also received ERB approval from
the Maulana Azad Medical College, or MAMC, for a second site for our clinical trial in India to treat severe COVID-19. MAMC was established
in 1958 and is located in New Delhi, India. MMAC is affiliated with the University of Delhi and is operated by the Delhi government.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We also recently announced that we also have begun
investigating the use of our Hemopurifier in the organ transplant setting. Our objective is to confirm that the Hemopurifier, in our translational
studies, when incorporated into a machine perfusion organ preservation circuit, can remove harmful viruses and exosomes from recovered
organs. We initially are focused on recovered kidneys, in a research collaboration with 34 Lives, PBC. We have previously demonstrated
the removal of multiple viruses and exosomes from buffer solutions, in vitro, utilizing a scaled-down version of our Hemopurifier. This
process potentially may reduce complications following transplantation of the recovered organ, which can include viral infection, delayed
graft function and rejection. We believe this new approach could be additive to existing technologies that currently are in place to increase
the number of viable kidneys for transplant.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Successful outcomes of human trials will also
be required by the regulatory agencies of certain foreign countries where we plan to market and sell the Hemopurifier. Some of our patents
may expire before FDA approval or approval in a foreign country, if any, is obtained. However, we believe that certain patent applications
and/or other patents issued to us more recently will help protect the proprietary nature of our Hemopurifier treatment technology.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In addition to the foregoing, we are monitoring
closely the impact of inflation, recent bank failures and the war in Ukraine on our business. Given the level of uncertainty regarding
the duration and impact of these events on capital markets and the U.S. economy, we are unable to assess the impact on our timelines and
future access to capital. The full extent to which inflation, recent bank failures and the war in Ukraine will impact our business, results
of operations, financial condition, clinical trials and preclinical research will depend on future developments, as well as the economic
impact on national and international markets that are highly uncertain.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We incorporated in Nevada on March 10, 1999. Our
executive offices are located at 11555 Sorrento Valley Road, Suite 203, San Diego, California 92121. Our telephone number is (619) 941-0360.
Our website address is www.aethlonmedical.com.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Our common stock is listed on the Nasdaq Capital Market under the symbol
&#x201c;AEMD.&#x201d;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the three months ended June 30, 2023, there
were no changes to our significant accounting policies as described in our Annual Report on Form 10-K for the fiscal year ended March
31, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--UseOfEstimates_z5zSVHVKBcxd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span id="xdx_866_zhHe5IOoqnyh"&gt;Basis of Presentation and Use of Estimates&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying unaudited condensed consolidated
financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for
interim financial information and with the instructions to Form 10-Q and Article 8 of the Securities and Exchange Commission, or SEC,
Regulation S-X. Accordingly, they should be read in conjunction with the audited financial statements and notes thereto for the fiscal
year ended March 31, 2023, included in the Company&#x2019;s Annual Report on Form 10-K filed with the SEC on June 28, 2023. The accompanying
unaudited condensed consolidated financial statements include the accounts of Aethlon Medical, Inc. and its wholly owned subsidiary, Aethlon
Medical Australia Pty Ltd, as well as its previously majority-owned subsidiary, Exosome Sciences, Inc., which dissolved in September 2022.
All significant inter-company transactions and balances have been eliminated in consolidation. The unaudited condensed consolidated financial
statements contain all normal recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the
condensed consolidated financial statements as of and for the three months ended June 30, 2023, and the condensed consolidated statement
of cash flows for the three months ended June 30, 2023. Estimates were made relating to useful lives of fixed assets, impairment of assets,
share-based compensation expense and accruals for clinical trial and research and development expenses. Actual results could differ materially
from those estimates. The accompanying condensed consolidated balance sheet at March 31, 2023 has been derived from the audited consolidated
balance sheet at March 31, 2023, contained in the above referenced 10-K. The results of operations for the three months ended June 30,
2023 are not necessarily indicative of the results to be expected for the full year or any future interim periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zPYjSofJx4X2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span id="xdx_867_zQFOIPS2Bxpk"&gt;Reclassifications&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Certain prior year balances within the unaudited
condensed consolidated financial statements have been reclassified to conform to the current year presentation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_ecustom--LiquidityAndGoingConcernPolicyTextBlock_zSKGnONx7Zhi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span id="xdx_864_zldIEJHyTHNe"&gt;LIQUIDITY AND GOING CONCERN&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Management expects existing cash as of June 30,
2023 to be sufficient to fund the Company&#x2019;s operations for at least twelve months from the issuance date of these condensed consolidated
financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zB8s2iKOa4sl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span id="xdx_86D_zFHX4mGOcFc"&gt;Restricted Cash&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;To comply with the terms of our laboratory and
office lease and our lease for our manufacturing space, see Note 10, we caused our bank to issue two standby letters of credit, or L/Cs,
in the aggregate amount of $&lt;span id="xdx_90B_eus-gaap--SecurityDeposit_c20220630__us-gaap--BalanceSheetLocationAxis__custom--RestrictedCashMember_pp0p0" title="Security deposit"&gt;87,506&lt;/span&gt; in favor of the landlord. The L/Cs are in lieu of a security deposit. In order to support the L/Cs,
we agreed to have our bank withdraw $87,506 from our operating accounts and to place that amount in a restricted certificate of deposit.
We have classified that amount as restricted cash, a long-term asset, on our balance sheet.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2023-04-01to2023-06-30">&lt;p id="xdx_84D_eus-gaap--UseOfEstimates_z5zSVHVKBcxd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span id="xdx_866_zhHe5IOoqnyh"&gt;Basis of Presentation and Use of Estimates&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying unaudited condensed consolidated
financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for
interim financial information and with the instructions to Form 10-Q and Article 8 of the Securities and Exchange Commission, or SEC,
Regulation S-X. Accordingly, they should be read in conjunction with the audited financial statements and notes thereto for the fiscal
year ended March 31, 2023, included in the Company&#x2019;s Annual Report on Form 10-K filed with the SEC on June 28, 2023. The accompanying
unaudited condensed consolidated financial statements include the accounts of Aethlon Medical, Inc. and its wholly owned subsidiary, Aethlon
Medical Australia Pty Ltd, as well as its previously majority-owned subsidiary, Exosome Sciences, Inc., which dissolved in September 2022.
All significant inter-company transactions and balances have been eliminated in consolidation. The unaudited condensed consolidated financial
statements contain all normal recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the
condensed consolidated financial statements as of and for the three months ended June 30, 2023, and the condensed consolidated statement
of cash flows for the three months ended June 30, 2023. Estimates were made relating to useful lives of fixed assets, impairment of assets,
share-based compensation expense and accruals for clinical trial and research and development expenses. Actual results could differ materially
from those estimates. The accompanying condensed consolidated balance sheet at March 31, 2023 has been derived from the audited consolidated
balance sheet at March 31, 2023, contained in the above referenced 10-K. The results of operations for the three months ended June 30,
2023 are not necessarily indicative of the results to be expected for the full year or any future interim periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="From2023-04-01to2023-06-30">&lt;p id="xdx_844_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zPYjSofJx4X2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span id="xdx_867_zQFOIPS2Bxpk"&gt;Reclassifications&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Certain prior year balances within the unaudited
condensed consolidated financial statements have been reclassified to conform to the current year presentation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <aemd:LiquidityAndGoingConcernPolicyTextBlock contextRef="From2023-04-01to2023-06-30">&lt;p id="xdx_845_ecustom--LiquidityAndGoingConcernPolicyTextBlock_zSKGnONx7Zhi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span id="xdx_864_zldIEJHyTHNe"&gt;LIQUIDITY AND GOING CONCERN&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Management expects existing cash as of June 30,
2023 to be sufficient to fund the Company&#x2019;s operations for at least twelve months from the issuance date of these condensed consolidated
financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

</aemd:LiquidityAndGoingConcernPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="From2023-04-01to2023-06-30">&lt;p id="xdx_84F_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zB8s2iKOa4sl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;span id="xdx_86D_zFHX4mGOcFc"&gt;Restricted Cash&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;To comply with the terms of our laboratory and
office lease and our lease for our manufacturing space, see Note 10, we caused our bank to issue two standby letters of credit, or L/Cs,
in the aggregate amount of $&lt;span id="xdx_90B_eus-gaap--SecurityDeposit_c20220630__us-gaap--BalanceSheetLocationAxis__custom--RestrictedCashMember_pp0p0" title="Security deposit"&gt;87,506&lt;/span&gt; in favor of the landlord. The L/Cs are in lieu of a security deposit. In order to support the L/Cs,
we agreed to have our bank withdraw $87,506 from our operating accounts and to place that amount in a restricted certificate of deposit.
We have classified that amount as restricted cash, a long-term asset, on our balance sheet.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:SecurityDeposit
      contextRef="AsOf2022-06-30_custom_RestrictedCashMember"
      decimals="0"
      unitRef="USD">87506</us-gaap:SecurityDeposit>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2023-04-01to2023-06-30">&lt;p id="xdx_805_eus-gaap--EarningsPerShareTextBlock_zQ8ymf3531b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;2. &lt;span id="xdx_825_zz9TCCGCHjE6"&gt;LOSS PER COMMON SHARE&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Basic loss per share is computed by dividing net
loss by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is computed
similar to basic loss per share, except that the denominator is increased to include the number of additional dilutive common shares that
would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive. Since we had net
losses for all periods presented, basic and diluted loss per share are the same, and additional potential common shares have been excluded,
as their effect would be antidilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of June 30, 2023 and 2022, an aggregate of
&lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230401__20230630_z8c1hk8ml2le" title="Antidilutive shares"&gt;2,291,234&lt;/span&gt; and &lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220401__20220630_zSjr9Inh5QU1" title="Antidilutive shares"&gt;2,227,286&lt;/span&gt; potential common shares, respectively, consisting of shares underlying outstanding stock options, warrants, and
restricted stock units were excluded, as their inclusion would be antidilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;











</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-04-01to2023-06-30"
      decimals="INF"
      unitRef="Shares">2291234</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-04-012022-06-30"
      decimals="INF"
      unitRef="Shares">2227286</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock contextRef="From2023-04-01to2023-06-30">&lt;p id="xdx_80F_eus-gaap--ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_zJkQvXRuWjnf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;3. &lt;span id="xdx_82A_zJdffVmSIG2i"&gt;RESEARCH AND DEVELOPMENT EXPENSES&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Our research and development costs are expensed
as incurred. We incurred research and development expenses during the three month periods ended June 30, 2023 and 2022, which are included
in various operating expense line items in the accompanying condensed consolidated statements of operations. Our research and development
expenses in those periods were as follows:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_ziCjsKHdpPu6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;span id="xdx_8B6_zxOMOTo6NeUl" style="display: none"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 66%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 13%; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 13%; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Three months ended&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230401__20230630_zCmEpxkSGW01" style="text-align: right" title="Research and development expense"&gt;678,922&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220401__20220630_zhhYNp2g0ZZg" style="text-align: right" title="Research and development expense"&gt;858,347&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zxWbjXIzjpb4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;

</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock contextRef="From2023-04-01to2023-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_ziCjsKHdpPu6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;span id="xdx_8B6_zxOMOTo6NeUl" style="display: none"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 66%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 13%; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 13%; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Three months ended&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230401__20230630_zCmEpxkSGW01" style="text-align: right" title="Research and development expense"&gt;678,922&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220401__20220630_zhhYNp2g0ZZg" style="text-align: right" title="Research and development expense"&gt;858,347&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      unitRef="USD">678922</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">858347</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="From2023-04-01to2023-06-30">&lt;p id="xdx_802_eus-gaap--NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_zrEKyKFsn9C1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;4. &lt;span style="text-transform: uppercase"&gt;&lt;span id="xdx_82B_zB8RcpZFh4m6"&gt;RECENT ACCOUNTING PRONOUNCEMENTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;None.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2023-04-01to2023-06-30">&lt;p id="xdx_80B_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zS0eteueYr6k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;5. &lt;span id="xdx_820_zKowBRU3e1Jf"&gt;EQUITY TRANSACTIONS IN THE THREE MONTHS ENDED JUNE 30, 2023&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;2022 At The Market Offering Agreement with H.C. Wainwright &amp;amp;
Co., LLC&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 24, 2022, we entered into an At The Market
Offering Agreement, or the 2022 ATM Agreement, with H.C. Wainwright &amp;amp; Co., LLC, or Wainwright, which established an at-the-market
equity program pursuant to which we may offer and sell shares of our common stock from time to time as set forth in the 2022 ATM Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The offering was registered under the Securities
Act of 1933, as amended, or the Securities Act, pursuant to our shelf registration statement on Form S-3 (Registration Statement No. 333-259909),
as previously filed with the SEC and declared effective on October 21, 2021. We filed a prospectus supplement, dated March 24, 2022, with
the SEC that provides for the sale of shares of our common stock having an aggregate offering price of up to $15,000,000, or the 2022
ATM Shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Under the 2022 ATM Agreement, Wainwright may sell
the 2022 ATM Shares by any method permitted by law and deemed to be an &#x201c;at the market offering&#x201d; as defined in Rule 415 promulgated
under the Securities Act, including sales made directly on the Nasdaq Capital Market, or on any other existing trading market for the
2022 ATM Shares. In addition, under the 2022 ATM Agreement, Wainwright may sell the 2022 ATM Shares in privately negotiated transactions
with our consent and in block transactions. Under certain circumstances, we may instruct Wainwright not to sell the 2022 ATM Shares if
the sales cannot be effected at or above the price designated by us from time to time.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We are not obligated to make any sales of the
2022 ATM Shares under the 2022 ATM Agreement. The offering of the 2022 ATM Shares pursuant to the 2022 ATM Agreement will terminate upon
the termination of the 2022 ATM Agreement by Wainwright or us, as permitted therein.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The 2022 ATM Agreement contains customary representations,
warranties and agreements by us, and customary indemnification and contribution rights and obligations of the parties. We agreed to pay
Wainwright a placement fee of up to 3.0% of the aggregate gross proceeds from each sale of the 2022 ATM Shares. We also agreed to reimburse
Wainwright for certain specified expenses in connection with entering into the 2022 ATM Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the three months ended June 30, 2023, we
raised net proceeds of $&lt;span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20230401__20230630__us-gaap--SecuritiesFinancingTransactionAxis__custom--OfferingAgreementMember_pp0p0" title="Proceeds from issuance of equity"&gt;1,086,119&lt;/span&gt;, net of $&lt;span id="xdx_90C_eus-gaap--PaymentsForCommissions_c20230401__20230630__srt--CounterpartyNameAxis__custom--HcWainwrightMember__us-gaap--SecuritiesFinancingTransactionAxis__custom--OfferingAgreementMember_pp0p0" title="Payment of commissions"&gt;27,999&lt;/span&gt; in commissions to Wainwright and $&lt;span id="xdx_90B_eus-gaap--PaymentsOfStockIssuanceCosts_c20230401__20230630__us-gaap--SecuritiesFinancingTransactionAxis__custom--OfferingAgreementMember__us-gaap--TransactionTypeAxis__custom--OtherOfferingExpenseMember_pp0p0" title="Payment of stock issuance costs"&gt;5,846&lt;/span&gt; in other offering expense, through the sale
of, &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230401__20230630__us-gaap--SecuritiesFinancingTransactionAxis__custom--OfferingAgreementMember_pdd" title="Stock issued new, shares issued"&gt;1,778,901&lt;/span&gt; shares of our common stock at an average price of $0.61 per share under the 2022 ATM Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Restricted Stock Unit Grants &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 28, 2023, the Board approved, pursuant
to the terms of the Amended and Restated Non-Employee Director Compensation Policy, or the Director Compensation Policy, the grant of
the annual restricted stock units, or RSUs, under the Director Compensation Policy to each of the three non-employee directors of the
Company then serving on the Board. The Director Compensation Policy provides for a grant of stock options or $50,000 worth of RSUs at
the beginning of each fiscal year for current directors then serving on the Board, and for a grant of stock options or $75,000 worth of
RSUs for a newly elected director, with each RSU priced at the average for the closing prices for the five days preceding and including
the date of grant, or $0.43 per share for the RSUs granted in April 2023. As a result, in April 2023 the three eligible directors each
were granted an RSU in the amount of &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230401__20230630__srt--CounterpartyNameAxis__custom--EligibleDirectorsEachMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVypdjt567xe" title="Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period"&gt;116,279&lt;/span&gt; shares under the Company&#x2019;s 2020 Equity Incentive Plan, or the 2020 Plan. The RSUs are
subject to vesting in four equal installments, with 25% of the restricted stock units vesting on each of June 30, 2023, September 30,
2023, December 31, 2023, and March 31, 2024, subject in each case to the director&#x2019;s Continuous Service (as defined in the 2020 Plan),
through such dates. Vesting will terminate upon the director&#x2019;s termination of Continuous Service prior to any vesting date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2023-04-012023-06-30_custom_OfferingAgreementMember"
      decimals="0"
      unitRef="USD">1086119</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:PaymentsForCommissions
      contextRef="From2023-04-012023-06-30_custom_HcWainwrightMember_custom_OfferingAgreementMember"
      decimals="0"
      unitRef="USD">27999</us-gaap:PaymentsForCommissions>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2023-04-012023-06-30_custom_OfferingAgreementMember_custom_OtherOfferingExpenseMember"
      decimals="0"
      unitRef="USD">5846</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-04-012023-06-30_custom_OfferingAgreementMember"
      decimals="INF"
      unitRef="Shares">1778901</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2023-04-012023-06-30_custom_EligibleDirectorsEachMember_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">116279</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2023-04-01to2023-06-30">&lt;p id="xdx_80F_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zh4Of6uKfiV6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;6. &lt;span id="xdx_821_zXza0wTgkuxi"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the three months ended June 30, 2023, we
accrued unpaid fees of $&lt;span id="xdx_90B_ecustom--AccruedDirectorFees_c20230630_pp0p0" title="Accrued director fees"&gt;57,000&lt;/span&gt; owed to our non-employee directors. Amounts due to related parties were comprised of the following items:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zfxWkxhgBzxj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure -  RELATED PARTY TRANSACTIONS (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;span id="xdx_8B7_zFQUqfZCc5Ea" style="display: none"&gt;Due to related parties&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;June 30, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Accrued Board fees&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--DueToRelatedPartiesCurrent1_c20230630__us-gaap--RelatedPartyTransactionAxis__custom--AccruedBoardFeesMember_pp0p0" style="width: 13%; text-align: right" title="Due to related parties"&gt;57,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--DueToRelatedPartiesCurrent1_iI_pp0p0_c20230331__us-gaap--RelatedPartyTransactionAxis__custom--AccruedBoardFeesMember_z3Zz2UjwkKN6" style="width: 13%; text-align: right" title="Due to related parties"&gt;57,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Accrued vacation to all employees&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--DueToRelatedPartiesCurrent1_c20230630__us-gaap--RelatedPartyTransactionAxis__custom--AccruedVacationMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Due to related parties"&gt;134,314&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--DueToRelatedPartiesCurrent1_iI_pp0p0_c20230331__us-gaap--RelatedPartyTransactionAxis__custom--AccruedVacationMember_zcnZNuBXvfhi" style="border-bottom: Black 1pt solid; text-align: right" title="Due to related parties"&gt;157,221&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total due to related parties&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--DueToRelatedPartiesCurrent1_c20230630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Due to related parties"&gt;191,314&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--DueToRelatedPartiesCurrent1_iI_pp0p0_c20230331_zqlhTr7UOLje" style="border-bottom: Black 2.5pt double; text-align: right" title="Due to related parties"&gt;214,221&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zrmPlp9dot9a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <aemd:AccruedDirectorFees contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">57000</aemd:AccruedDirectorFees>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="From2023-04-01to2023-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zfxWkxhgBzxj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure -  RELATED PARTY TRANSACTIONS (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;span id="xdx_8B7_zFQUqfZCc5Ea" style="display: none"&gt;Due to related parties&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;June 30, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Accrued Board fees&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--DueToRelatedPartiesCurrent1_c20230630__us-gaap--RelatedPartyTransactionAxis__custom--AccruedBoardFeesMember_pp0p0" style="width: 13%; text-align: right" title="Due to related parties"&gt;57,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--DueToRelatedPartiesCurrent1_iI_pp0p0_c20230331__us-gaap--RelatedPartyTransactionAxis__custom--AccruedBoardFeesMember_z3Zz2UjwkKN6" style="width: 13%; text-align: right" title="Due to related parties"&gt;57,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Accrued vacation to all employees&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--DueToRelatedPartiesCurrent1_c20230630__us-gaap--RelatedPartyTransactionAxis__custom--AccruedVacationMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Due to related parties"&gt;134,314&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--DueToRelatedPartiesCurrent1_iI_pp0p0_c20230331__us-gaap--RelatedPartyTransactionAxis__custom--AccruedVacationMember_zcnZNuBXvfhi" style="border-bottom: Black 1pt solid; text-align: right" title="Due to related parties"&gt;157,221&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total due to related parties&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--DueToRelatedPartiesCurrent1_c20230630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Due to related parties"&gt;191,314&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--DueToRelatedPartiesCurrent1_iI_pp0p0_c20230331_zqlhTr7UOLje" style="border-bottom: Black 2.5pt double; text-align: right" title="Due to related parties"&gt;214,221&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <aemd:DueToRelatedPartiesCurrent1
      contextRef="AsOf2023-06-30_custom_AccruedBoardFeesMember"
      decimals="0"
      unitRef="USD">57000</aemd:DueToRelatedPartiesCurrent1>
    <aemd:DueToRelatedPartiesCurrent1
      contextRef="AsOf2023-03-31_custom_AccruedBoardFeesMember"
      decimals="0"
      unitRef="USD">57000</aemd:DueToRelatedPartiesCurrent1>
    <aemd:DueToRelatedPartiesCurrent1
      contextRef="AsOf2023-06-30_custom_AccruedVacationMember"
      decimals="0"
      unitRef="USD">134314</aemd:DueToRelatedPartiesCurrent1>
    <aemd:DueToRelatedPartiesCurrent1
      contextRef="AsOf2023-03-31_custom_AccruedVacationMember"
      decimals="0"
      unitRef="USD">157221</aemd:DueToRelatedPartiesCurrent1>
    <aemd:DueToRelatedPartiesCurrent1 contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">191314</aemd:DueToRelatedPartiesCurrent1>
    <aemd:DueToRelatedPartiesCurrent1 contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">214221</aemd:DueToRelatedPartiesCurrent1>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock contextRef="From2023-04-01to2023-06-30">&lt;p id="xdx_800_eus-gaap--OtherLiabilitiesDisclosureTextBlock_z3kwzUfWljNb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;7. &lt;span id="xdx_828_z0TAQbGAXDR5"&gt;OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Other current liabilities were comprised of the following items:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_zXcTSEyQ5Mi1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - OTHER CURRENT LIABILITIES (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b style="display: none"&gt;&#160;&lt;span id="xdx_8BA_zXYdGoNH7Hhc"&gt;Schedule of other current liabilities&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20230630_zEH6GLdHbBAh" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230331_zQ957KJvXEmb" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;June 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;March 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maOLCzQ3w_zPZRgFpIl6l2" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left; padding-bottom: 1pt"&gt;Accrued professional fees&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 13%; text-align: right"&gt;511,377&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 13%; text-align: right"&gt;588,592&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OtherLiabilitiesCurrent_iTI_pp0p0_mtOLCzQ3w_zOXzui78EuN6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total other current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;511,377&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;588,592&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zs2gpAoUZyNi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;











</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="From2023-04-01to2023-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_zXcTSEyQ5Mi1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - OTHER CURRENT LIABILITIES (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b style="display: none"&gt;&#160;&lt;span id="xdx_8BA_zXYdGoNH7Hhc"&gt;Schedule of other current liabilities&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20230630_zEH6GLdHbBAh" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230331_zQ957KJvXEmb" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;June 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;March 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maOLCzQ3w_zPZRgFpIl6l2" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left; padding-bottom: 1pt"&gt;Accrued professional fees&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 13%; text-align: right"&gt;511,377&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 13%; text-align: right"&gt;588,592&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OtherLiabilitiesCurrent_iTI_pp0p0_mtOLCzQ3w_zOXzui78EuN6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total other current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;511,377&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;588,592&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">511377</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">588592</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">511377</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">588592</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="From2023-04-01to2023-06-30">&lt;p id="xdx_801_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zuldErmVJz5e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;8. &lt;span id="xdx_828_zHlX2EKmNST"&gt;STOCK COMPENSATION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following tables summarize share-based compensation
expenses relating to RSUs and stock options and the effect on basic and diluted loss per common share during the three month periods ended
June 30, 2023 and 2022:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zGurrYfR5HYj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK COMPENSATION (Details - Stock compensation)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B7_zLlfHkJvLm6b" style="display: none"&gt;Schedule of share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230401__20230630_zTPPbrMJoBDk" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20220401__20220630_z9iNGfWe6rri" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;June 30, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;June 30, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_zKJQPqFYtrE7" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left; padding-bottom: 1pt"&gt;Vesting of stock options and restricted stock units&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 13%; text-align: right"&gt;250,114&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 13%; text-align: right"&gt;215,437&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ShareBasedCompensation_z5ejZmZOPirc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total stock-based compensation expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;250,114&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;215,437&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Weighted average number of common shares outstanding &#x2013; basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230401__20230630_zPnUc9bvkZo2" title="Weighted Average Number of Shares Outstanding, Basic"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230401__20230630_zpmVNJyN3tn9" title="Weighted Average Number of Shares Outstanding, Diluted"&gt;24,314,759&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220401__20220630_zzXzg3Go3Ia6" title="Weighted Average Number of Shares Outstanding, Basic"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220401__20220630_zCAWDsHqTi2h" title="Weighted Average Number of Shares Outstanding, Diluted"&gt;15,486,621&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Basic and diluted loss per common share attributable to stock-based compensation expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20230401__20230630__us-gaap--TransactionTypeAxis__custom--StockBasedCompensationMember_zR6l4AGdErhf" title="Earnings Per Share, Basic"&gt;&lt;span id="xdx_905_eus-gaap--EarningsPerShareDiluted_c20230401__20230630__us-gaap--TransactionTypeAxis__custom--StockBasedCompensationMember_zf0SAlcFLh03" title="Earnings Per Share, Diluted"&gt;(0.01&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--EarningsPerShareBasic_c20220401__20220630__us-gaap--TransactionTypeAxis__custom--StockBasedCompensationMember_z6RqknH9NQ8h" title="Earnings Per Share, Basic"&gt;&lt;span id="xdx_904_eus-gaap--EarningsPerShareDiluted_c20220401__20220630__us-gaap--TransactionTypeAxis__custom--StockBasedCompensationMember_zFYuWmwJwh54" title="Earnings Per Share, Diluted"&gt;(0.01&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_z0m3BW9VrZf2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;All of the stock-based compensation expense recorded
during the three months ended June 30, 2023 and 2022, an aggregate of $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensation_pp0p0_c20230401__20230630_zm6msLBzMNAf" title="Stock based compensation"&gt;250,114&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--ShareBasedCompensation_pp0p0_c20220401__20220630_zTc9NqgLfgMa" title="Stock based compensation"&gt;215,437&lt;/span&gt;, respectively, is included in payroll and
related expense in the accompanying condensed consolidated statements of operations. Stock-based compensation expense recorded during
each of the three months ended June 30, 2023 and 2022 represented an impact on basic and diluted loss per common share of $(0.01) in each
period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We review share-based compensation on a quarterly
basis for changes to the estimate of expected award forfeitures based on actual forfeiture experience. The cumulative effect of adjusting
the forfeiture rate for all expense amortization is recognized in the period the forfeiture estimate is changed. The effect of forfeiture
adjustments for the three months ended June 30, 2023 was insignificant.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Stock Option Activity&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We did not issue any stock options during the three months ended June
30, 2023 and 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Stock options outstanding that have vested as
of June 30, 2023 and stock options that are expected to vest subsequent to June 30, 2023 are as follows:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_zPxYiqdu59v5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK COMPENSATION (Details - Options vested and expected to vest)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B4_zlWPl0Lg8kQ8" style="display: none"&gt;Schedule of options outstanding that have vested and are expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term in&lt;br/&gt; Years&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 55%"&gt;Vested&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_znw6ZxLH8uyc" style="width: 11%; text-align: right" title="Options vested"&gt;842,610&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z898JzduWEz" style="width: 11%; text-align: right" title="Weighted average exercise price options vested"&gt;2.44&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zi2naYs42RUh" title="Weighted average remaining contractual term options vested"&gt;7.68&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Expected to vest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zkYpWV7RMHh5" style="border-bottom: Black 1pt solid; text-align: right" title="Options expected to vest"&gt;860,243&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zG2gi0sDRvi4" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price options expected to vest"&gt;2.06&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zHFw2Ra7oCP9" title="Weighted average remaining contractual term options expected to vest"&gt;8.24&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zdDfdmkzR0Lb" style="border-bottom: Black 2.5pt double; text-align: right" title="Total options outstanding"&gt;1,702,853&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zA99rQN4stca" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A summary of stock option activity during the
three months ended June 30, 2023 is presented below:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zpeyqAuknZUa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK COMPENSATION (Details - Option activity)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;span id="xdx_8BF_zRzgQXvZi0ec" style="display: none"&gt;Schedule of stock option activity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Range of&lt;br/&gt; Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average &lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Stock options outstanding at March 31, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_z3pOEl44lBc3" style="width: 12%; text-align: right" title="Stock options Outstanding, beginning balance"&gt;1,718,253&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.&lt;span id="xdx_90F_ecustom--RangeOfExercisePricesOptionBeginning_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember" title="Range of exercise prices, Option beginning"&gt;69 - 142.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_z2JUJH9ay0rd" style="width: 12%; text-align: right" title="Outstanding, Weighted Average Exercise Price, beginning price"&gt;2.31&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zgL3fFC96Xa9" style="text-align: right" title="Stock options exercised"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_z2i1Rs0mwySc" style="text-align: right" title="Exercised, Weighted Average Exercise Price"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zp0WfYMCMOkj" style="text-align: right" title="Stock options granted"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_ecustom--RangeOfExercisePricesOptionGranted_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zvVKIdRqSxCb" title="Range of exercise prices, Option Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0538"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zGm19iob5Qua" style="text-align: right" title="Granted, Weighted Average Exercise Price"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Cancelled/Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zE2KTIKrnx1e" style="border-bottom: Black 1pt solid; text-align: right" title="Stock options cancelled/forfeited"&gt;15,400&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_901_ecustom--RangeOfExercisePricesOptionCancelledexpired_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember" title="Range of exercise prices, Option cancelled/expired"&gt;1.21&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_z8BkxuQwIyQ5" style="padding-bottom: 1pt; text-align: right" title="Cancelled/Forfeited, Weighted Average Exercise Price"&gt;1.21&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Stock options outstanding at June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zup67D97zlbc" style="border-bottom: Black 1pt solid; text-align: right" title="Stock options outstanding, ending balance"&gt;1,702,853&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.&lt;span id="xdx_903_ecustom--RangeOfExercisePricesOptionEnding_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember" title="Range of exercise prices, Option ending"&gt;69 - 142.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zZFqik4v6IZf" style="padding-bottom: 1pt; text-align: right" title="Outstanding Weighted Average Exercise Price, ending price"&gt;2.25&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Stock options exercisable at June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zqsaEtlrvuld" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock options exercisable"&gt;842,610&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_ecustom--RangeOfExercisePricesOptionExercisable_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember" title="Range of exercise prices, Option exercisable"&gt;1.28 - 142.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zLuv9sYiaHIh" style="padding-bottom: 2.5pt; text-align: right" title="Exercisable, Weighted Average Exercise Price"&gt;2.44&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zx9AOH1eomBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 30, 2023, our outstanding stock options
had no intrinsic value since the closing share price on that date of $&lt;span id="xdx_904_eus-gaap--SharePrice_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zzGmAYmf6dCh" title="Share price"&gt;0.36&lt;/span&gt; per share was below the weighted average exercise price of
our outstanding stock options.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At June 30, 2023, there was approximately $&lt;span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pp0p0_c20230630_z3ac1kRDRaLh" title="Unrecognized compensation costs"&gt;1,719,000&lt;/span&gt;
of unrecognized compensation cost related to share-based payments, which is expected to be recognized over a weighted average period of
&lt;span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230401__20230630_zI2ReLzaQR42" title="Unrecognized compensation cost amortization period"&gt;1.84&lt;/span&gt; years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="From2023-04-01to2023-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zGurrYfR5HYj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK COMPENSATION (Details - Stock compensation)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B7_zLlfHkJvLm6b" style="display: none"&gt;Schedule of share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230401__20230630_zTPPbrMJoBDk" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20220401__20220630_z9iNGfWe6rri" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;June 30, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;June 30, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_zKJQPqFYtrE7" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left; padding-bottom: 1pt"&gt;Vesting of stock options and restricted stock units&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 13%; text-align: right"&gt;250,114&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 13%; text-align: right"&gt;215,437&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ShareBasedCompensation_z5ejZmZOPirc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total stock-based compensation expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;250,114&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;215,437&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Weighted average number of common shares outstanding &#x2013; basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230401__20230630_zPnUc9bvkZo2" title="Weighted Average Number of Shares Outstanding, Basic"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230401__20230630_zpmVNJyN3tn9" title="Weighted Average Number of Shares Outstanding, Diluted"&gt;24,314,759&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220401__20220630_zzXzg3Go3Ia6" title="Weighted Average Number of Shares Outstanding, Basic"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220401__20220630_zCAWDsHqTi2h" title="Weighted Average Number of Shares Outstanding, Diluted"&gt;15,486,621&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Basic and diluted loss per common share attributable to stock-based compensation expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20230401__20230630__us-gaap--TransactionTypeAxis__custom--StockBasedCompensationMember_zR6l4AGdErhf" title="Earnings Per Share, Basic"&gt;&lt;span id="xdx_905_eus-gaap--EarningsPerShareDiluted_c20230401__20230630__us-gaap--TransactionTypeAxis__custom--StockBasedCompensationMember_zf0SAlcFLh03" title="Earnings Per Share, Diluted"&gt;(0.01&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--EarningsPerShareBasic_c20220401__20220630__us-gaap--TransactionTypeAxis__custom--StockBasedCompensationMember_z6RqknH9NQ8h" title="Earnings Per Share, Basic"&gt;&lt;span id="xdx_904_eus-gaap--EarningsPerShareDiluted_c20220401__20220630__us-gaap--TransactionTypeAxis__custom--StockBasedCompensationMember_zFYuWmwJwh54" title="Earnings Per Share, Diluted"&gt;(0.01&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      unitRef="USD">250114</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">215437</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      unitRef="USD">250114</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">215437</us-gaap:ShareBasedCompensation>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-04-01to2023-06-30"
      decimals="INF"
      unitRef="Shares">24314759</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-04-01to2023-06-30"
      decimals="INF"
      unitRef="Shares">24314759</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-04-012022-06-30"
      decimals="INF"
      unitRef="Shares">15486621</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-04-012022-06-30"
      decimals="INF"
      unitRef="Shares">15486621</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-04-012023-06-30_custom_StockBasedCompensationMember"
      decimals="INF"
      unitRef="USDPShares">-0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-04-012023-06-30_custom_StockBasedCompensationMember"
      decimals="INF"
      unitRef="USDPShares">-0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-04-012022-06-30_custom_StockBasedCompensationMember"
      decimals="INF"
      unitRef="USDPShares">-0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-04-012022-06-30_custom_StockBasedCompensationMember"
      decimals="INF"
      unitRef="USDPShares">-0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      unitRef="USD">250114</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">215437</us-gaap:ShareBasedCompensation>
    <us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock contextRef="From2023-04-01to2023-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_zPxYiqdu59v5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK COMPENSATION (Details - Options vested and expected to vest)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B4_zlWPl0Lg8kQ8" style="display: none"&gt;Schedule of options outstanding that have vested and are expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term in&lt;br/&gt; Years&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 55%"&gt;Vested&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_znw6ZxLH8uyc" style="width: 11%; text-align: right" title="Options vested"&gt;842,610&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z898JzduWEz" style="width: 11%; text-align: right" title="Weighted average exercise price options vested"&gt;2.44&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zi2naYs42RUh" title="Weighted average remaining contractual term options vested"&gt;7.68&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Expected to vest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zkYpWV7RMHh5" style="border-bottom: Black 1pt solid; text-align: right" title="Options expected to vest"&gt;860,243&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zG2gi0sDRvi4" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price options expected to vest"&gt;2.06&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zHFw2Ra7oCP9" title="Weighted average remaining contractual term options expected to vest"&gt;8.24&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zdDfdmkzR0Lb" style="border-bottom: Black 2.5pt double; text-align: right" title="Total options outstanding"&gt;1,702,853&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2023-04-012023-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">842610</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">2.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2023-04-012023-06-30_us-gaap_StockOptionMember">P7Y8M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2023-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">860243</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">2.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2023-04-012023-06-30_us-gaap_StockOptionMember">P8Y2M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">1702853</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2023-04-01to2023-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zpeyqAuknZUa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK COMPENSATION (Details - Option activity)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;span id="xdx_8BF_zRzgQXvZi0ec" style="display: none"&gt;Schedule of stock option activity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Range of&lt;br/&gt; Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average &lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Stock options outstanding at March 31, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_z3pOEl44lBc3" style="width: 12%; text-align: right" title="Stock options Outstanding, beginning balance"&gt;1,718,253&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.&lt;span id="xdx_90F_ecustom--RangeOfExercisePricesOptionBeginning_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember" title="Range of exercise prices, Option beginning"&gt;69 - 142.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_z2JUJH9ay0rd" style="width: 12%; text-align: right" title="Outstanding, Weighted Average Exercise Price, beginning price"&gt;2.31&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zgL3fFC96Xa9" style="text-align: right" title="Stock options exercised"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_z2i1Rs0mwySc" style="text-align: right" title="Exercised, Weighted Average Exercise Price"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zp0WfYMCMOkj" style="text-align: right" title="Stock options granted"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_ecustom--RangeOfExercisePricesOptionGranted_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zvVKIdRqSxCb" title="Range of exercise prices, Option Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0538"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zGm19iob5Qua" style="text-align: right" title="Granted, Weighted Average Exercise Price"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Cancelled/Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zE2KTIKrnx1e" style="border-bottom: Black 1pt solid; text-align: right" title="Stock options cancelled/forfeited"&gt;15,400&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_901_ecustom--RangeOfExercisePricesOptionCancelledexpired_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember" title="Range of exercise prices, Option cancelled/expired"&gt;1.21&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_z8BkxuQwIyQ5" style="padding-bottom: 1pt; text-align: right" title="Cancelled/Forfeited, Weighted Average Exercise Price"&gt;1.21&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Stock options outstanding at June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zup67D97zlbc" style="border-bottom: Black 1pt solid; text-align: right" title="Stock options outstanding, ending balance"&gt;1,702,853&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.&lt;span id="xdx_903_ecustom--RangeOfExercisePricesOptionEnding_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember" title="Range of exercise prices, Option ending"&gt;69 - 142.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zZFqik4v6IZf" style="padding-bottom: 1pt; text-align: right" title="Outstanding Weighted Average Exercise Price, ending price"&gt;2.25&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Stock options exercisable at June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zqsaEtlrvuld" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock options exercisable"&gt;842,610&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_ecustom--RangeOfExercisePricesOptionExercisable_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember" title="Range of exercise prices, Option exercisable"&gt;1.28 - 142.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zLuv9sYiaHIh" style="padding-bottom: 2.5pt; text-align: right" title="Exercisable, Weighted Average Exercise Price"&gt;2.44&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-03-31_us-gaap_OptionMember"
      decimals="INF"
      unitRef="Shares">1718253</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <aemd:RangeOfExercisePricesOptionBeginning contextRef="From2023-04-012023-06-30_us-gaap_OptionMember">69 - 142.50</aemd:RangeOfExercisePricesOptionBeginning>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-03-31_us-gaap_OptionMember"
      decimals="INF"
      unitRef="USDPShares">2.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-04-012023-06-30_us-gaap_OptionMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2023-04-012023-06-30_us-gaap_OptionMember"
      decimals="INF"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2023-04-012023-06-30_us-gaap_OptionMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-04-012023-06-30_us-gaap_OptionMember"
      decimals="INF"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2023-04-012023-06-30_us-gaap_OptionMember"
      decimals="INF"
      unitRef="Shares">15400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <aemd:RangeOfExercisePricesOptionCancelledexpired contextRef="From2023-04-012023-06-30_us-gaap_OptionMember">1.21</aemd:RangeOfExercisePricesOptionCancelledexpired>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-04-012023-06-30_us-gaap_OptionMember"
      decimals="INF"
      unitRef="USDPShares">1.21</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-06-30_us-gaap_OptionMember"
      decimals="INF"
      unitRef="Shares">1702853</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <aemd:RangeOfExercisePricesOptionEnding contextRef="From2023-04-012023-06-30_us-gaap_OptionMember">69 - 142.50</aemd:RangeOfExercisePricesOptionEnding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-06-30_us-gaap_OptionMember"
      decimals="INF"
      unitRef="USDPShares">2.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2023-06-30_us-gaap_OptionMember"
      decimals="INF"
      unitRef="Shares">842610</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <aemd:RangeOfExercisePricesOptionExercisable contextRef="From2023-04-012023-06-30_us-gaap_OptionMember">1.28 - 142.50</aemd:RangeOfExercisePricesOptionExercisable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-06-30_us-gaap_OptionMember"
      decimals="INF"
      unitRef="USDPShares">2.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2023-06-30_us-gaap_OptionMember"
      decimals="INF"
      unitRef="USDPShares">0.36</us-gaap:SharePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">1719000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2023-04-01to2023-06-30">P1Y10M2D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <aemd:WarrantsTextBlock contextRef="From2023-04-01to2023-06-30">&lt;p id="xdx_80E_ecustom--WarrantsTextBlock_zSByTrxnjJrk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;9. &lt;span id="xdx_82C_z2ZUIz3WD1e5"&gt;WARRANTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the three months ended June 30, 2023 and
2022, we did not issue any warrants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A summary of warrant activity during the three
months ended June 30, 2023 is presented below:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zVXbLadZcZF1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Warrant (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;span id="xdx_8BB_za3QfCelP4vb" style="display: none"&gt;Schedule of warrant activity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Range of&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 52%"&gt;Warrants outstanding at March 31, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zWNsfZCtHYsc" style="width: 12%; text-align: right" title="Number of Warrants Outstanding, Beginning"&gt;326,753&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zSRXugrKKOO6" title="Range of Exercise Price Outstanding, Beginning"&gt;1.50 &#x2013; 2.75&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zRNuM9uEtTyk" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning"&gt;2.01&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zeJLxO6WH7Rk" style="text-align: right" title="Number of Warrants Exercised"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zj6W3O0zGRz4" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Cancelled/Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z8VwIxOdpkCg" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants Cancelled/Expired"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_903_ecustom--RangeOfExercisePriceCancelledExpired_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zW2BXRxcebO2" title="Range of Exercise Price Cancelled Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0582"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zQ85u3WPAGxa" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price Cancelled/Expired"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants outstanding at June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zN9SeW3qrN71" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Outstanding, Ending"&gt;326,753&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_ecustom--RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z1GO87z1Iip4" title="Range of Exercise Price Outstanding, Ending"&gt;1.50 &#x2013; 2.75&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zZgFv6xD2Khb" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price Outstanding, Ending"&gt;2.01&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants exercisable at June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zcgM8KbVIsYh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Exercisable, Ending"&gt;326,753&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_ecustom--RangeOfWeightedAverageExercisePriceExercisable_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zYDtsUiuVKf" title="Range of Exercise Price Exercisable"&gt;1.50 &#x2013; 2.75&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z5kdpqMiJhQg" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price Exercisable"&gt;2.01&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zCpxlDF1liT4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;











</aemd:WarrantsTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2023-04-01to2023-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zVXbLadZcZF1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Warrant (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;span id="xdx_8BB_za3QfCelP4vb" style="display: none"&gt;Schedule of warrant activity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Range of&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 52%"&gt;Warrants outstanding at March 31, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zWNsfZCtHYsc" style="width: 12%; text-align: right" title="Number of Warrants Outstanding, Beginning"&gt;326,753&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zSRXugrKKOO6" title="Range of Exercise Price Outstanding, Beginning"&gt;1.50 &#x2013; 2.75&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zRNuM9uEtTyk" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning"&gt;2.01&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zeJLxO6WH7Rk" style="text-align: right" title="Number of Warrants Exercised"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zj6W3O0zGRz4" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Cancelled/Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z8VwIxOdpkCg" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants Cancelled/Expired"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span id="xdx_903_ecustom--RangeOfExercisePriceCancelledExpired_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zW2BXRxcebO2" title="Range of Exercise Price Cancelled Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0582"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice_d0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zQ85u3WPAGxa" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price Cancelled/Expired"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants outstanding at June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zN9SeW3qrN71" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Outstanding, Ending"&gt;326,753&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_ecustom--RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z1GO87z1Iip4" title="Range of Exercise Price Outstanding, Ending"&gt;1.50 &#x2013; 2.75&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zZgFv6xD2Khb" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price Outstanding, Ending"&gt;2.01&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrants exercisable at June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zcgM8KbVIsYh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Exercisable, Ending"&gt;326,753&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_ecustom--RangeOfWeightedAverageExercisePriceExercisable_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zYDtsUiuVKf" title="Range of Exercise Price Exercisable"&gt;1.50 &#x2013; 2.75&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z5kdpqMiJhQg" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price Exercisable"&gt;2.01&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-03-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">326753</us-gaap:ClassOfWarrantOrRightOutstanding>
    <aemd:RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="From2023-04-012023-06-30_us-gaap_WarrantMember">1.50 &#x2013; 2.75</aemd:RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-03-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">2.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2023-04-012023-06-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <aemd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice
      contextRef="From2023-04-012023-06-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">0</aemd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2023-04-012023-06-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <aemd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-04-012023-06-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">0</aemd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-06-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">326753</us-gaap:ClassOfWarrantOrRightOutstanding>
    <aemd:RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2 contextRef="From2023-04-012023-06-30_us-gaap_WarrantMember">1.50 &#x2013; 2.75</aemd:RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-06-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">2.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <aemd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber
      contextRef="AsOf2023-06-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">326753</aemd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber>
    <aemd:RangeOfWeightedAverageExercisePriceExercisable contextRef="From2023-04-012023-06-30_us-gaap_WarrantMember">1.50 &#x2013; 2.75</aemd:RangeOfWeightedAverageExercisePriceExercisable>
    <aemd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-06-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">2.01</aemd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2023-04-01to2023-06-30">&lt;p id="xdx_80D_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z63ZiPipM6tf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;10. &lt;span id="xdx_821_zAI29AWVPZOl"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;LEASE COMMITMENTS&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Office, Lab and Manufacturing Space Leases&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December 2020, we entered into an agreement
to lease approximately 2,823 square feet of office space and 1,807 square feet of laboratory space located at 11555 Sorrento Valley Road,
Suite 203, San Diego, California 92121 and 11575 Sorrento Valley Road, Suite 200, San Diego, California 92121, respectively. The agreement
carries a term of 63 months and we took possession of the office space effective October 1, 2021. We took possession of the laboratory
space effective January 1, 2022. In October 2021, we entered into another lease for approximately 2,655 square feet of space to house
our manufacturing operations located at 11588 Sorrento Valley Road, San Diego, California 92121. The term is for &lt;span id="xdx_90E_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtM_c20220831_z0G5iFq60q5f" title="Lease term"&gt;55&lt;/span&gt; months and we took
possession of the manufacturing space in August 2022. The current monthly base rent under the office and laboratory component of the lease
is $&lt;span id="xdx_90C_ecustom--MonthlyBaseRent_pp0p0_c20230401__20230630__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--OfficeAndLaboratoryMember_zhE6WvDJjb6h" title="Monthly base rent"&gt;13,772&lt;/span&gt;. The current monthly base rent under the manufacturing component of the lease is $&lt;span id="xdx_90D_ecustom--MonthlyBaseRent_pp0p0_c20230401__20230630__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--ManufacturingMember_z5EHKGyZIRl7" title="Monthly base rent"&gt;12,080&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The office, lab and manufacturing leases are coterminous
with a remaining term of &lt;span id="xdx_907_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20230630__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--OfficeLabAndManufacturingLeasesMember_zdW5HSWLbN28" title="Lease term"&gt;45&lt;/span&gt; months. The weighted average discount rate is &lt;span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20230630__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--OfficeLabAndManufacturingLeasesMember_z7Yo9e7WhLPd" title="Weighted average discount rate"&gt;4.25%&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of our June 30, 2023 balance sheet, we have
a right-of-use lease asset of $&lt;span id="xdx_90E_eus-gaap--OperatingLeaseRightOfUseAsset_c20230630_pp0p0" title="Right of use lease asset"&gt;1,086,108&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In addition, the lease agreements for the new
office, lab and manufacturing space required us to post a standby L/C in favor of the landlord in the aggregate amount of $&lt;span id="xdx_906_eus-gaap--LettersOfCreditOutstandingAmount_iI_pp0p0_c20230630__us-gaap--PropertySubjectToOrAvailableForOperatingLeaseAxis__custom--NewOfficeAndLabSpaceMember_zDvYTQHYHJE7" title="Line of credit"&gt;87,506&lt;/span&gt; in lieu
of a security deposit. We arranged for our bank to issue standby L/Cs for the new office and lab in the amounts of $46,726 in the fiscal
year ended March 31, 2021 and for the manufacturing space in the amount of $40,780 in the fiscal year ended March 31, 2022. We transferred
like amounts to a restricted certificate of deposit which secured the bank&#x2019;s risk in issuing those L/Cs. We have classified those
restricted certificates of deposit on our balance sheet as restricted cash with a balance of $&lt;span id="xdx_904_eus-gaap--RestrictedCash_iI_c20230630_zcriddthYLmj"&gt;87,506&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Mobile Clean Room&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In addition, we rented a mobile clean room on
a short term, month-to-month basis, where we housed our manufacturing operations until our permanent manufacturing space was completed.
The mobile clean room was located on leased land near our office and lab and we paid $&lt;span id="xdx_901_ecustom--PaymentForRentPerMonth_c20230401__20230630_pp0p0" title="Payment for rent per month"&gt;2,000&lt;/span&gt; per month for the right to locate it there.
The arrangement was terminated in September 2022 and the mobile clean room was returned to the vendor that leased it to us.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Overall, our rent expense, which is included in
general and administrative expenses, approximated $&lt;span id="xdx_90F_eus-gaap--OperatingLeaseExpense_c20230401__20230630_pp0p0" title="Operating Lease, Expense"&gt;105,000&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--OperatingLeaseExpense_c20220401__20220630_pp0p0" title="Operating Lease, Expense"&gt;140,000&lt;/span&gt; for the three month periods ended June 30, 2023 and 2022, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;LEGAL MATTERS&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We may be involved from time to time in various
claims, lawsuits, and/or disputes with third parties or breach of contract actions incidental to the normal course of our business operations.
We are currently not involved in any litigation or any pending legal proceedings.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="AsOf2022-08-31">P55M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <aemd:MonthlyBaseRent
      contextRef="From2023-04-012023-06-30_custom_OfficeAndLaboratoryMember"
      decimals="0"
      unitRef="USD">13772</aemd:MonthlyBaseRent>
    <aemd:MonthlyBaseRent
      contextRef="From2023-04-012023-06-30_custom_ManufacturingMember"
      decimals="0"
      unitRef="USD">12080</aemd:MonthlyBaseRent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2023-06-30_custom_OfficeLabAndManufacturingLeasesMember">P45M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2023-06-30_custom_OfficeLabAndManufacturingLeasesMember"
      decimals="INF"
      unitRef="Pure">0.0425</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">1086108</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="AsOf2023-06-30_custom_NewOfficeAndLabSpaceMember"
      decimals="0"
      unitRef="USD">87506</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:RestrictedCash contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">87506</us-gaap:RestrictedCash>
    <aemd:PaymentForRentPerMonth
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      unitRef="USD">2000</aemd:PaymentForRentPerMonth>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2023-04-01to2023-06-30"
      decimals="0"
      unitRef="USD">105000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">140000</us-gaap:OperatingLeaseExpense>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2023-04-01to2023-06-30">&lt;p id="xdx_80C_eus-gaap--SubsequentEventsTextBlock_zZLApxorVNP6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;11. &lt;span id="xdx_82C_zF59TVWfnzp3"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Management has evaluated events subsequent to
June 30, 2023 through the date that the accompanying consolidated financial statements were filed with the Securities and Exchange Commission
for transactions and other events which may require adjustment of and/or disclosure in such financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In July 2023, Mr. Nikolas Gikakis was appointed
as a member our Board of Directors and as a member of the Nominating and Corporate Governance Committee of the Board, or the N&amp;amp;CG
Committee. Pursuant to the Director Compensation Policy, upon his appointment to the Board, Mr. Gikakis (i) will receive an (a) annual
cash retainer of $40,000 for his service on the Board, and (b) an additional annual cash retainer of $5,000 for his service as a member
of the N&amp;amp;CG Committee, and (ii) was granted, on the date of his appointment to the Board, restricted stock units for 195,414 shares
of our common stock under the 2020 Plan, which will vest in equal quarterly installments over one year from the date of grant, in each
case subject to Mr. Gikakis&#x2019;s Continuous Service (as defined in the 2020 Plan) as of each such vesting date. The Director Compensation
Policy also provides for further annual grants to its independent directors, at the beginning of each fiscal year, of restricted stock
units with a grant date fair value of $50,000 or, at the option of our Board, options to purchase shares of our common stock, subject
to vesting as determined by our Board. Mr. Gikakis has also entered into our standard form of indemnification agreement for directors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>49
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MA4D+C7BV0LIL1 &[_]CR;$W[>Z 8P91Z+>Q=,=\/ ]J#W*^1^X/(ORG#DQ-
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ML12X8H(3"<NNU6M<#]HF/@_XR6"K]OK$.%D(\60&XZAK.480)!!JPT"QV<
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M#@-)AQ@*Y4LH]\HV]LK"1F3<.C+N0=7OVS<N@O 3^'IWY0/3V)7 7]?9:?U
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M_9-Z]>/@>/^E>N[]Q;W>6ZA\\T;OVE8R.Y 74MMOV]=Y1_(6:_>XO N,O%Z
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M+#62"-8QD3(Y#3-/28B!-KJ5&'&O%0@I%>L1F@P@031&_E<5DP\ZVVH)%3D
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MT*@VZ(T^O+OHMC^=H=RI*7?.H?_?8SH+>9QPV((W2\%=J4 =]C YZ&$LM='
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MZWP7D)ZX@722:*)FU*J3_S+(8E^0$0%D^!E> WZN5L9K9AH@Y4[R#.,ZS.M
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MT4'OY*@;VG3]X$W!E_Z%\6CS_'6M,"%9VH#W2V-\_4 &FE^!+OX-4$L#!!0
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MO<57A77^:O0PF=P^3<;W3U,QO+\1HX?[I]O[C^/[T>UX>M'U<,&&W6P+=]W
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MFHE^V%"8 'V^X5R='9.@>BJ#OU!+ P04    " #NB0I79U"0M'H"  !S!0
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MW?= UBFO)UJ4+ED;H4U.W3 W#R-*6V#V,R'T86(;-$]M_!=02P,$%     @
M[HD*5PB3P"O" P  _ D  !D   !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL
MK59+;]LX$+[[5PS4HF@!50_J836U#=C9[&Y;Y($XVQX6>Z EVA(BB2Y)Q>F_
MWR%E*TZCJ#GT8@_%F6^^>9&<[+BXE3EC"NZKLI93*U=J>^*Z,LU91:7#MZS&
MG347%56X%!M7;@6CF3&J2I=X7NQ6M*BMV<1\NQ*S"6]46=3L2H!LJHJ*'PM6
M\MW4\JW#A^MBDRO]P9U-MG3#EDS]L[T2N'([E*RH6"T+7H-@ZZDU]T\6L=8W
M"E\+MI-',NA(5IS?ZL6G;&IYFA K6:HT L6_.W;*RE(#(8WO>TRK<ZD-C^4#
M^I\F=HQE124[Y>6W(E/YU$HLR-B:-J6ZYKN_V3Z>2..EO)3F%W:M[CBT(&VD
MXM7>&!E41=W^T_M]'HX,$N\9 [(W((9WZ\BP_(,J.IL(O@.AM1%-"R948XWD
MBEH79:D$[A9HIV;+F\O3+W!Z>7YU=K&<WWRZO("W-W15,OENXBITH-7<= ^V
M:,'(,V !G/-:Y1+.ZHQEC^U=)-:Q(P=V"S((^+FI'0@\&XA'@@&\H(LV,'C!
M,WAGWYM"_8!_YRNI!#;$?WTQMA!A/X0>DA.YI2F;6C@%DHD[9LW>O/)C[^,
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MSYC0"KB_YEP=%MI!]^";_0]02P,$%     @ [HD*5_5+U-YW @  _@4  !D
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M"&UFU!USLT5!V@!SOQ5"'PV;H-W+R1]02P,$%     @ [HD*5WM!.+1I @
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M-=L$)RL('8#G*\[5P= )ZED=_ 902P,$%     @ [HD*5W3 W)K7 P  U P
M !D   !X;"]W;W)K<VAE971S+W-H965T,C@N>&ULM5=;C^HV$/XKH[2J=J7M
MYL)]"TBP<+H<=8%RZ5%UU >3#,3:Q.;89MF5^N-K.R'0'LC#JCQ XLM\_L;S
MV3-I[[EXD3&B@K<T8;+CQ$IM'UQ7AC&F1-[S+3(]LN8B)4HWQ<:56X$DLD9I
MX@:>5W=30IG3;=N^J>BV^4XEE.%4@-RE*1'O?4SXON/XSJ%C1C>Q,AUNM[TE
M&YRC6FZG0K?< B6B*3)).0.!ZX[3\Q_Z?LT8V!E_4-S+DW<PKJPX?S&-4=1Q
M/,,($PR5@2#Z\8J/F"0&2?/XEH,ZQ9K&\/3]@/[).J^=61&)CSSY0B,5=YRF
M Q&NR2Y1,[Y_PMPA2S#DB;3_L,_G>@Z$.ZEXFAMK!BEEV9.\Y1MQ8A"T+A@$
MN4%@>6<+698#HDBW+?@>A)FMT<R+==5::W*4F:C,E="C5-NI[O#WY6CQ)RQF
MO?&\][@83<9S&(UA\334O]EP",^3\>)I#L/Q8#B S\OQ$"K>'01>4(&; 2I"
M$PEC(@0QNWO;=I4F9:#=,"?0SP@$%PA4X)DS%4L8L@BC?]N[VIG"H^#@43\H
M!?R\8_='CLOY &Y^O 49$X&R!+Y2;%C%PE<O;5A"-W25( RHT,KB0C,G80Q?
MGS%=H?@+_H892B5HJ#""N>+A"RP951)N9O.EO"TFGMNJTJ7- 7V06Q)BQ]$G
M4*)X1:?[TP]^W?NEQ+%JX5C5HE<N.#;'<">HHBCA$V6$A91M8"$(DR0[0%]_
MTQ8P4IC*L^2K5R!?*\C72J,R-^']N:^/9P2//-5WEB26=$\KDVU0WR,*5N]P
M.F]*WFUW;T]$= ?#;SNJWF'$=/!V9D#"1,4H0,6$P61KX.0=_*KQ]!!E,$5!
M>:3C?4Y;V99DI&N6M+D?7[N^7P\:K;;[>L;9>N%LO=39R7JME];1Z6T$9JZ5
MB:H4[(-Q:114&]<55>,*Y)L%^6;I/D\%#Q$C"6O!4Z!2[K0#"'P-:+5RCF^&
M6#^-N->L^_Z%D+<**JUR?=M[Q%#0PF6XO\M%=^@J$V'K>Q$V&LV6YY^GY'O'
MU.%]5(>:4'9XBCG#-W,HL52IY>M],-K^22KTKRO6'/]_YA\<^0?E>LTO-"U0
M6>C%2C;D4IW51HYXJM=:LUJ_H(QCCO3+DV2Y,IY"^*+KQ;TP%5.Y(*Z1$/UC
M1O2OG!+]:^1$_Y@4_?*L>"*(D*>IEH/)86>)UK[3@4Y3K?_>6NY)H9FBV-AR
M6FKP'5-9S5GT%B5[+RM4C].S>O^9B UE$A)<:U/OOJ$9B*R$SAJ*;VW9NN)*
M%\'V-=:?'2C,!#V^YEP=&F:!XD.F^P]02P,$%     @ [HD*5WJBZPK" @
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MA;#$><RG9/L-*CVNY M(S(HGVI:Q3E=#0<XX22JPR"")TO*-'RL?=@"F\P+
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M+>YY0&6 ^+XDA#]WY%5"W1S]OU!+ P04    " #NB0I7SQQ#:18"   F!
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MM.DK-\S-0P9I$\QZ)H0^!;:Y^K^&Z!]02P,$%     @ [HD*5PP;/#=: @
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M,T!H YQ?<*[N.SI ^>$2_ =02P,$%     @ [HD*5Q05,2(K P  _0@  !D
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MY=F%+1M(EII+THI)=>4RKUMUR06N%ZCO:\;D<: #%-?FR;]02P,$%     @
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MLCN691T0KBS\0O^;N:SF/\A".*9,D*=L)P5&:%"FM+J&C3: &;(M%&=M[Z
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MW7C\L'QN3M@9<+9P#;W_!5!+ P04    " #NB0I7JF<489@!   +%P  $P
M %M#;VYT96YT7U1Y<&5S72YX;6S-F,UNPC 0A%\ERA418[NE/P(N;:\MA[Z
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ME?])U@^MEW_]>[9=DUJ5S<&?=?_ 9U]02P$"% ,4    " #NB0I7!T%-8H$
M  "Q    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( .Z)"E?L'Q'1[@   "L"   1              "  :\   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( .Z)"E>97)PC$ 8  )PG   3
M          "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
M[HD*5Q,67*_O!0  M1\  !@              ("!#0@  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( .Z)"E=R[7B8GP4  . 5   8
M          " @3(.  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M    " #NB0I7AF#VA+<"  !&!P  &               @($'%   >&PO=V]R
M:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ [HD*5_5FF6GV P  3@T
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M965T."YX;6Q02P$"% ,4    " #NB0I7:_])5DH#  ""!P  &
M    @('#/@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @
M[HD*5S)9%G7F @  P@8  !D              ("!0T(  'AL+W=O<FMS:&5E
M=',O<VAE970Q,"YX;6Q02P$"% ,4    " #NB0I7'I#[FBD"    !0  &0
M            @(%@10  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4
M Q0    ( .Z)"E=8K=!,=P<  !$2   9              " @<!'  !X;"]W
M;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ [HD*5XM3R6&; @
MW 4  !D              ("!;D\  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX
M;6Q02P$"% ,4    " #NB0I7%=IS#H4"  "_!0  &0              @(%
M4@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( .Z)"E=/
M#[& 6 4  )T-   9              " @?Q4  !X;"]W;W)K<VAE971S+W-H
M965T,34N>&UL4$L! A0#%     @ [HD*5W,)D1"R @  H 8  !D
M     ("!BUH  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .Z)"E=G4)"T>@(  ',%   9              "
M@?MQ  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ [HD*
M5PB@;69N @  =@4  !D              ("!K'0  'AL+W=O<FMS:&5E=',O
M<VAE970R,BYX;6Q02P$"% ,4    " #NB0I7")/ *\(#  #\"0  &0
M        @(%1=P  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0
M   ( .Z)"E?U2]3>=P(  /X%   9              " @4I[  !X;"]W;W)K
M<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ [HD*5R BZ]4? @  ,P0
M !D              ("!^'T  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q0
M2P$"% ,4    " #NB0I7:( XD5H"  "C!0  &0              @(%.@
M>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( .Z)"E=[03BT
M:0(  +<%   9              " @=^"  !X;"]W;W)K<VAE971S+W-H965T
M,C<N>&UL4$L! A0#%     @ [HD*5W3 W)K7 P  U P  !D
M ("!?X4  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " #N
MB0I7>J+K"L("  !%"@  &0              @(&-B0  >&PO=V]R:W-H965T
M<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( .Z)"E?/'$-I%@(  "8$   9
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M970S-"YX;6Q02P$"% ,4    " #NB0I7:'+0LA\#  "4"@  &0
M    @('"G   >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    (
M .Z)"E>O3U<JA ,  %0-   9              " @1B@  !X;"]W;W)K<VAE
M971S+W-H965T,S8N>&UL4$L! A0#%     @ [HD*5SE;Y?1R!   Y!@  !D
M             ("!TZ,  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"
M% ,4    " #NB0I7KY[CR2,#   2$@  #0              @ %\J   >&PO
M<W1Y;&5S+GAM;%!+ 0(4 Q0    ( .Z)"E>7BKL<P    !,"   +
M      "  <JK  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( .Z)"E=J0K4CC0,
M "49   /              "  ;.L  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M    " #NB0I7F3ZBA'P!  "6%@  &@              @ %ML   >&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #NB0I7JF<489@!   +
M%P  $P              @ $AL@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
1    +0 M #(,  #JLP     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>61</ContextCount>
  <ElementCount>172</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>21</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="aethlon_i10q-063023.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="aethlon_i10q-063023.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="aethlon_i10q-063023.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="aethlon_i10q-063023.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="aethlon_i10q-063023.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="aethlon_i10q-063023.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="aethlon_i10q-063023.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="aethlon_i10q-063023.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganization</Role>
      <ShortName>NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="aethlon_i10q-063023.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - LOSS PER COMMON SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/LossPerCommonShare</Role>
      <ShortName>LOSS PER COMMON SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="aethlon_i10q-063023.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/ResearchAndDevelopmentExpenses</Role>
      <ShortName>RESEARCH AND DEVELOPMENT EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="aethlon_i10q-063023.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/RecentAccountingPronouncements</Role>
      <ShortName>RECENT ACCOUNTING PRONOUNCEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="aethlon_i10q-063023.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - EQUITY TRANSACTIONS IN THE THREE MONTHS ENDED JUNE 30, 2023</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302023</Role>
      <ShortName>EQUITY TRANSACTIONS IN THE THREE MONTHS ENDED JUNE 30, 2023</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="aethlon_i10q-063023.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="aethlon_i10q-063023.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/OtherCurrentLiabilities</Role>
      <ShortName>OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="aethlon_i10q-063023.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - STOCK COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/StockCompensation</Role>
      <ShortName>STOCK COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="aethlon_i10q-063023.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - WARRANTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/Warrants</Role>
      <ShortName>WARRANTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="aethlon_i10q-063023.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="aethlon_i10q-063023.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="aethlon_i10q-063023.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationPolicies</Role>
      <ShortName>NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="aethlon_i10q-063023.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesTables</Role>
      <ShortName>RESEARCH AND DEVELOPMENT EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/ResearchAndDevelopmentExpenses</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="aethlon_i10q-063023.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/RelatedPartyTransactions</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="aethlon_i10q-063023.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/OtherCurrentLiabilitiesTables</Role>
      <ShortName>OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/OtherCurrentLiabilities</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="aethlon_i10q-063023.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - STOCK COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/StockCompensationTables</Role>
      <ShortName>STOCK COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/StockCompensation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="aethlon_i10q-063023.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - WARRANTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/WarrantsTables</Role>
      <ShortName>WARRANTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/Warrants</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="aethlon_i10q-063023.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationDetailsNarrative</Role>
      <ShortName>NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="aethlon_i10q-063023.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - LOSS PER COMMON SHARE (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/LossPerCommonShareDetailsNarrative</Role>
      <ShortName>LOSS PER COMMON SHARE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/LossPerCommonShare</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="aethlon_i10q-063023.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesDetails</Role>
      <ShortName>RESEARCH AND DEVELOPMENT EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="aethlon_i10q-063023.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - EQUITY TRANSACTIONS IN THE THREE MONTHS ENDED JUNE 30, 2023 (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302023DetailsNarrative</Role>
      <ShortName>EQUITY TRANSACTIONS IN THE THREE MONTHS ENDED JUNE 30, 2023 (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302023</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="aethlon_i10q-063023.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure -  RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="aethlon_i10q-063023.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="aethlon_i10q-063023.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - OTHER CURRENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/OtherCurrentLiabilitiesDetails</Role>
      <ShortName>OTHER CURRENT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/OtherCurrentLiabilitiesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="aethlon_i10q-063023.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - STOCK COMPENSATION (Details - Stock compensation)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/StockCompensationDetails-StockCompensation</Role>
      <ShortName>STOCK COMPENSATION (Details - Stock compensation)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/StockCompensationTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="aethlon_i10q-063023.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - STOCK COMPENSATION (Details - Options vested and expected to vest)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest</Role>
      <ShortName>STOCK COMPENSATION (Details - Options vested and expected to vest)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/StockCompensationTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="aethlon_i10q-063023.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - STOCK COMPENSATION (Details - Option activity)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity</Role>
      <ShortName>STOCK COMPENSATION (Details - Option activity)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/StockCompensationTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="aethlon_i10q-063023.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - STOCK COMPENSATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/StockCompensationDetailsNarrative</Role>
      <ShortName>STOCK COMPENSATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/StockCompensationTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="aethlon_i10q-063023.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Warrant (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/WarrantDetails</Role>
      <ShortName>Warrant (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="aethlon_i10q-063023.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>37</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="aethlon_i10q-063023.htm">aethlon_i10q-063023.htm</File>
    <File>aemd-20230630.xsd</File>
    <File>aemd-20230630_cal.xml</File>
    <File>aemd-20230630_def.xml</File>
    <File>aemd-20230630_lab.xml</File>
    <File>aemd-20230630_pre.xml</File>
    <File>aethlon_ex3101.htm</File>
    <File>aethlon_ex3102.htm</File>
    <File>aethlon_ex3201.htm</File>
    <File>aethlon_ex3202.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="278">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>54
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "aethlon_i10q-063023.htm": {
   "axisCustom": 0,
   "axisStandard": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 278,
    "http://xbrl.sec.gov/dei/2023": 30
   },
   "contextCount": 61,
   "dts": {
    "calculationLink": {
     "local": [
      "aemd-20230630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "aemd-20230630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "aethlon_i10q-063023.htm"
     ]
    },
    "labelLink": {
     "local": [
      "aemd-20230630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "aemd-20230630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "aemd-20230630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "elementCount": 277,
   "entityCount": 1,
   "hidden": {
    "http://aethlonmedical.com/20230630": 5,
    "http://fasb.org/us-gaap/2023": 29,
    "http://xbrl.sec.gov/dei/2023": 5,
    "total": 39
   },
   "keyCustom": 24,
   "keyStandard": 148,
   "memberCustom": 12,
   "memberStandard": 9,
   "nsprefix": "aemd",
   "nsuri": "http://aethlonmedical.com/20230630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://aethlonmedical.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://aethlonmedical.com/role/ResearchAndDevelopmentExpenses",
     "shortName": "RESEARCH AND DEVELOPMENT EXPENSES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://aethlonmedical.com/role/RecentAccountingPronouncements",
     "shortName": "RECENT ACCOUNTING PRONOUNCEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - EQUITY TRANSACTIONS IN THE THREE MONTHS ENDED JUNE 30, 2023",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302023",
     "shortName": "EQUITY TRANSACTIONS IN THE THREE MONTHS ENDED JUNE 30, 2023",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - RELATED PARTY TRANSACTIONS",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://aethlonmedical.com/role/RelatedPartyTransactions",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - OTHER CURRENT LIABILITIES",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://aethlonmedical.com/role/OtherCurrentLiabilities",
     "shortName": "OTHER CURRENT LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - STOCK COMPENSATION",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://aethlonmedical.com/role/StockCompensation",
     "shortName": "STOCK COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "aemd:WarrantsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - WARRANTS",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://aethlonmedical.com/role/Warrants",
     "shortName": "WARRANTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "aemd:WarrantsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://aethlonmedical.com/role/CommitmentsAndContingencies",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - SUBSEQUENT EVENTS",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://aethlonmedical.com/role/SubsequentEvents",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION (Policies)",
     "menuCat": "Policies",
     "order": "19",
     "role": "http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationPolicies",
     "shortName": "NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesTables",
     "shortName": "RESEARCH AND DEVELOPMENT EXPENSES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://aethlonmedical.com/role/RelatedPartyTransactionsTables",
     "shortName": "RELATED PARTY TRANSACTIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - OTHER CURRENT LIABILITIES (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://aethlonmedical.com/role/OtherCurrentLiabilitiesTables",
     "shortName": "OTHER CURRENT LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - STOCK COMPENSATION (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://aethlonmedical.com/role/StockCompensationTables",
     "shortName": "STOCK COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "aemd:WarrantsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - WARRANTS (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://aethlonmedical.com/role/WarrantsTables",
     "shortName": "WARRANTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "aemd:WarrantsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "AsOf2022-06-30_custom_RestrictedCashMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SecurityDeposit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION (Details Narrative)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationDetailsNarrative",
     "shortName": "NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "AsOf2022-06-30_custom_RestrictedCashMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SecurityDeposit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - LOSS PER COMMON SHARE (Details Narrative)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://aethlonmedical.com/role/LossPerCommonShareDetailsNarrative",
     "shortName": "LOSS PER COMMON SHARE (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesDetails",
     "shortName": "RESEARCH AND DEVELOPMENT EXPENSES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-012023-06-30_custom_EligibleDirectorsEachMember_us-gaap_RestrictedStockUnitsRSUMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - EQUITY TRANSACTIONS IN THE THREE MONTHS ENDED JUNE 30, 2023 (Details Narrative)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302023DetailsNarrative",
     "shortName": "EQUITY TRANSACTIONS IN THE THREE MONTHS ENDED JUNE 30, 2023 (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-012023-06-30_custom_EligibleDirectorsEachMember_us-gaap_RestrictedStockUnitsRSUMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "aemd:DueToRelatedPartiesCurrent1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure -  RELATED PARTY TRANSACTIONS (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://aethlonmedical.com/role/RelatedPartyTransactionsDetails",
     "shortName": "RELATED PARTY TRANSACTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "aemd:DueToRelatedPartiesCurrent1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "aemd:AccruedDirectorFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://aethlonmedical.com/role/RelatedPartyTransactionsDetailsNarrative",
     "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "aemd:AccruedDirectorFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - OTHER CURRENT LIABILITIES (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://aethlonmedical.com/role/OtherCurrentLiabilitiesDetails",
     "shortName": "OTHER CURRENT LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - STOCK COMPENSATION (Details - Stock compensation)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://aethlonmedical.com/role/StockCompensationDetails-StockCompensation",
     "shortName": "STOCK COMPENSATION (Details - Stock compensation)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-012023-06-30_us-gaap_StockOptionMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - STOCK COMPENSATION (Details - Options vested and expected to vest)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest",
     "shortName": "STOCK COMPENSATION (Details - Options vested and expected to vest)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-012023-06-30_us-gaap_StockOptionMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "AsOf2023-03-31_us-gaap_OptionMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - STOCK COMPENSATION (Details - Option activity)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity",
     "shortName": "STOCK COMPENSATION (Details - Option activity)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "AsOf2023-03-31_us-gaap_OptionMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - STOCK COMPENSATION (Details Narrative)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://aethlonmedical.com/role/StockCompensationDetailsNarrative",
     "shortName": "STOCK COMPENSATION (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "aemd:WarrantsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "AsOf2023-03-31_us-gaap_WarrantMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - Warrant (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://aethlonmedical.com/role/WarrantDetails",
     "shortName": "Warrant (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "aemd:WarrantsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "AsOf2023-03-31_us-gaap_WarrantMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "AsOf2022-08-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "AsOf2022-08-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfessionalFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfessionalFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EarningsPerShareBasic",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "AsOf2022-03-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "AsOf2022-03-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganization",
     "shortName": "NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - LOSS PER COMMON SHARE",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://aethlonmedical.com/role/LossPerCommonShare",
     "shortName": "LOSS PER COMMON SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "aethlon_i10q-063023.htm",
      "contextRef": "From2023-04-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 21,
   "tag": {
    "aemd_AccretionOfRightofuseLeaseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "AccretionOfRightofuseLeaseAsset",
        "negatedLabel": "Accretion of right-of-use lease asset"
       }
      }
     },
     "localname": "AccretionOfRightofuseLeaseAsset",
     "nsuri": "http://aethlonmedical.com/20230630",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aemd_AccruedBoardFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Board Fees [Member]"
       }
      }
     },
     "localname": "AccruedBoardFeesMember",
     "nsuri": "http://aethlonmedical.com/20230630",
     "presentation": [
      "http://aethlonmedical.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "aemd_AccruedDirectorFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued director fees"
       }
      }
     },
     "localname": "AccruedDirectorFees",
     "nsuri": "http://aethlonmedical.com/20230630",
     "presentation": [
      "http://aethlonmedical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aemd_AccruedVacationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Vacation [Member]"
       }
      }
     },
     "localname": "AccruedVacationMember",
     "nsuri": "http://aethlonmedical.com/20230630",
     "presentation": [
      "http://aethlonmedical.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "aemd_DisclosureWarrantsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants"
       }
      }
     },
     "localname": "DisclosureWarrantsAbstract",
     "nsuri": "http://aethlonmedical.com/20230630",
     "xbrltype": "stringItemType"
    },
    "aemd_DueToRelatedParties": {
     "auth_ref": [],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Due to related parties"
       }
      }
     },
     "localname": "DueToRelatedParties",
     "nsuri": "http://aethlonmedical.com/20230630",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aemd_DueToRelatedPartiesCurrent1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Due to related parties [Default Label]",
        "verboseLabel": "Due to related parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent1",
     "nsuri": "http://aethlonmedical.com/20230630",
     "presentation": [
      "http://aethlonmedical.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aemd_EligibleDirectorsEachMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Eligible Directors Each [Member]"
       }
      }
     },
     "localname": "EligibleDirectorsEachMember",
     "nsuri": "http://aethlonmedical.com/20230630",
     "presentation": [
      "http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302023DetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "aemd_HcWainwrightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hc Wainwright [Member]"
       }
      }
     },
     "localname": "HcWainwrightMember",
     "nsuri": "http://aethlonmedical.com/20230630",
     "presentation": [
      "http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302023DetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "aemd_IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExercise": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares upon vesting of restricted stock units and net stock option exercises"
       }
      }
     },
     "localname": "IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExercise",
     "nsuri": "http://aethlonmedical.com/20230630",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aemd_IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExerciseShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares upon vesting of restricted stock units and net stock option exercise, shares"
       }
      }
     },
     "localname": "IssuanceOfCommonSharesUponVestingOfRestrictedStockUnitsAndNetStockOptionExerciseShares",
     "nsuri": "http://aethlonmedical.com/20230630",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "aemd_LiquidityAndGoingConcernPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIQUIDITY AND GOING CONCERN"
       }
      }
     },
     "localname": "LiquidityAndGoingConcernPolicyTextBlock",
     "nsuri": "http://aethlonmedical.com/20230630",
     "presentation": [
      "http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "aemd_ManufacturingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Manufacturing [Member]"
       }
      }
     },
     "localname": "ManufacturingMember",
     "nsuri": "http://aethlonmedical.com/20230630",
     "presentation": [
      "http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "aemd_MonthlyBaseRent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Monthly base rent"
       }
      }
     },
     "localname": "MonthlyBaseRent",
     "nsuri": "http://aethlonmedical.com/20230630",
     "presentation": [
      "http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aemd_NewOfficeAndLabSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Office And Lab Space [Member]"
       }
      }
     },
     "localname": "NewOfficeAndLabSpaceMember",
     "nsuri": "http://aethlonmedical.com/20230630",
     "presentation": [
      "http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "aemd_OfferingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Agreement [Member]"
       }
      }
     },
     "localname": "OfferingAgreementMember",
     "nsuri": "http://aethlonmedical.com/20230630",
     "presentation": [
      "http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302023DetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "aemd_OfficeAndLaboratoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office And Laboratory [Member]"
       }
      }
     },
     "localname": "OfficeAndLaboratoryMember",
     "nsuri": "http://aethlonmedical.com/20230630",
     "presentation": [
      "http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "aemd_OfficeLabAndManufacturingLeasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Lab And Manufacturing Leases [Member]"
       }
      }
     },
     "localname": "OfficeLabAndManufacturingLeasesMember",
     "nsuri": "http://aethlonmedical.com/20230630",
     "presentation": [
      "http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "aemd_OtherOfferingExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Offering Expense [Member]"
       }
      }
     },
     "localname": "OtherOfferingExpenseMember",
     "nsuri": "http://aethlonmedical.com/20230630",
     "presentation": [
      "http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302023DetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "aemd_ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Par value of shares issued for vested restricted stock units and net stock option exercise"
       }
      }
     },
     "localname": "ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise",
     "nsuri": "http://aethlonmedical.com/20230630",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aemd_PaymentForRentPerMonth": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment for rent per month"
       }
      }
     },
     "localname": "PaymentForRentPerMonth",
     "nsuri": "http://aethlonmedical.com/20230630",
     "presentation": [
      "http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aemd_RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price Outstanding, Beginning"
       }
      }
     },
     "localname": "RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://aethlonmedical.com/20230630",
     "presentation": [
      "http://aethlonmedical.com/role/WarrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "aemd_RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price Outstanding, Ending"
       }
      }
     },
     "localname": "RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2",
     "nsuri": "http://aethlonmedical.com/20230630",
     "presentation": [
      "http://aethlonmedical.com/role/WarrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "aemd_RangeOfExercisePriceCancelledExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price Cancelled Expired"
       }
      }
     },
     "localname": "RangeOfExercisePriceCancelledExpired",
     "nsuri": "http://aethlonmedical.com/20230630",
     "presentation": [
      "http://aethlonmedical.com/role/WarrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "aemd_RangeOfExercisePricesOptionBeginning": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of exercise prices, Option beginning",
        "label": "Range of exercise prices, Option beginning"
       }
      }
     },
     "localname": "RangeOfExercisePricesOptionBeginning",
     "nsuri": "http://aethlonmedical.com/20230630",
     "presentation": [
      "http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity"
     ],
     "xbrltype": "stringItemType"
    },
    "aemd_RangeOfExercisePricesOptionCancelledexpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of exercise prices, Option cancelled/expired",
        "label": "Range of exercise prices, Option cancelled/expired"
       }
      }
     },
     "localname": "RangeOfExercisePricesOptionCancelledexpired",
     "nsuri": "http://aethlonmedical.com/20230630",
     "presentation": [
      "http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity"
     ],
     "xbrltype": "stringItemType"
    },
    "aemd_RangeOfExercisePricesOptionEnding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of exercise prices, Option ending",
        "label": "Range of exercise prices, Option ending"
       }
      }
     },
     "localname": "RangeOfExercisePricesOptionEnding",
     "nsuri": "http://aethlonmedical.com/20230630",
     "presentation": [
      "http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity"
     ],
     "xbrltype": "stringItemType"
    },
    "aemd_RangeOfExercisePricesOptionExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of exercise prices, Option exercisable",
        "label": "Range of exercise prices, Option exercisable"
       }
      }
     },
     "localname": "RangeOfExercisePricesOptionExercisable",
     "nsuri": "http://aethlonmedical.com/20230630",
     "presentation": [
      "http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity"
     ],
     "xbrltype": "stringItemType"
    },
    "aemd_RangeOfExercisePricesOptionGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of exercise prices, Option Granted"
       }
      }
     },
     "localname": "RangeOfExercisePricesOptionGranted",
     "nsuri": "http://aethlonmedical.com/20230630",
     "presentation": [
      "http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity"
     ],
     "xbrltype": "stringItemType"
    },
    "aemd_RangeOfWeightedAverageExercisePriceExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price Exercisable"
       }
      }
     },
     "localname": "RangeOfWeightedAverageExercisePriceExercisable",
     "nsuri": "http://aethlonmedical.com/20230630",
     "presentation": [
      "http://aethlonmedical.com/role/WarrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "aemd_RestrictedCashMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash [Member]"
       }
      }
     },
     "localname": "RestrictedCashMember",
     "nsuri": "http://aethlonmedical.com/20230630",
     "presentation": [
      "http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Warrants Exercisable, Ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber",
     "nsuri": "http://aethlonmedical.com/20230630",
     "presentation": [
      "http://aethlonmedical.com/role/WarrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://aethlonmedical.com/20230630",
     "presentation": [
      "http://aethlonmedical.com/role/WarrantDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "aemd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://aethlonmedical.com/20230630",
     "presentation": [
      "http://aethlonmedical.com/role/WarrantDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "aemd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Cancelled/Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://aethlonmedical.com/20230630",
     "presentation": [
      "http://aethlonmedical.com/role/WarrantDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "aemd_StockBasedCompensationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Based Compensation [Member]"
       }
      }
     },
     "localname": "StockBasedCompensationMember",
     "nsuri": "http://aethlonmedical.com/20230630",
     "presentation": [
      "http://aethlonmedical.com/role/StockCompensationDetails-StockCompensation"
     ],
     "xbrltype": "domainItemType"
    },
    "aemd_WarrantsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WARRANTS"
       }
      }
     },
     "localname": "WarrantsTextBlock",
     "nsuri": "http://aethlonmedical.com/20230630",
     "presentation": [
      "http://aethlonmedical.com/role/Warrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r414",
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r111",
      "r112",
      "r168",
      "r171",
      "r274",
      "r382",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302023DetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r111",
      "r112",
      "r168",
      "r171",
      "r274",
      "r383",
      "r384"
     ],
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302023DetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Changes and Error Corrections [Abstract]"
       }
      }
     },
     "localname": "AccountingChangesAndErrorCorrectionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r17",
      "r391"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/OtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/OtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r23",
      "r24",
      "r54",
      "r94",
      "r290",
      "r303",
      "r306"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.",
        "label": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r1",
      "r10",
      "r24",
      "r235",
      "r238",
      "r267",
      "r299",
      "r300",
      "r427",
      "r428",
      "r429",
      "r433",
      "r434",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r47",
      "r391",
      "r452"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r314",
      "r433",
      "r434",
      "r435",
      "r441",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r36",
      "r37",
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive shares"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/LossPerCommonShareDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r74",
      "r93",
      "r110",
      "r145",
      "r148",
      "r150",
      "r152",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r228",
      "r232",
      "r249",
      "r287",
      "r337",
      "r391",
      "r402",
      "r438",
      "r439",
      "r446"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r90",
      "r95",
      "r110",
      "r152",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r228",
      "r232",
      "r249",
      "r391",
      "r438",
      "r439",
      "r446"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302023DetailsNarrative",
      "http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity",
      "http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest",
      "http://aethlonmedical.com/role/StockCompensationDetailsNarrative",
      "http://aethlonmedical.com/role/WarrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r40",
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r79",
      "r288",
      "r315",
      "r332",
      "r391",
      "r402",
      "r424"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r26",
      "r92",
      "r381"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r27",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r26",
      "r58",
      "r108"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and restricted cash",
        "periodStartLabel": "Cash and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r0",
      "r58"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "periodEndLabel": "Weighted Average Exercise Price Outstanding, Ending",
        "periodStartLabel": "Weighted Average Exercise Price Outstanding, Beginning"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/WarrantDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Number of Warrants Outstanding, Ending",
        "periodStartLabel": "Number of Warrants Outstanding, Beginning"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/WarrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r64",
      "r157",
      "r158",
      "r379",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r392",
      "r393",
      "r394",
      "r396",
      "r397",
      "r398",
      "r399",
      "r433",
      "r434",
      "r441",
      "r451",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r46",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r11",
      "r46",
      "r324",
      "r343",
      "r455",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r46",
      "r289",
      "r391"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, par value $0.001 per share; 60,000,000 shares authorized as of June 30, 2023 and March 31, 2023; 24,835,321 and 22,992,466 shares issued and outstanding as of June 30, 2023 and March 31, 2023, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "auth_ref": [
      "r425"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.",
        "label": "Deposits"
       }
      }
     },
     "localname": "DepositsAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r7",
      "r146"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r104",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r133",
      "r135",
      "r137",
      "r138",
      "r139",
      "r143",
      "r244",
      "r245",
      "r284",
      "r298",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Basic loss per share",
        "verboseLabel": "Earnings Per Share, Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical",
      "http://aethlonmedical.com/role/StockCompensationDetails-StockCompensation"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r104",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r135",
      "r137",
      "r138",
      "r139",
      "r143",
      "r244",
      "r245",
      "r284",
      "r298",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Diluted loss per share",
        "verboseLabel": "Earnings Per Share, Diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical",
      "http://aethlonmedical.com/role/StockCompensationDetails-StockCompensation"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r132",
      "r140",
      "r141",
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "LOSS PER COMMON SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/LossPerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r253"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of exchange rate on changes on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r213"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Unrecognized compensation costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/StockCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Unrecognized compensation cost amortization period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/StockCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r11",
      "r87",
      "r100",
      "r101",
      "r102",
      "r113",
      "r114",
      "r115",
      "r119",
      "r127",
      "r129",
      "r144",
      "r153",
      "r156",
      "r183",
      "r214",
      "r215",
      "r216",
      "r220",
      "r221",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r243",
      "r254",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r267",
      "r299",
      "r300",
      "r301",
      "r314",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r63",
      "r279"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Patents, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r56",
      "r347"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r6"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Accounts payable and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": {
     "auth_ref": [
      "r6"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Accounts Payable, Related Parties",
        "verboseLabel": "Due to related parties"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r6"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r380"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r6"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestAndOtherIncome": {
     "auth_ref": [],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).",
        "label": "Interest income"
       }
      }
     },
     "localname": "InterestAndOtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LaborAndRelatedExpense": {
     "auth_ref": [
      "r430"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.",
        "label": "Payroll and related expenses"
       }
      }
     },
     "localname": "LaborAndRelatedExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Line of credit"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r18",
      "r110",
      "r152",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r229",
      "r232",
      "r233",
      "r249",
      "r323",
      "r386",
      "r402",
      "r438",
      "r446",
      "r447"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r51",
      "r75",
      "r292",
      "r391",
      "r432",
      "r436",
      "r442"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r21",
      "r91",
      "r110",
      "r152",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r229",
      "r232",
      "r233",
      "r249",
      "r391",
      "r438",
      "r446",
      "r447"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows provided by financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows used in investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r58",
      "r59",
      "r60"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows used in operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r55",
      "r60",
      "r76",
      "r89",
      "r96",
      "r98",
      "r102",
      "r110",
      "r118",
      "r122",
      "r123",
      "r124",
      "r125",
      "r128",
      "r129",
      "r136",
      "r145",
      "r147",
      "r149",
      "r151",
      "r152",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r245",
      "r249",
      "r296",
      "r345",
      "r365",
      "r366",
      "r387",
      "r400",
      "r438"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "NET LOSS ATTRIBUTABLE TO AETHLON MEDICAL, INC."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r39",
      "r70",
      "r96",
      "r98",
      "r128",
      "r129",
      "r295",
      "r429"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "LOSS ATTRIBUTABLE TO NONCONTROLLING INTERESTS"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r84",
      "r85",
      "r86",
      "r88",
      "r116",
      "r117",
      "r120",
      "r121",
      "r130",
      "r131",
      "r154",
      "r155",
      "r222",
      "r223",
      "r224",
      "r239",
      "r242",
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r252",
      "r261",
      "r262",
      "r268",
      "r280",
      "r281",
      "r282",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "RECENT ACCOUNTING PRONOUNCEMENTS"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/RecentAccountingPronouncements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosures of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r38",
      "r183",
      "r433",
      "r434",
      "r435",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoninterestIncomeOtherAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER INCOME"
       }
      }
     },
     "localname": "NoninterestIncomeOtherAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OffsettingAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Offsetting Assets [Line Items]"
       }
      }
     },
     "localname": "OffsettingAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/StockCompensationDetails-StockCompensation"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OffsettingAssetsTable": {
     "auth_ref": [
      "r52",
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements.",
        "label": "Offsetting Assets [Table]"
       }
      }
     },
     "localname": "OffsettingAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/StockCompensationDetails-StockCompensation"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OPERATING EXPENSES"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r145",
      "r147",
      "r149",
      "r151",
      "r387"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "OPERATING LOSS"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r443"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r264"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Lease liability, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r264"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Lease liability, less current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r263"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Right-of-use lease asset",
        "verboseLabel": "Right of use lease asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r266",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r265",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "verboseLabel": "Lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OptionMember": {
     "auth_ref": [
      "r71",
      "r333",
      "r338",
      "r355",
      "r361",
      "r374",
      "r375",
      "r376",
      "r392",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific commodity, or financial or equity instrument, at a specified price during a specified period (an American option) or at a specified date (a European option) which were purchased or otherwise acquired, excluding options written (for which a premium was received).",
        "label": "Options Held [Member]"
       }
      }
     },
     "localname": "OptionMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity",
      "http://aethlonmedical.com/role/StockCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r11",
      "r16",
      "r97",
      "r99",
      "r103",
      "r254",
      "r255",
      "r260",
      "r283",
      "r297",
      "r427",
      "r428"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "negatedLabel": "Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTax": {
     "auth_ref": [
      "r2",
      "r100",
      "r103",
      "r219",
      "r225",
      "r226",
      "r254",
      "r258",
      "r260",
      "r283",
      "r297"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Tax",
        "negatedLabel": "COMPREHENSIVE LOSS"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1": {
     "auth_ref": [
      "r4",
      "r9",
      "r69"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent",
        "negatedLabel": "OTHER COMPREHENSIVE LOSS"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParent1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other current liabilities.",
        "label": "Schedule of other current liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/OtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r19",
      "r391"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://aethlonmedical.com/role/OtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other current liabilities",
        "totalLabel": "Total other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets",
      "http://aethlonmedical.com/role/OtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other liabilities.",
        "label": "OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/OtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PaymentsForCommissions": {
     "auth_ref": [
      "r5"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for commissions during the current period.",
        "label": "Payment of commissions"
       }
      }
     },
     "localname": "PaymentsForCommissions",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302023DetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payment of stock issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302023DetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedLabel": "Tax withholding payments or tax equivalent payments for net share settlement of restricted stock units and net stock option expense"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r426"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from the issuance of common stock, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r3",
      "r308"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from issuance of equity"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302023DetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfessionalFees": {
     "auth_ref": [
      "r400",
      "r453",
      "r454"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.",
        "label": "Professional fees"
       }
      }
     },
     "localname": "ProfessionalFees",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r89",
      "r96",
      "r98",
      "r106",
      "r110",
      "r118",
      "r128",
      "r129",
      "r145",
      "r147",
      "r149",
      "r151",
      "r152",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r227",
      "r230",
      "r231",
      "r245",
      "r249",
      "r285",
      "r294",
      "r313",
      "r345",
      "r365",
      "r366",
      "r387",
      "r388",
      "r389",
      "r401",
      "r429",
      "r438"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net loss",
        "totalLabel": "NET LOSS"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r8",
      "r286",
      "r293",
      "r391"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by property that could be leased or is available for lease.",
        "label": "Property Subject to or Available for Operating Lease [Axis]"
       }
      }
     },
     "localname": "PropertySubjectToOrAvailableForOperatingLeaseAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A descriptive title of whether the property is subject to or available for operating lease."
       }
      }
     },
     "localname": "PropertySubjectToOrAvailableForOperatingLeaseDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r272",
      "r273",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party."
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [
      "r348",
      "r349",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r269",
      "r270",
      "r271",
      "r273",
      "r275",
      "r310",
      "r311",
      "r312",
      "r350",
      "r351",
      "r352",
      "r371",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r44",
      "r217",
      "r448"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "auth_ref": [
      "r77",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.",
        "label": "RESEARCH AND DEVELOPMENT EXPENSES"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/ResearchAndDevelopmentExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r424",
      "r431",
      "r449",
      "r450"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted cash",
        "periodEndLabel": "Restricted cash",
        "verboseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets",
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets:"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302023DetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r48",
      "r66",
      "r291",
      "r302",
      "r306",
      "r309",
      "r325",
      "r391"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated undistributed earnings (deficit).",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r87",
      "r113",
      "r114",
      "r115",
      "r119",
      "r127",
      "r129",
      "r153",
      "r156",
      "r214",
      "r215",
      "r216",
      "r220",
      "r221",
      "r234",
      "r236",
      "r237",
      "r240",
      "r243",
      "r299",
      "r301",
      "r314",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Schedule of share-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/StockCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r42",
      "r43",
      "r348",
      "r349",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "verboseLabel": "Due to related parties"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/RelatedPartyTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature and amounts of capitalized costs of a research and development nature that were acquired in a transaction other than a business combination, the amount of such assets charged to expense during the period, and identification of the income statement caption in which the charges are included.",
        "label": "Research and development expenses"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Schedule of options outstanding that have vested and are expected to vest"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/StockCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r184",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity",
      "http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest",
      "http://aethlonmedical.com/role/StockCompensationDetailsNarrative",
      "http://aethlonmedical.com/role/WarrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r14",
      "r15",
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule of stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/StockCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of warrant activity"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/WarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuritiesFinancingTransactionAxis": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of securities financing transactions, including, but not limited to those measured at fair value or cost.",
        "label": "Securities Financing Transaction [Axis]"
       }
      }
     },
     "localname": "SecuritiesFinancingTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302023DetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SecuritiesFinancingTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Securities Financing Transaction [Line Items]"
       }
      }
     },
     "localname": "SecuritiesFinancingTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302023DetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SecuritiesFinancingTransactionTable": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule, as of the balance sheet date, of security financing transactions by type, the aggregate value of securities financing transactions by type and aggregate acquisition price by type of security financing transaction.",
        "label": "Securities Financing Transaction [Table]"
       }
      }
     },
     "localname": "SecuritiesFinancingTransactionTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302023DetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SecuritiesFinancingTransactionTypeDomain": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement of financing transaction securities held."
       }
      }
     },
     "localname": "SecuritiesFinancingTransactionTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302023DetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r425"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security deposit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r6"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Stock based compensation",
        "verboseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://aethlonmedical.com/role/StockCompensationDetails-StockCompensation",
      "http://aethlonmedical.com/role/StockCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302023DetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [
      "r184",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity",
      "http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest",
      "http://aethlonmedical.com/role/StockCompensationDetailsNarrative",
      "http://aethlonmedical.com/role/WarrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Number of Warrants Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/WarrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.",
        "label": "Number of Warrants Cancelled/Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/WarrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Stock options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Exercisable, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Stock options cancelled/forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r190",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Total options outstanding",
        "periodEndLabel": "Stock options outstanding, ending balance",
        "periodStartLabel": "Stock options Outstanding, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity",
      "http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r190",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Weighted average exercise price options vested",
        "periodEndLabel": "Outstanding Weighted Average Exercise Price, ending price",
        "periodStartLabel": "Outstanding, Weighted Average Exercise Price, beginning price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity",
      "http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Weighted average exercise price options expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Options expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302023DetailsNarrative",
      "http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity",
      "http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest",
      "http://aethlonmedical.com/role/StockCompensationDetailsNarrative",
      "http://aethlonmedical.com/role/WarrantDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Exercised, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Cancelled/Forfeited, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Granted, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/StockCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining contractual term options vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Weighted average remaining contractual term options expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r205"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Vesting of stock options and restricted stock units"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/StockCompensationDetails-StockCompensation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Options vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r65",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).",
        "label": "STOCK COMPENSATION"
       }
      }
     },
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/StockCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r11",
      "r22",
      "r87",
      "r100",
      "r101",
      "r102",
      "r113",
      "r114",
      "r115",
      "r119",
      "r127",
      "r129",
      "r144",
      "r153",
      "r156",
      "r183",
      "r214",
      "r215",
      "r216",
      "r220",
      "r221",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r243",
      "r254",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r267",
      "r299",
      "r300",
      "r301",
      "r314",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r144",
      "r278",
      "r307",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r324",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r334",
      "r335",
      "r336",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r344",
      "r346",
      "r347",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r367",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
      "http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r144",
      "r278",
      "r307",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r324",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r334",
      "r335",
      "r336",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r344",
      "r346",
      "r347",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r367",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
      "http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r11",
      "r45",
      "r46",
      "r66",
      "r308",
      "r367",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Issuances of common stock for cash under at the market program, shares",
        "verboseLabel": "Stock issued new, shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
      "http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302023DetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r11",
      "r45",
      "r46",
      "r66",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r11",
      "r45",
      "r46",
      "r66",
      "r314",
      "r367",
      "r377",
      "r401"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Issuances of common stock for cash under at the market program"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r46",
      "r49",
      "r50",
      "r62",
      "r326",
      "r343",
      "r368",
      "r369",
      "r391",
      "r402",
      "r432",
      "r436",
      "r442",
      "r455"
     ],
     "calculation": {
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.",
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "BALANCE \u2013 JUNE 30, 2022",
        "periodStartLabel": "BALANCE - MARCH 31, 2022",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets",
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r65",
      "r109",
      "r169",
      "r170",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r183",
      "r241",
      "r370",
      "r372",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity.",
        "label": "EQUITY TRANSACTIONS IN THE THREE MONTHS ENDED JUNE 30, 2023"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302023"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r276",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosures of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransactionDomain": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement between buyer and seller for the exchange of financial instruments."
       }
      }
     },
     "localname": "TransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302023DetailsNarrative",
      "http://aethlonmedical.com/role/StockCompensationDetails-StockCompensation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransactionTypeAxis": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction Type [Axis]"
       }
      }
     },
     "localname": "TransactionTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/EquityTransactionsInThreeMonthsEndedJune302023DetailsNarrative",
      "http://aethlonmedical.com/role/StockCompensationDetails-StockCompensation"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r28",
      "r29",
      "r30",
      "r80",
      "r81",
      "r82",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Basis of Presentation and Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationOrganizationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [
      "r392",
      "r393",
      "r396",
      "r397",
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/WarrantDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r134",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted average number of common shares outstanding diluted",
        "verboseLabel": "Weighted Average Number of Shares Outstanding, Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical",
      "http://aethlonmedical.com/role/StockCompensationDetails-StockCompensation"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r133",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted average number of common shares outstanding basic",
        "verboseLabel": "Weighted Average Number of Shares Outstanding, Basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical",
      "http://aethlonmedical.com/role/StockCompensationDetails-StockCompensation"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org//260/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iv)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(i)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(i)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org//850/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org//855/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(17))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(14))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(17))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(19))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(9))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r403": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r404": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r405": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r406": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r407": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r408": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r409": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r411": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r412": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r413": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r414": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r415": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r416": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r417": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r418": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r419": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r421": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r422": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org//450/tableOfContent",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(18))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(k)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org//235/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org//440/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org//505/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org//718/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "83",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480647/815-10-15-83",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "730",
   "Topic": "985",
   "URI": "https://asc.fasb.org//985-730/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org//250/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>55
<FILENAME>0001683168-23-005524-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001683168-23-005524-xbrl.zip
M4$L#!!0    ( .Z)"E<KJ&!GB0L  %]P   1    865M9"TR,#(S,#8S,"YX
M<V3M76USXC@2_GY5]Q]\?+G9NB,D83.SDTUVRX"3,$,PBR&9O2];BBU -<9B
M)#N!^_77DE\ &XQXJV'W/%4[:TO=4K>>[G:K;30WOT['KO:*&2?4NRU=G)V7
M-.S9U"'>\+;4M\JZ56\V2]JOO_S];QK\N?E'N:S=$>PZUUJ#VN6F-Z _:VTT
MQM?:/?8P0SYE/VM/R U$"[TC+F9:G8XG+O8Q=(0S76M79Q<?D58N*XS[A#V'
MLGZWF8P[\OT)OZY4WM[>SCSZBMXH^\K/;#I6&]#RD1_P9+3SZ7GT1XW]D7 [
M8?[79SJA'Z9=\F6(O9\"X^7+Y-%$GQO/J.//KJXN/__^=?HZ[GX8H#'Z,/M*
MW;M/K[C^V_/(N!S_AOA]..4-MT=XC#0 P^.W):%?I-Y;]8RR8>7R_/RB\N6Q
M94FZ4DAX/76)]W45^<7'CQ\KLC<FS5!.7Y@;#UVMB.X7Q'$R,O22''KB<1]Y
M]A*]XR<,B\17E;!SB92L)'T?DI*8U,$I.H[MLR%]K4 'T%]68\* EX<(31+B
M >(O<M"H8XF8,S]+"(UIHK(_FV"^DC3L6F)P?)9B6%HUZ*Z(;L%S63ZOEJL7
M,2?"8R=A0M@?N=0;8X?8R!4V+6<Y?U\5GNGB,?;\.\K&#3Q @0N*? N02P8$
M.R7-1VR(?6&D?()LK#1F;._(\RBX!?AFU"+:)A,"=I\T0).PDVM&7=P#731Q
M 7Z9-Y$@J=0I1)B21D#-\')AR'A0!P^(1Z0 D3=>:&7A>X%0&2XEYTTE39P=
M*>#8,;U?Y/6$80[L4K$6-$3\$4D^+ZA@!^Y.K'/Y\CBC]G@Y#['.GH,]F 8N
M.'6)@WSLU) K/-4:8>SS&(2-=$H(70(L(ICB&"*SW3#:EM$05Y;9:C;T'MS4
M]);>KAN:]6 8/4M[U_=0X!"8\H<"SOW@[" &RS'"OF!4Q7:920GHZKY :^^6
M9BV WQ[X9/VY.3 G(M,"L?(<>@V#$N _J@%N]>!_CT8;P#;O-+-C=/5>$P@*
M'S\"U*K.KL*M9 17AS."PO\/:A263^VO(^HZL)TRO@7$GRG:PPI&)5-XOXLI
M6#VS_OG!;#6,KO5/S?BMW^S]7D2&@QE!'?'1G4O?5)\!<WHER#_L GE=MQZT
MNY;Y7#P"E(%N(S]@V!S4 DX\S+GN0;[&"2#665@'DPV11_XKKT/ =^!3 OXG
ML>\BW'8IA_'AIJWW^EU#P%OK6\VV85F:WA;9GM64H'>ZA@4&(*.^9G;O]7;S
M/_*FP#T/]Q;EO(-9G8['U+-&\'P,<5W1KH3;QS1N+1.0@L<Q..SC(T!C/>A=
MH\ D#Y,N*(N8/0)?:N!7[-*)B'[&="(B:Q1H-]"H8'5QGL9*N)#>K3](SVH8
M3T;+[(BHJAE?.B+J6@5N^;C9H*QNVS3P?.(-.XQZ<&F'S[X8MUP:)=PNLKC5
M!4IZO6[VV[UF^QZBH=F&ZWKX4"Q@RX,M3$%[#'D<V7*;TO1Z(X;Q(X6] C<@
MHW$^!1ZNGH>E5@'CECQ*L%ZF88V2U5Y7;UMZ/=S.--M:[\& _[J&H4$\[3U8
MF@$Y44/[U&\;6O7\WYJ8L4 \WU%=D9?";G 9P]A%U_0JH5C-.F=+YJ@=O9L"
MLP I#R03]NFL'C"Q8V\1]$)<D"%^_*WK5(+HQS1$)K@4)"C];E>$T593KS5;
MS5ZS>-[E(R3W\>*U*N0<"UN";+,2*E=I5.3.7:2-(O<H4OF-<#PC!M$J3C22
M.Z7%?Y]>_&>]"Y&J2!TVE4?&8^++U T2\3J5*1WV["1.Y1$H ?,A#8S81C5[
M8:U#I.EU4V9\1KM>Q*M-\2IXX?A;(/9)K_.,/-.JA$NF/F'U:Q8D;'*W]%0D
MW8>O-W6H2^:.M0>_$KZ9.L;.]2?M73QS48+<H^S10R^N6O$CHE2!^7+[$HCV
M+AR_ '.G+=8RC+DT2@"NJ(6LVVX5R.VS[UH$+I]$";=,L6/M'JR ;;?-V")@
MZSJ5H,I4-+(;LP*CK79HB]"DVI00R10PXMU:@<.1DL\&]A%Q>5N Y9-7O&L2
MFAE'">],:62/9#220$M$*&QERQ>DJVU!@4X)ZTPE9N4+U +'P^XNHM54V5[$
MI$IH9LHW"ON+:(("SP.^M5OMLWN.H60!F4+1'F_U"J\_U#8TY>_Y1$HX9PI&
MN3O1PL</@%[*FY6I5?"LKJ@,;82S<,O]:@Q+7KF!1@G$3'4HI\I0N.1.989H
MV<JJ+X/7TRLAFJD;K2I&Q.XHOAV&631[89H"W]WP-2<RF#YA#C$6,F.1#MMP
MV:.B:0/8&YB5D%<J0\V1CZ;47N6<&O(<#4>S:CZ5S84I[&,*.CQ=7Y,??:@2
M*T&=J6^I0*VA:(X"UIU@3653F\F4H%3XJJ=(GW:L(R^E2ZDV)7"R7_V$@Q3)
MT-Z?_ZQVJFT8E!#<[O.@_WM/$W^)$T:Z>*#)DTFNQ7$8MR5.Q-DPI:AMQ/#@
MMB1.Q"C'1U3\ 6J?3<=N3")FR#F91%I'>J6BB>,A$+,SHV1.3H%!Z 0SL?&I
MQ,+' _C$%^R+KQHT,0\$A,H!-7?1R[:: PMVCZAR2XQ_#%V%=V^I:\JFCZ1Q
M?3[+,?0&[]I6[V6'/)+:C622K-8WE>6C8> ^?7S,#2A.F:]YF=-H\@X3"H]!
M:E%;#I7#(N[*,5]9-)4O+LO5B[,I=^:2;B/$?!FV$R+FVT&(-4<:K9J?KR,7
M%]*85"==<S12[J0K>2K8]7G<LK,(BP<I[2&#'&8K(3:?SK1.G$V<\I[O9 3R
MIVELMHTA+++$-[NA,3\"2PV(F#X$09R*M>NT.UA!=O*U)A"=FB6S0!%[_^AB
M[C,BRA'B)_&/>/PB3J<2(LH7D*OZB.N*KSMN2SX+1*04QZ-=0P0EU.G)0.\$
M+"J]A8$_.0[LVJ%C1+RFC\>"$O0+7CC$V$!0WS,:3&Y+X7 $2/+$-@<#F- ;
MZD.&9=>RY.N[3T'X!_L9!GIC9#A*R;VRYQ1$EE7P>%6C5]"I)<^C. 45#)<,
M"0C1( S;/F7<0';*X/-)3D$)W;9A<J=&$7/N,.;+\J_M/2'1GU 8S%9*GND\
M!<%E":H&:8VS6(=:EG\#S2FH ;Y); S[?=BV4'DVZ2P3--<2G(("C\@+!LCV
M Q%AED5?W74*0H>+"BL*Z[HD90N#M?!5"&PF/@7%VOAMT6 LD= L:Y-+<0HJ
M- +<HPNOZ^6O>D+95W=M%#K<A?EQUTMXU.!MR6;8(7ZL2M@YIA[V$9L=0)$F
MYX&8R!PL?/?'^Q/JB?=:8#_F8)[+R5#5A^VLJ/VUL2_OPW<7QA0SFXA]7[@*
M1QAW"]S_W&L8\A]K)9/1M_:CD()+_@,]U;'@ @5$UDH' <<R7.F<8W_Q^9Y/
M=K*& >XOS[<V!^&B"RBQ<T=9^!IY)\<Z\)@GNW;S=P+Q[PMT&(G!8RT)M#D4
M*+J*]=K9V'WQ##V .LF/)/#4K[F 1*S%JHX]GG!^/,P!9&Z1;P$!C&=@0/<4
MUJ%. 7D6_@YUEM%$G?Q$]%OQI(Z^UKK(>9@OD)SJ0SW:$L5[4;&?2^V64EVG
MJD@7>4.(='&\ZD!DPSR,834\))X'5I:4G-1HOW<@R!'S7@0"<0+]1H7FE">L
M3EV8B.MB!T\G8&XJ>JU@.6$%#<]1L[^$\)25"=N$>"H:+5&?B%IU%W%N#J(G
MJLEDNK@D?=+)HUY^D5)VUS&^]Q+(9#!31=*%H,/P9+[:;$[303/1IK\AYLCJ
M:V^$O.A[PUA9I^EUI/S/6&B)'?T5,S3$2XN1%+&^V_1[Y!) )64ZDF,EP<S8
M'/]6T/Z5+ ITDMS\>]G4M@*<E%7M$I,N#Q#7+O\,5KAE7!'*M(.E^OLQ9U!/
MK(]28HG SS/V]<]]=:Z_HI$<)$(=?MYM#>HH<4G^N-2=U>0G4UY2D,DV[V@8
M!RW!S:)_ZTN(!+%?"CDOIJWI/8&RV$TE_(0#+O\'4$L#!!0    ( .Z)"E>+
MPFLBUPP  ,>2   5    865M9"TR,#(S,#8S,%]C86PN>&UL[5WK<]NX$?_>
MF?X//'6FDYNI+#_R.#M);VB)CGE52%6DDFN_W, D9&%" 0I!R7;_^@(DY8CB
M"]2#@#O-C&.)!A;[VP5V%\""^/#KXSS05C"DB."/G;.3TXX&L4=\A.\_=B9.
M5W?ZIMG1: 2P#P*"X<<.)IU?__[G/VGLWX>?NEWM!L' O](&Q.N:>$K>:Q:8
MPROM$\0P!!$)WVM?0+#D3\@-"F"H]<E\$< (LC\D#5]I;T[.+H'6[0K0_0*Q
M3\+)V'RF.XNB!;WJ]1X>'DXP68$'$GZC)QZ9BQ%T(A MZ3.UT\?3]%]2_4.
M\+<K_M\=H%!C\L+TZI&BCQW>;MKLP\4)">][YZ>G9[W?/P\=;P;GH(LPEYL'
M.^M:G$I1O;/+R\M>_-=UT5S)Q[LP6+=QT5NS\TR9_155E-_@A*(K&K,W)!Z(
M8K77-J.5EN#?NNMB7?ZH>W;>O3@[>:1^9RW\6((A"> 83C7^FVGON54 HQGK
M6'/H(P\$7&T]7J37)ZQ;,G[CRK,03C]V )S[K(WSB].W%Z>\A;]D"D5/"]8]
M*>*]JZ/U]FP=^Q!3Z+,/E 3(!Q'TKT' A>C,((QH/6NB%-KE>P1"B*,9C'C%
M_4$4DCLZ(CYFX9PU3.VIO>!VAG7DW51234H2DOV5U(!NJQB=B'C?9B3PF>DW
MOB]1]+0WO'*2K2+K SJ["<C#_MTP1^F0."SF[4)H3Z^7%&%(J8[9@*:(-3L*
M(64,Q#W%#N\!1O^)/]?AV9WB(7$-":4C&++@8DZP,V,=O8[O\AJ'Y&O,1 !"
M;\:D,H K&) %U[+QN.!=H+:OB-4^++\>:T'W/++$$0L#1R'![*.7=,YZ?D5J
M'Y+?9,2[(< 4>+&1,['+V(.?";-TU&!CS?]MB>'%*6>TCO_=J!U6_@&W!\Q2
M9_FHEWQUO4/R:#,7$O:7(7<F0P3N4( B5-^9:ZH=DL/8)_")!ALG0D:LM,(A
MN?H*0J:9^E&T7>ZP?FP^1U$\')E182Z(#U,VYQ/0GT#5@^IP>4?A]R6W=RL1
MVU-67J[W'#$/+R+<_2FWY[5<<!?LZ[NR--JPH*)<B]1NP9J*L2M4^:B658S/
MFFK'L+)BC!67EFLS!C "** 69RU"J]I(]G M'#<B;XI+G$)[MB_E8#_CMT5$
M7CS<5".'H=Z&M1?6DU#U%CD6UD53.BWX+$&AB]4^JM=*V^KN/U&HI=0*#GL1
MZ_X+I*Q+,*/#+8W'/KJ$/]H9E!C9%A'JK(^O!%8-&Y)I X'PP!8F<(2H27 $
M%Y=N:9[:5)X[D*I"PMCTED&LF"'[GJD!'R/(?>":#H?2;*LK0A&ODNY!GFE=
MOF&YY,RSCVG)H_,CO'658?:<<?B\CLVYM:V!83G&@']R[*$YT%WVY5H?ZE;?
MT)Q;PW =[=4$@Z6/6!,_KW<,U\@"XF70!'S+DFSM"JZW?^.-R2F@=_'NY))V
M[P%8]'A'Z,$@HNLG<=>(NT7ZX ^=4@8I=4=KV@&X@T'<XA]IN:UB/2F\\JV!
M<A:3OVYSMM$_]-#32.C#\&/G;$V&1:F97I'?Y$U+].AR/H_)=)FVYNOZTY#,
MJP25"H44<+HI+]9(1WN Z'X6Q<S)D2^;+RT \M,XG5F+.%01["%"E<6T<RY5
M.PVDH)+R$@;K1K J Z1$]LI+>122!613CA'S!Q$/"=F4,)[<6K!R;%354F-0
ME(Z&>L J*2C=[L?W0P@H''-N[.F$C6,.LEQ#-=7$5'0A1T5"D%72T0W"#.V0
M19R^B2. []%=D'!+*X=173TQ+;V6HR4QT"JI:<PFN2'B$][JP&N[G)@:WLA1
M0S$HE<0^@ M"$9NM)7V#8*\N]"JO(::*MW)440=4):5L+-351L)%927%A$DJ
M"AV!)[[!4S_+*RDO.V8LE_YV_%@)^( =*K_.PI_\,5A"EVPL36]L4&](FQ<M
M+"D[$JR7<RGKZ@W9;%BTAO94.PCJZLF.!84'@Y@ E%(9GVDW,;6E%62'@N)*
MJH:LDG8*LM8JG9]2?J-$_"]#\B4C620V%*BJD-=I9LG4#AG+,_/S6BHJ*VF-
M/4DWX?S$9\(JUMMS)64/]XJS$*2&=?6ZC^[[B$,&P0@@W\1]L$#1CW,K!<%[
M6079XUM8+360E=*.YRWGRS@$3O(YR'P1PAG$%*V@B3TRASQ_RX*1/77!8^64
MJQDAV>&GN#9W$Y%*6A[S#7(,?0.$F'D?N@%I *?(0Q6.5Z2N["A56)?B@E!)
M?1N!A8[])OZXOJ9L7R>*K3S>;:8QB4%A$WQUQR'+8'[H;:,<LN^R,TV*3ZQF
MTDXN]DT[T5YE6OE93H)-S4'D#.378I =E_WZ;%@,KGVCV2-CK+LF*R _Y^9Y
M.K-]E+%B^O:CJ+2-[RFD-([.;F 5R_F2LFUEJ;SS>]V%&)7R:>".A,PBINNO
M*:(*3U927K9]%]5)-5Z5-).\\R5@O.K^'&%$HR2KLE9%M15EA_RBNA*4@$I*
M>X;V8T(B8(PW"RMCW/((RE;1BD_09Q32E9EA-451M2(VR\B6?Y[?,K$7*$BA
MD6#B"(:01NN$QX3;<AV4E9?M6&KU40U4)958,!(Q2UO%9 ^(0JX+(JTM):DJ
M=SV*0G2WC'@^@4OXE@/!$9-'$(_HI"L)ZD:,E.P!)**_G26DE*NI6I:L7+2M
MK2A[# HBJ]+J2]38B(2QB#,=,EG>.-M9F]5$98_6W31] #F^D/6T)J^"RZPR
MO3G<*I-Z2VP5RZ09(;S=10B.:_?_<6L/!\;8^2M8$/I>,_XY,=U_95;>I,L@
M_Z*Y#/1WNT#OZ\ZM=C.TORJPRLBL.8?(0JT58L*[?II0GGK^/!U)3P%79O,T
MH?'_Z:)@=-50*R\J=!Y YE(\E![<YF\ZYH+%OC[G+B7[ L3"1':!VK)=[MXJ
M;"(DE90;OX3F&L0V-?^FAX*LII+RLM<S]U9@M2".GV:N>UX8=QI[&A_W(M,E
MA7%N7-DQ-UZMMI;L=(3=]2($3\'Y#(NZ0\[A ":_39R>/A[ *0Q#6'P*N6I1
M;C=ZLH]L[3TB]Q.DXGUB?:J%OU\6K?ALK$D/**HM^US8$?1=+J07HMWTS!*/
M Y@E6T)?*-]^5WIB/>#=2^P!(H)4*:S*(UD;K3%<05R5@RU054S1O[PD19>(
M1VV=;O7.VD."HMU\MS.$ER])WT*B4TG[)3(P\0K2/9=>"FE(6GH!3_%2FDMT
M[_L2A;#T72$52S,-:"BZ=%.AU>VEF\8"4RIT*<%_@S# WGZ]NI"&M 5%#T*?
MWC#UFY0N>3:N/=TX,52YSEA75=$^7*'#_/*CF'A4LL?K@9=Z#I>XX/$KBF9\
M!X2!OB%ATZ6MW2DJNGK9H ?L*4RE;!H7!?_AEG<%@@37YAMBXM33S0<;)4<P
M1,3/QRM>L/3C-#MO!O ]'#,Q&=,I]"K\8-M\R+9#<N2>SW=H&JHJ>59&96%6
M14=["/-XFP,J"[/*2"OD;A-H]G03KHWW$FRYY3Q*8[)W0I3HA$=4HWK)0WO<
MXY=)&_F%O[,:42\@E-%C7RS=G8P-GAQR/7%,RW <3;?X@3S'C%-&1F/#,2PW
MSAK2[/$GW3+_'7\Y>H9,Q16 &4B7VY"&-@,Q,L9:W_[\F7'MW.ICX^CL"MX&
MN,GZV>DVZUS8^KA_&^M@8'PQAO:(9^]HQN\CGMWCM !#Z)+ #(RS/(P^9UKO
M]^V)Y9K6)]:-;(M][B>Y2$='L>-5@1E4Y]NHTBPQ=ZQ;CMY/TNA,2W-O#?8S
M-@R-=3;WUM$,:V ,M-\FEJ%=G/Y-2UHXNMIJ;AC,0+O(*VP8IXN-]/$6PJ-S
M7G?Q8(;QU]N,VTSZ;*!/QF/>X8:F?FT.3==L8:"47RF2X?C--L=Q^B$W37Q
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MD^+K2NY2S?">7T!+*K48<.QRBVH&0[.5M7)5I#:3_W<'*&1/_@M02P,$%
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MF<R(1;)623 _!015+!3R"E+?M(*UZ<Z OVQP7[0$,8>IS0)D*-WN3]5A30F
M[HWVC5=JSB#S4G"8.MR6X*3;T6J(>_K ;FE^48VNHY+7+T[I=@WK62T4D(F
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M)J.$4L@[%TS(1 ^K$D5,%HXY6>!P2^@Z F?744)Y2HW>D@1)%H0&PV*CZ#1
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MP,43WM.U<!A,9Y%ZEN&2;H.JUR1AKP+ 4',(ZBYAJS)04!2"$EX*N_H=ED<
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M3!7)-@TM(]&.V#O=A,R:;E&(.@[XY&D>Q+IPCPEFMT>6K$# 5\NFZW6&<Y8
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MWS&'CS8> ATLNP2I20ZQSH%IKPX343KJTN;$US!.%BM?[JK$=OE17LT17V$
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MH=9K'KF8][%GQM8E0"F,UBGA"R!V/1@],07O)KX]8[$7UI-,E<M%(>O/,^S
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M:[0+[.S*\M2_Y:FZ;)F.PM^W$7L]*Z7H\M<9K5!.YR(69MT\*3:W[+4!]>\
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MAOX3_7/U)_H_+/,7_<O_ U!+ P04    " #NB0I7F8G^:@TG  #7B@( %0
M &%E;60M,C R,S V,S!?<')E+GAM;.U=;7/CN)'^?E7W'W1S55=[5>>=L;TO
MF<WN7<F2/*/$(RF2/)/DRQ9-03:S%*D%*;_LKS\ I&2*)(#F:T,:I2J)QP9
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M,V[Q=BUN4L[L!\?=\7I)_94,G1@)7S+1)%#L$^V@V67?7_ Y7+O6?3Z<J29
M/,\Q ,VE!@O1/@ELZJR3:H $V+V60'PO4/'-H:UEF+=K9TKN'3Y?/I7=!9IZ
M7Y!T 0)_B;E3**E%XD#7\S:6.R5KGVJ WV\)Q/L[3+SS:$."^6\;9N01ZKY
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MJ%&T+3*7OWS?IY?OS9@MV,E@VNF-/WUB*W3VL3L=X"S-](MS^H4I[V'&6X&
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MRXX Y/S[P^%\80@.91?1VP49644S]0K.!.QN/1PQ1,/R4,39X(NB7R_@(GE
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M7C]?>G6.7IES[]#1JW;_ U!+ P04    " #NB0I7^* #BSX'  "N)P  $@
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M++CF*D%(%@P63*>X[K(%%R+'"0LN->*\<FA.\ 2]H7<COG*8)(F(N*;HGL:
MPT2;!<M"YP4.@5&P*>=Z+:@XHWJV* (6JZ7!&';MUT94:=4> =,S)GG>G-RG
M_ 'LJ.26"LW">69.]UT&3S+^[]5:IP7A;FW!NK1DO;8I%XMHNUN(B.I Y# H
MTX#U5O*( \P8%BV09Z3<O5^(F3"E>EB0%"DZC52V3*EN-K6D^1^%T#Q#+#EQ
MO<W< 3ND\NV<',3X)JG7GI3>NNS665I=Q93KK"QCBXKS?YNOXU6^A,03G*WX
MQ[O","%Y7*\)"7F!67HFG;N'GPF:6FJ>$_T6>@.6IH@)UPB68G+R)>8CM\I4
M)4(R&=$X[A2+<D\Z_VA5I*OL*;Q'2C#Y)F/;8]O:\!3:YZA. W<T"J;VP!M_
M_M1H-\K/4]MQUI]_FLL[$9L%F;;?G<%,Z9CK9J32E"USCO=Y]:Y1]G*]T*]Z
MNE[HK+>J')RTWVU3&SH_;(?__+7SM>E7.B)X(:^3.E/&J*RQ]=GO74Q0^7:"
M;28L$^G#Z??"+6US\2=?L=/H.YBW^!3L8HZ5@V.K"[QW1!OTGX^D8FF%"M&E
M+/H=.DAUKE(1-_8([B@_HA[%'V'[0;>_%PQ=?Q?;+GO? GW*HU'+O\_12\3O
M+Z(7M:SEM-YX8,\*\9N.Z=G^Z/F(CLKKJ;^7;U%[%HC749Q&/R1UCQZI.XM(
MO)DDZ:5[?2LC1M5KJZ8 U5[S%&\ATI(<I#(0<]3V^ <[2-AI(&F\\H%-QXRD
M+E(:18PN.9@]X$X)]I4RHAFT8!+[8=Q&R/F+_3 4**+Z*8)M_]!]W#^H;TR_
MUW/ P=T"-^:Z7LM8S!$VRC,G1RPQU<YE2USUFQL2#Y$P7<DM'3F<QX!@SB4*
M:KH3.U&3(H2"(8J-XL-:\%<$M/Z[!5=^]5O[W/<#B]?S2P]^Z('/Z@D0/2CZ
M"U!+ P04    " #NB0I7"V$^F; $   T$0  $@   &%E=&AL;VY?97@S,C R
M+FAT;=U8;4_;2!#^'BG_812I)Y"<-U*J%M)(CNT4<R%);4>"CQM[G>S5WDW7
MZP+WZSMK.R$$4*]2CA.'("^SL[O//#.[S^#^17 U'M1K_0O'M/$=]$\_<(.Q
M,^BWRW<<;5?#_>'4O@$_N!D[GQNQX.H,NIVU@H"E-(,)O05/I(0;I<$ GTH6
M-W B3IW][KQS2(E<,GX&VK73&/2'B$G_S0ZXHG-]X0[= 'HGK9.#KGX.BMZI
M)DG8$DTAY8K*QN /OLC6Y__R)AB6Y7B!.W(M,W"G$YC-/7]N3@((IN#-QPYT
M>Z39?7^T.(;IJ%X++ASP'6ONN8'K^.!<6Q?FY(L#IA7@.'0_]=X;8/I@7CD3
MV[%?@2:,P)S8&E2!O]L[[6@DB&L6.!Y\Z.EO17E"]^,VAOG$#1R<%9@!AF%-
M;0>.<'C>\EM6Z]%BQ\8K!8&DV=.91K6;@PV43YT/12":?],;FA/';TZOQ\Y-
MO59Q?]+IO/FR_"O/%(OO*R/C$=6+=EJGC#<&+H=0<$Y#Q02'6Z96H%84ON9$
M(K+DOE[SZ%I(!2(&DZI5@EY7-&(A20QP>=@R0,ABBD>7+%.2<(4F#B,A4T3>
M_ IQY;!&I"("B@ BN,PYA5['0(9/>D RB%F"YBT GX:Y9(IAS(1'X-R%*\*7
MM%ZS1)JR+--H\5>[1D116%%)18R0#+@DFJEA"T:2?-,462M&8Q@Q3GC(2 +3
M.&8AE3JD?>!HUEP9L,YEEJ,)E("=&JYXTC5LU&L(FT1BK1#XKO_&2Y=7M8=/
MY()PFC6G=PF]!S,L"-759> X46>'SOU>FO^[ NNV(-@M*-C4$Z_7MC5B:-IN
M5RS4R6<96$4:L,@*'M% E"+A"GE&RIV[%5LP54B& 7&>X**A2->)+I9M 4GZ
M/6>2IH@ETUP_I.Z('.N:[9X>1?@AKM?VZFU3:YLLE?>OSG5:U*ZA*_)_FZ^3
M,E^,X[%-2_[Q@E"$<1K5:XQ#EF.6GDGG[HDG3 ^M)<TT_0:N!B1)$!/.T2<0
M!]:8C\PH4A5O3R;N%+%B3WWHT2M/RNP)O#P*,-DV8P_'MO6ZR0C,(>J>Y8S'
M_LRTW,F7SXU.H_@^,VU[\_VW@=RR2*VT:^?=.2R$C*ALAB))R#JCJ!35IT;1
M)?8#;[/!#WU4\#;>)'<AE!)IHVHF^X&]<:S6/^V\0VD<35$)=R V8Y*RY/[L
M5R +WXS]3<N8&@,;4QJ=@9DOL:C05E[H_;;>0+>P]E,@56PE4 2<D/ ;=)&@
M3"0LVA)Q8*#MK V7V$'YA3)XYI^.OXL27[P-M4\A[Y.LQ/JA+)Z+\:6L'"Z>
M/95[T[&\(-!O.J9GFZ7G(VH7-\K@(/]2'5@X7D>)&H- JW[X2/5)J$6=<"W)
M^KY_D!<EZK6R6< N0-($KR"M,1EPH2"BJ/G1/VPG8:>;U/9J#6Q&%EH"0R%1
MW/0-!XM[W"G&)I.'>@0]",?F&+=A?/EB<PPY*HG<1_#05_0>]Q7BB>NO>A$X
MNEWAQE36:RF)*,)&V:9Z(1*K:N>B/Z[ZT"V)QTB8K&28_2C&,2!84HY"F^S$
MKJE)$$).$,6V$X!-(U 2<#@%WB\X_?1#/_4H'X/HIR4_ 5!+ P04    " #N
MB0I7$-I[>.;"  !"KP8 %P   &%E=&AL;VY?:3$P<2TP-C,P,C,N:'1M[+UK
M<^+(DC#\W1'^#[7>G2=F(H0;B7OWC-_ @&VZ;7 #[ML70J#"J"TD6A?;\.O?
MS"I)"!!WA+'-V3VG,4A565EYSZRL?_^_YYY&'JEIJ8;^WXEX&C\A5&\;BJK?
M_W?BV)U8]N3_.SL^^K=KPW/PK&[]=]*U[?['#Q^>GIY.GQ*GAGG_0<SE<A^>
M\9D3_M#'Y]#GI'A<_/#CYKK>[M*>'%-URY;U-O5?TE3]8?;X^*O_:,O4U+%'
M\1MODL2'J:'A5V7T0O#A] ?^X]BC=NBC*?ZH[3VJ6D92$C/SX.!/^"\\SWI6
M1)AAA?3'>>UZ]+@=_OSHT0^V*>M6QS![L@U[B".E8G$I)J4#@\0LVAX;"/X^
MO3<>%XZ3C25$;YRIS1E?*?[<DBT?XPJ=0+<W)_P ;T@)[T&3=F8.F_X OWH/
M.E;L7I;[_L,=V6JQ!]T?QD:%[TQ#HU;HT^R7L<<5VXS9@SZUPD&!GS_@S_B.
M%(LG FAI&XYNFX/PM;H_CDUEF?8T4/#EV$,R[2G^4S*UNYJA]ZBBMF7MM&WT
MV+/Q=")^PIB3R@K\2_ __]JJK=&S?S_P?^'7'K5E@B/%Z!]'??SOI&#H-M7M
M6 ,6=$+:_*__3FSZ;'_@//P!W_O@#OOO_\1BY$*EFO*1U*G]B53D'OU(GI7G
M3Z1<9!^:<:G0O*O_)14O\_E;^ ?!(['8LF\GBDU<<'-ZH4UOH2N,EKS@;R7C
MXCJOIRZ:%&@45@'_7](!CX,"(,B4M;*NT.<O=-",PW^R64G*B:N,FPN,F^]1
M78'_VA>:?-_LR)I%5QDJ$QBJX)@F#J1:@+.?5#9+NE*4;=KD/U_7XT\W@_CP
MYNM__ZTR12(P1=%H.[VQ.2[@&ZNYXC:/879\S%MJJH;"1_VZ"E;3YT!XQ:;8
M="4M'QR^6F4,J5GORB:%!3698N&#6.R[5<8I(BRW[EB)*9 V&SS7O'5,VDP&
M1^G#-^X8+4,9$,L>:/2_DP[P]$<BQOLV::@]F*9"GTC-Z,FZP+\08!Y3[3#I
MH:B/WGN*:O4U>?"1Z(9.V8_J\T<4 ]1$^<+^4A6%ZDS:X)_P8 6VT53;7) \
MVS44YQ>FT4/BB,63L;AH&_QS.@8"B^BP.)B*JA]#F>OD;,1=_WX8FV([LXZQ
MWLD9X[U()IK%F"=G,:Y"(IEU!J^>G.'C.Y@QP,DG9U_GK?'"E-MH:[A#N5K\
M8]TVV@]=0P.BLTJ@L>S!R1A0>:O:X8 @#ION:\V*H>-3H-K!$KDOP_/ 7_8-
M[;6H>4)4T*; 1I**S!,'>_*$.+K*!P3.!+5K?=15#;2@Z< &>5![("X+=MFR
M'*H4'1- X(CX)FL.!?9COU@G<] [0JZ_IAJH;K#/E))LZC"B%;X:*9Y^%:O)
MMX%.' TX0*G:76H6C%[?I%VJ6^HC+</N]>BL!69>Q0)7(4$IGMW:FM!V^H@0
MH\=3[0!>>X;.M=!=W]"_ 1  3[53@P_ @X!_MOH[F-W*ZTJ%VNSO:A_'+#U3
MLZU:-!I2%5-O:M7KD[2X/9[=!T2L1/KB]MDYK_QV+!NUD-4P\HJBXC.@C&15
M*>L%N:_:LL90@BZJ@ML$>\0\W1IZ199J4["('M4VY7*@1MO&O<Y&82)A172X
M>X!HG8$#27KK.%A2(DC)MXZ(]86$M#UIN:>X64EN2-NW<VY-HZ/:UX:UJJY?
M@L.W;V.N#>V,C9X!.9KW>P/YVLR3V+Z$77L5*Y%Y(K%UP&>A#I<"^K_::<C/
M6V> Q/;9-8)UK,@:VS==(EC3DJHWL3T7),+%K,0[R>V+KN7C$1N '9&#NQAL
M:2*,LKZ\36W?6%G?29=\<I+6XXWT]H5P%*M9?[O2V[>[HUC@2FR4?B/V\FQT
M+-:ZF>U+P#W#P9(<G'DC'G84S)_9OG3;,]RL)#<RVY>%"UR%C3A\^\;"VM"N
M9CUGMF]PK@_YVLR3?3$;<XMKV("&%F<*0\QA'ET.AR:%CD@@EEV3]7M:[7BA
MZ%N8C%I\@$M3ADF56>"NE=<,@?:[;.)$,\#-2@O!+6 L7M- 23WW57-)@#^,
MY=<1?I-V0&[!4!9_ HNL/EJL>@X60EA)W,<NJZ!"4&)>N<OILX53LI^Q;NF_
M$TOM]37*2WO<J<8'Y]-9AF-ZL\%CK-3@HXLZAH8Y*6&O!,E[C;+TOO^M_[VJ
MX"\=E9J$+86&EJ85RE_&2P$F7QY-]R%T/G>V/M,FTU!8MFS:F(X_&RW'&VGT
MV]1KE.?PST;K'DVOC+WB?3\&@/>EB]+9>!YYE=E8//?*<,NK+^VST0+\*=Q?
MMHVD5TB XT@*4E)42&)EBZ\92;QH)@HDS3(77AFZQH2:M(Y0DW8CU,9B3M,F
M[TMA?81(>H^N3. ']R<%@'GN:VI;=:T#HJ@]-+BP?GYDS@'.\'UNRZ%99NCH
M&>6?5>ODS'ML:MW_?@B=(@C>AW#X]IN[9NS[?.?A?=# 7!R\,WJ8$=AY'X00
MOOAW1@'+.[3O@RB6QL<[HY.YT;WW01KS4/#&J6$R9WFP'U_>?I1>8-\/]N/^
MVH\O00\'^W&?[,<7D0@'^_'5V8\O02<'^W%?[<<=4L,KB^WN"DEK5/Z^#XYY
M<7-[SU.6&Y9:OP\BVBM[_;43U,'@?W&#_[63T,%C>"4>PVLGM(/+L5<NQ^L@
MIU7*A-\'#>V7$;Y_)38;5FR_#R+:7R/\%1+4P0C?+R/\%9+0P0A_C4;X*R2T
M@Q&^OT;X_I'3C)/]!]/[Y<M-=G1BXF Y[[/E_,+T<#!\7]SP?6F)<+!;7X?=
M^L)T<C []\KLW#$U'$*W^V<_2B^P[P?[<7_MQY>@AX/]N$_VXXM(A(/]^.KL
MQY>@DX/]N*_VXPZIX567*^^,9=J.91N]YNBN@X)L==\&IYS+&G:5JG<IM:^-
M-NN=QYF$MZ$*6?);Y8R9U5;N]E<['8H-2//W)F7"Y6U00)VV'1/L9VI=J#K0
M JRP@=<V\AYM 5J8L?X7S>_L;9'53"JZ:G\'&_7)5.^[+J;>*'U9I@W>N8-*
MM0^[,L#[YP+4-(V'Q81T(.N])>L96/1_1LO;>Z;TC&U:WXH7$CF=K0)-8&J\
MB34X_<P=.%#Z2I1>TM1[M:71HFK2MFV85DENNY91( HS?2M6K7[WNBE^@4"?
M@Y?MTGC^23:5$76/@C]S<'Z@\7DI)9>R\^VVZ5#EW #\7E#Z1F*'-<IB/[=(
MLN&2.7S=;SR!Y'4_.NS]WNW]+CI?A?#]-YF[_^]LZ\>7_2ZY_K#S+[[S+]!Z
MP:4!9BV=3]Z?\39(8;8[-&_5!V-QN0+X P'M(P&]FI+WL=L[7CF=S/!)@TM\
MJY;%PD/J@8O W_1F3ZWSH$>6$0,'\GAC F%&>^5WL,7[L[LOV,GML,\'(3_%
M_.-WG[U-JAA;X[ME_\-.'P3 @2Q>6@#LHC0R^]K;W69?+.9:[734-LWKRK7<
M,DS9-LS!V^",6], C-F#NM/Z3=MVPZB:^4=9U>261B\,LPH_RK:JWU]3V:+C
MQ3'A"#E(UY4(ZT;6G8[<MAVL\GG?)!6"B@,Q+9$-YJP(? C<.(9#AN W4ABP
MF9Q:@)PWKOHGZ*5"GX+2N]Z7VV^DM'-=(IF-D;=$&7C3.R,+O.E]$J >H,0Q
MZ9EJ&4E)S'R$9[S!O)_&I\#19HQ?[\HFM69.X>*+/;3V' #?[8QY%/412&P:
MM_@NNVD=K95I"EL!!Y,PAHT:F+1(=:.GZHNF78R7R7G#!O9^'\/"$@B]A6D6
M;%D?/BZY8>[5\H&+Y/F]]E16&/?\^P'@@W_Q__[M$\L>:"!#.D"V'XD8[]ND
M =QM$6!,4C-ZLB[P+P12!W+O?"(]V;Q7]8\$'XV?G/UK]64].$K,4H?T(\GT
M;?A1)EV3=OX[^=\_8C,>ET[.&B@0B-$A!>03W09TRV?_?L!!X)_^V5:@^D20
M!6.RIM[#5VV*9;@G9__O?\5T_%/$D]Q5RHU2D=0;^4:I'O%<]5+AKE9NE$MU
MDJ\42>E'X2I?N2R10O7FIEROEZN5B 'X+EM=D.FV 2\73PNG1(JGDKFWL(T7
MU=H-X:2-'/JL/#=S\7B3*E2-Q8I&VT&%@U&-9AOU13P9%YM-]BD-VGZ8.3__
M^J>B6/8ED/R_P'VZH3-)I;:)JR!JR!;C+HIMC'3/"=%EU.TPX<?@?"=G8CSV
ME7'T:,RWQ$!_W\CF ZGJ])^WL)I)$DI-D-!7!SP;:FJ#&NT;IAU.37=/8KUH
MIJR^F5Z;FCJ&V9/M_T[49_MCRS T"@:-Z= P,IN "3&5RR33GV80'<?CK/_]
M>I>O-4JUZY_'1[72;;76(+=WM?I=OM(@C2H!"=8 ,47$!*G6B)CZ6_F'5"](
MXZI$ L+-%VSY0@-_%G.)Y%L@#K"+B=VEY(^'<,(M2@*N*U6FQ,_Y!.W<LH=+
MW,T-IQR3EOY4OA6_?W:R6Z$<!5L%P'M=11X,*%A+>A@!C0%V<O;9T2E)Q 6"
MH[YAR56MO855+%1Z6.7'6@C-$UE?\EWGC_10+YO;E%@=6;-"1=8D4*[,2JXG
MLQJU?*5>1L%T$%HSA9;MH]R36AW83-+$_]@&^^<M+'=D2Y.+\G6)5.YNSDNU
M*=F<<+FDQ$(.%ZI&@>+8F=XP[B@:O^\RI?SM@[P-\W!R3@S\B+%$)IG-O&%I
M.\OO%)/,\6Q-";+\V!;5Z+UJ(0W;>#0S?)MHW+C\K@W:/_JYK6W3^+PG9WEJ
M=S7@H1NJJ&U9$TA9;Y_.W+;6CG;P[]*SW+89\.BKFS[01+:(U:=MC"$J1 7\
MVA9I=YG]LF.#W6:1A#;5-, ('B7_[P3PC7_W947Q_EX9D"=5L;OX:/RO3Z1E
MF HU8VU#T^2^!=3E?>+AFG]MTYO@D9HV;J 'M&WTO9#.O[;B/>4.GL*QER/J
MCMQ3M<''15 '&0 6Z8[.9#3JT8_$Z8.4;LL(^21CY,88 [M\F7W,*ZK8*Q(L
M.':.V1P4#&4&GT@Y^J.KB:7*<'T^"6C[F$7;F/*Q:=\T'I$&Q\W,)> \.=/I
MHZS(,QG)_<=67FZ/IC=B7$(UY.>R&Z[G1Z_F:934P_//U-=+(ZYN3U3- .#D
M3$S$$NF$E$WEEL O_(^Y'K-$B_R_&<T0L&8,[/9 ?CNF:H$,9A8-R#PU2%_L
M,?->UM4A^_N?N104,>#ET]II_924>GW-& #DXYM$*L;I/]%M@">$EUUWX/D@
M(-,OAX"T:_XKC?%?7E%,:EGN/]>J3L5PWOMU8YJ_:<=X:">WQGLADP/?B:E4
MBM2KM5JI G[(M_SU=>DGJ57SQ1E\*,R,(<R:10I?XD^K_*OV).<O#3G")8(Q
M7+\K-TI$BL^*$RRYH@)\K)H-XTD/7\_MKZ_=Q.="_;*J;7L]HZEA-?D**99+
ME]6E5Q-*@DQ25<U;T(8@E68HX;+5^*Z7^W=Q97L^1?C\X!3EUU&LDQS>,FS;
MZ.V:R3-A&+XUP-[0?JG]V4;.LWZCUKI6/7'5W39^QV8_.<M)HB2^9LWJ+@NU
M:-\$BE'[LD;H,VT[MOJ(#@7F^ZT7U:& ;(+8GJ$I/S#GXNPM>,@CRD^[E(\2
M*F]2>3:M#WY7OK>NJ30LKA\V'M%Z<#Y ?5K,_3.#NJ?$8=$%&;MM:K==0Y\;
M5GFZO!2-AU;C,K,-J3XY)S!F4HS%$^GXRT15_AZ%#O[?_V8E,?/)@N<TVD<0
MB<Y@%-!LU1ST?H^/9, YK%MYW9FTWXX%QNT E*G?/,Z-1U"3*J3OF):#@0G;
M@,&X]2Y*?[?^.3X"\8.!RGS;_A@U;&\@-#&]L?Z$B23,%ZZ]_8$B$F$,HU%.
M$%0I[ &%MEVG[R-Q=$"Q!I;IR5FCW+@N81R_E"]<D<)UOEX?8_O(89S.R+@,
M,1"E5D.UM5!9?D)L_.F_$_8$:F3&',1[=PMR<A(,'C.O5DB]42U\$<C_Q4_C
M<9'<YFOHL=R5YDC/94V!$64F#I39J.6+Y<HEJ?^\.:]>OQ11>F9UPY11P-4'
MO9:AS:=(_B3ACVZ!$,>F/CG+EVYF^<6OC=:6)85*_F8DH_P$)+#B]ZLR?%,K
M79;KC5*M5'PI*LE/B*[2<[LKZ_=T5@[&)Q;O!>*]07CZ9$O19@JC3@>:PZ!$
M)->+^5D56*20ORTW\M?D)E_[4FKXA!:]:S'+%MF\PK.L8VK*IJ0U(.TN;3_@
M P_DJ4M9X!1MK$""Z&_Q']*5+=)1-3#/9$V#'S$E;QT?F?2/HZ+1!K9:B[I/
MP*"^W9; ."M/J+O&6\#H\W<>##JFR'*))%'8@0+V:-^D;<HDBB@15J1BD;]A
M/-AK8CGM+K&Z!J:ICH_<?+7=E>U)Z)]DM"Y'8"*,_&UW%?\(1-85\K?$5]D"
MDH'?6<T[/L\>A9<0#'<<K$^P&!0,2MFR22Y.%'E@G<+VS,W%%!S3A+=Y30.*
M-ENV'2O<^5$NC6*ZWG>^E[87GPB?_^3L)U9)A]._6RM&*@;Q2S"V1HF[<316
MHO?C(R0#H(">:MM ,^"0M6W3T%%): -"06$,"+LM!3MC/5)2E&V98+*>3+##
M:(R@3U-SX,ED/(44#PX@WLV#K%*/-<C?B([,)RDAG<(#KK^CLG1L'].QZS '
M68$W., ^R5/KG],I!SXYD5OT\8!H<,DKG)X+W]KW4O?V=__']J+JX?//H^=@
M6=#QT8BXQXN&W@6= V7)1(-Q*9';X,OBL0L@!-QY$X5BZ+<$4!H+_<'J 8/
M-*8G7&!7>X#R@8!* (8#P8EKN"?WIO%D=[V?06C6*670*;2CZJP$B<4:,2HB
MQ3_- I']+'[R'IMZP/U=\!Z8":#WX/$1:@+WZ1G0>I.J.N=D<))BDJ?<@AKM
M-#KR>8W1B& 2?D9(?QMQX.LI6D');(Y4UY)U A&"F%\&N/53 1%"/JOV?52O
M9A9@6?>&.0A7 1=_NL-S^FN@2JGM6?IL<L;P;7?RL.J2,>C YI^08NSG!2;0
M7.*)$.WU67)K2CF+8QO"WCMW+/ DK1DV)AT6*I5A]_/EX'>4!Q%"X%ET""$B
M9IA7[1#A%I;"E<G4!DIC&^B]=<E>*O!WPC=2?&K5'_M:MYS;ZD9.U6?/ 6Q1
MB7;4B;F=65F=.<8,YFLFC+#C(V:%J9U)\QO]#.9=@/S1#>8<.!8WA&!>?F0D
MI"@;C"F<3!O@[$\JS(V4I,.2#)01CZK%#"!V'8^LH2[$,CJ60,)3SXIL*A;!
M0CQ5F7!-+-]M_UO^)]2F>2\N(#.-K2Y85#ZK_@V[Q>Q37B8[W_@#QPE<$ ];
M,[.@KES$>>9R]^>&*?WN]GX.OFSGU,]\[@["@YIRH5I\9;209\Y%WKEW,'+#
M3S$)T\RI$,.Q&<<PWIF5M'$#*Z.;V/E)^NKHW:9:=K<U&\\UA^GL>;;>S]BW
MU=]^-)0/0O@HA T#2V(#D<!(_N9?F+PM]W2 9PX<)V.T,NIGD8W%<^/TH3L]
MQ; 5VE9!99\0]X/UWTFY<G%"\& Z&\+K&2 EA6PB)21&12X>?#ZM\)/XB/<V
M7Z/%U^CFDOJR21YES:$1>DW[/^#_Q&)@B%)-^4ANY7OZ"=[ZXU"]C68$B<4\
MBT51'[V972^-)RT^DG--!LDFPN"6H:F*-U\,C*./)(U5Y.X7W@MI9N:,_,F@
M_SCI7XY/.>T83CB0T];47.-MG%<UVF%O3/IFB<1?XQ6HTT\D9U5Y![#KX?43
MP1/8'TG>E%MJ^Q-+07#<5XQ/A#<ZM3Z2*U51J(X[X$X=&.J#-Q;^/ NFQ 1,
M[-['Z5):SQCR&CI,[;9)Y8=8BP*K IA]1B++[;!/J@$"#)+?V(S!U2$N..EM
MI[?$WC+CHG27U^["%6B-_#FO'BA4*XU2I1%U9XBW$P'*_K5-Q^HV7VN0\NDR
M<9UL>JLS3W1"29R<790K^4JAG+\FH":KM9M\@S7LD,^6@2X=^>&4Y&8N=:CK
MO$7PO.%7+"&=<1QAR35M#_QRHW1#Q'!"C([JDD&J8RUJ;K@P6D!T!TK;-:5%
MO*8)NDAAS5:E6*K42T544?7J=;F8QSY&Y_EK()<2J5^52HTZR3?(Y[M*R>_F
M0/Z^J^3OBMCRZ!_6@^@F7RM<<> 3HM?QX4!=[YJZTC.I:R2"T#:JWI9J3 G6
M">A#UD^A<54KE<@-&$U7=5*",8H3](<TAPV*@X3XP@27.A#<"Q-<9DF"8P6J
M5]7K8JE6=TOJ2>GK7;GQ\U438/I @"],@-DE";"0KU^1B^OJ]]<M\3('@GMA
M@LN=G%6JC5(=VQ/-H+PPPW^/:"A[H*&HW4UIQ^ZF&#\YN\E7\I>,V%P%6R?%
M<KUPQSLJH2R#!ZY_ULM,'HYH%(F8=>!BS]1*];OK22-Q+8(5,P<"BXS $KLF
M,/'D["MV92N#1"M_*S%:@2^NO;^1U*ZK];L:=L@]K]XUW+)\4BO7OZQ%/Y)T
MH)_(Z">Y:_J1F)W6J%6O>0?EVUJU4"HBN1R(8X^(@T?M9X3MHZ..Q,E9%4SR
MVDKQ^5"Z2!SHXLT$T<7DR=EUZ1)L%"8M2GCV<DUQ<2"+",DBOVNZ2)V<H5E!
M+O*%1K5V((F](XF=^S]IO YB=.B6U//7)>;$N$'&B?L;[NJL1, 5*VL24/)
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M>)W[!<UBYKHUC0ZU+%:R=4'9.6.1U09V+[\ <_5U3?HQ_/)#>I&+L,,\WB#
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MZMXKC'CA#>8J Q; L0$V@"== C; ]E)4^5XW,& %^/$7>7R$_H'24VU7CJ!
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MPZLF3R_7:=^FO18,XI9\2&C>L*'Z)ECQAF-I ^^8.X8GGGBLUL\Q CAZP$U
MXZM#_CBP1)A+X2"P28$@ #U.1VXS9W9R$:>DZIC</E58,$,&.]6C))D%@+VQ
MF 5YCR?%["X8@#I6;ZK6\9%\?Z\YL'"5^QN7%18[1$O-T-W0S.2L D\V:_(
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M JZX/O)EJH<U!1;=X-H9#TU!WH$;8K)\N+&O@ HUP @;^3F-336]. ;K \/
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M9!_!]R:#7@V+4D4Y'\I7E;@T)V4%^^W0[2Z@[$YL(C8-EFJ]IP7:<WH2])0
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MW9VJH]H*672,;)@L,J\J;2,BY,@.B=S655G(2*(DTHG%1&K". (?)CIUF(A
M=%NH9U=?R7[WA5I'\1]+@VC01,((,CEELPO;2L9XO2HL@!RJ;1C/0L^P"/E8
M8!20[T#99N"0E%:+3B&4&[8!=T(K5\1]X7;B"-X![NZ,#G-*2!AJ1^DPTKY
M[IL/#>.&7;<!E@:[97($8S>=)%<R<H=T6O+KCN%8"@7#Z :XQ^@I+/(\<K_I
M]*1[F7P9]/CQI%4+USCJV/!GIY^3XU*4,EV WD8.KBA=6=7YOVID)# RF_8%
M&II2-!TC8CMZG%"/7I+1EX3GG\#OX]13W1#,T)+VHNF]F!A:JX_4,?H,SK?6
M'[\3DYP-(42WNS-.,\'+H=>GZD+6:1/!P$@%SKCAX-704<GM ]B#@)\X.E%1
M_10,,_IX&; /#!V^R<D45K^[0RYL#!PDY_D6+NA$A[AOW0[ >4SR-EV:0%WV
MH.K4GPC=$^W=S+[*J@;:WY%A!D^3^@KX=%3D$T7AW%TY=QMT"LG;U_SI4SWI
M.70O1H]AJJT_LI<YTRGHTAXGKFP).""Q2"HE30(!F?_B@T04?N%"V'WG/^V^
M T^ZZR JG)P=#QZ*%2WU&3<=LJ8EW+$4B:8G KU\$SRBFBM](B!Z4 0%B1)I
MD$A#\E8U#)#:JDY>J-V=OFIWR&-M<M'J/MLA'G(?"):?L$:\;N-26O0_*4N7
M640L$.$0H!VJFW*J;MXF3JJWY_62E'[GZQ4JD6;,._]3M^AI_O@=G_'H4<DU
MABK4)&8?U*P+)F"D$7DT35F8NJH\&ZE"!KI43'![X!WW/NF*4_=&1DG==LXO
MF^.>[=#MSPK,+[K]J>[E=]/-#*\SDWE[DD_H71*KGE!(&%SSG]]+Z&4MM*V(
MAAU$=V&-% 2K0Y1RU.L[A 1V=V3J']LS6GM$-^?6&U$([5"\P,G,0+/?6M>$
M6.'7/IK'1]L+X<'W8.R1Z1:CO9'95HV,%DTG(V(T_<T?3&+]@?<9=A;QZ6BN
M(4N-*?B#KO0!#6[:VTJM!E-Y<2#CF=PV&( ]1#D3,(.H/A#.#W)@5[3D5\/T
M[%6]J1DFV)OX;[E-IF^#;)816R24+),!@\XF3Q@A@1R95_4G9%)PDC 8P*6(
M97+V?K4</4)<%N=?[VM7)_<GIP5/B3Q7=8QE-W"=L^A_UK;FD;635_AQ)DFG
M(HGH9/!,<IN:JCB((4@(@&CX)B)4*80D5!L=&#(-<S:1RD""U67]&:B& G7Y
MB"9 B",6IDLW>"HH#?^()R,I*<G_TE)A#[L[ #?'D+ "0"#4*<1GF& +>U/0
M&:*15#H:G$&8-(%$_35DMU9+(894<W='4Y^])8.?!1Q*-E%BX*UN0+"&[)&!
MN+(S8U"*>)0 HTCFA0/#E(/4/Q:1Z]8S+ A.CZ* &829X?1P>A#_0@,R[<C0
M^'L##/#P:2W_O. GP-OQO2A$A@=6+%L=@6G1_'NSX&<K[L]SY-?!J/ZP8:K-
MIMVY/^\^S6*4X#C+>1D6(?4U/09K\WM?&'554X0<>0QT,I#1_5;N;>_!ZU-+
M'G1C8C'@GANX9Y/LF1 ]Z$I6QS!MM) BU*K8LXT]_ ]P!:B(;XJ0MPKU=3:%
MJ;Y.PNVJAE\AGY%OH4LE1-X @BXX4#2%+&]_=P<,F?$EPK>X]Y1P!3[>37Q/
MB9B4J4@=D97,#]B3U>8X<_IZ1[)4$T3SU&VBW:-+(]01$]3VV ]1FJ)_"$"4
MJ<$WS6,2/M\TQ\E$\--W/6;2-!Q<;P_N(X$Z-,AM>OX"D9*(?<SN2O82>/"6
MJ*L!+XH(Z*K2L]T0BX1W8D^\8%,AE*%3V%SXUBMY7W 1LLUO7,65.-\%5KH,
MYJ6F48!TI"& #M8MQ0<FK.H8CH;CW-UI*SK\ @]2;I*#5LF#(&/ @_V2+, 7
MM@@A_:.)9DZ!CC 'Z;N_HU%! !? GRYFZ/ ?K8WTQ6AB*O'#J8Z=5V:N\Y+<
M\Y(^Y;PDU\<J+>VTB.(W[;2X@/!!U#)@YXE(M0(%J@T$%+\8)T,:P''V7+C(
MUFJ%RC=) ;@%6V  6.6J_FIHKV"H$+HBY-O%X";^?R+.7V5RO>!%)LJUVK7
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M)GE\@["..O@16[3D&5V)+4=O\EI)COR'67NTH2WY3E\!2#G&);SI"&17 Z)
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MPR*Y+Q3N3HJ'Q=I2+;E_Z^Y&5H_R_5/^)13>L#J- M,2)@(P'H1D,1H.S6D
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M5$V%-@D;R^'>W0G/Y*2_A'[L" '7D:$1NS80&K)C$27"UU8,YJDK@D560?Y
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M+GAS9%!+ 0(4 Q0    ( .Z)"E>+PFLBUPP  ,>2   5              "
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MC   865T:&QO;E]E>#,Q,#$N:'1M4$L! A0#%     @ [HD*5_B@ XL^!P
MKB<  !(              ( !/Y0  &%E=&AL;VY?97@S,3 R+FAT;5!+ 0(4
M Q0    ( .Z)"E=IKH1+S@0  "\2   2              "  :V;  !A971H
M;&]N7V5X,S(P,2YH=&U02P$"% ,4    " #NB0I7"V$^F; $   T$0  $@
M            @ &KH   865T:&QO;E]E>#,R,#(N:'1M4$L! A0#%     @
M[HD*5Q#:>WCFP@  0J\& !<              ( !BZ4  &%E=&AL;VY?:3$P
B<2TP-C,P,C,N:'1M4$L%!@     *  H D (  *9H 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
